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Summary
Bioreducible antitumour agents are prodrugs which are intended to be inactive 
in normal cells, but are able to undergo metabolic reduction in cancer cells to 
produce toxic species which can damage biomolecules. This reduction can occur 
readily in solid tumours due to two factors which are unique to them: a) tumour 
hypoxia; and b) the expression of high levels of reductase enzymes. Each of these 
factors can promote specific cytotoxicity to the tumour and in principle could create a 
selective anti-tumour agent. The overall aim of this work was to synthesise powerful 
alkylating agents and then target them selectively to cancer cells as inactive 
prodrugs.
Following on from previous work on A/-oxides of c/s- and trans- 
2,6-disubstituted-A/-methylpiperidine, compounds (A), where X is a carbamate or 
halogen, were synthesised and subjected to biological evaluation against two 
human carcinoma cell lines, HT29 and BE cells, under oxic and hypoxic conditions. 
They showed promising cytotoxicity towards the cancer cells and good DNA 
crosslinking activity.
The DNA sequence specificity of these compounds for guanines warranted 
further study of structure/activity relationships. To optimise the selectivity and 
cytotoxicity of this type of compound a series of compounds was formed examining 
variables such as ring size; number of rings in the system; number of carbons 
between rings (2-8); stereochemistry; leaving group; number of atoms between 
nitrogen and the leaving group and the number of potential alkylating sites. These 
compounds underwent biological evaluation against the human leukaemic K562 cell 
line. Results from the biological testing were inconclusive in understanding 
structural/biological activity relationships.
An area of chemistry which is as yet unexplored is that of macrocyclic 
alkylating agents as potential anti-cancer agents. A selection of cyclic alkylating 
agents was synthesised from a ring size of three in the monoalkylating aziridine
chloride (B) to larger macrocyclic systems of up to 23 membered rings with the 
potential of six alkylating functions. Also macrocyclic systems incorporating other 
heteroatoms in the ring such as oxygen and sulfur were made. The incorporation of 
other functional groups such as amide or benzyl moieties in the macrocyclic systems 
was also examined as in the synthesis of (C).
Variations on the size of the ring; the number of potential alkylating sites; the 
number of carbons between the nitrogens; and the number and type of heteroatoms 
in the macrocyclic system have been examined.
The methods used to form these compounds varied depending on available 
starting materials from high dilution techniques to condensation reactions between 
amines and esters or acid chlorides. The high dilution method employed the 
cyclisation between amines protected with tosyl groups, and alcohols, also protected 
as tosylates. This was followed by sulfonamide cleavage and alkylation using 
ethylene oxide to obtain the alcohols. The hydroxyl groups were substituted by 
chlorine atoms to form the alkylating A/-chloroethyl moieties.
The results of the biological evaluation of the macrocyclic compounds 
indicated that (C) was an excellent DNA crosslinker and also very cytotoxic to the 
cancer cell line.
The potential hypoxia selectivity was investigated by the formation of nitro 
benzyl compounds such as (D). Nitrobenzyl quaternary compounds have been 
shown to undergo fragmentation after one electron reduction to an alkylating system. 
A selection of the macrocyclic systems formed were developed into o- and p- 
subtituted nitrobenzyl quaternary compounds. The results of the biological evaluation 
of these compounds were very disappointing and showed that none of the 
compounds tested was reduced under hypoxic conditions to give an alkylating agent.
Contents
Chapter 1
1.1.1 Cancer 1
1.2.1 How Prominent is Cancer? 2
1.3.1 What Stage of Life are you Likely to Develop this Disease? 3
1.4.1 What Happens when Cancer Occurs? 3
1.4.2 Cell Cycle 5
1.4.3 Programmed Cell Death 6
1.5.1 What Causes Cancer? 6
1.5.2 Carcinogens 7
1.5.3 National Population 8
1.5.4 Solar Radiation 9
1.5.5 Ionising Radiation 9
1.5.6 Medical Exposure 9
1.5.7 Radon and Radium 9
1.5.8 Diet 10
1.6.1 Oncogenes 11
1.6.2 Tumour Suppressor Genes 12
Chapter 2
2.1.1 Diagnosis 13
2.1.2 Tumour Markers 14
2.1.3 Staging of Cancer 15
2.2.1 Treatments 16
2.2.2 Surgery 17
2.2.3 Uses of Surgery 17
2.2.4 Radiotherapy 17
2.2.5
ii
Uses of Radiotherapy 18
2.2.6 Chemotherapy 18
2.2.6.1 Alkylating Agents 19
2.2.6.2 Antimetabolites 22
2.2.6.3 Natural Products 24
2.2.6.4 Vinca Alkaloids 25
2.2.6.5 Anthracycline Antibiotics 25
2.2.6.6 Miscellaneous 26
2.2.7 Treatments by the Immune System 28
2.3.1 Chemoprevention 29
2.3.2 Tamoxifen 31
2.4.1 Selectivity and Multidrug Resistance 32
2.5.1 Pharmacokinetics and Pharmacodynamics 34
2.6.1 Hypoxia
2.6.2 What is Hypoxia? 34
2.7.1 Bioreducibility 34
2.7.2 Bioreducible Agents 35
2.8.1 Gene Targeting 38
2.8.2 Angiogenesis 39
Chapter 3
3.1.1 Previous Work 40
3.2.1 Variations on the Lead Compound 43
3.2.2 Ring Size 43
3.2.3 Number of Rings 44
3.2.4 Number of Carbons between Nitrogens 44
3.2.5 Stereochemistry 44
3.2.6 Leaving Group 44
3.2.7
in
Number of Atoms between Nitrogen and Leaving Group 44
3.3.1 Synthesis of Analogues 45
3.3.2 Bispyrrolidine Derivatives 45
3.3.3 Single Ring Systems 49
3.3.4 Straight Chain Systems 53
3.4.1 Biological Evaluation 56
3.4.2 Sequence Specificity 56
3.4.3 Agarose Gel method for the Determination of DNA 57
3.4.4
Interstrand Crosslinking 
MTT Based Cytotoxicity Assay 58
3.5.1 Conclusions from Biological Testing 58
3.5.2 Leaving Groups 60
3.5.3 Ring Systems and Linker Length 60
3.5.4 Ring Size and Stereochemistry 61
Chapter 4
4.1.1 Macrocyclic Alkylating Agents 62
4.2.1 History of Macrocycles 62
4.3.1 Nomenclature 63
4.3.2 Methods of Synthesising Azamacrocycles 64
4.3.3 Synthesis Using Templates 64
4.3.4 High Dilution Synthesis 66
4.4.1 Sulfonamide Cleavage 68
4.5.1 Results and Discussion 69
4.6.1 Synthesis of Macrocyclic Compounds 70
4.6.2 Available Starting Materials 70
4.6.3 High Dilution Synthesis 74
iv
4.6.4 Linear System Formation Before Cyclisation 77
4.6.5 Condensation cyclistations 81
Chapter 5
5.1.1 Heterocyclic Alkylating Agents 84
5.2.1 Synthesis of Oxa, Aza Macrocyclic Alkylating Agents 84
5.2.2 Available Starting Materials 84
5.2.3 High Dilution Synthesis 87
5.2.4 Diaza Macrocyclic /V-Tosylated Compounds 88
5.2.5 Triaza Macrocyclic /V-Tosylated Compounds 90
5.2.6 Tetraaza Macrocyclic A/-Tosylated Compounds 91
5.3.1 Synthesis of Thio, Aza Macrocyclic Alkylating Agents 92
5.3.2 Available Starting Materials 92
5.3.3 High Dilution Synthesis 93
5.4.1 Detosylation Attempts on Sulfonamide Macrocycles 93
5.4.2 Concentrated Sulfuric Acid Method 93
5.4.3 Hydrobromic and Glacial Acetic Acid 95
5.4.4 Lithium Aluminium Hydride Reduction Method 95
5.4.5 Na/ Liquid Ammonia Reduction Method 96
5.4.6 Sodium/ Naphthalene Reduction Method 96
5.4.7 Phenyldimethylsilyl Lithium Method 97
5.4.8 Detosylation Conclusions 99
5.5.1 Biological Evaluation of Macrocyclic Compounds 99
5.5.2 Results of Biological Evaluation of Aza Macrocyclic
Alkylating Agents 100
5.5.3 Results of Biological Evaluation of Aza, Oxa and Aza,
Thio Macrocyclic Alkylating Agents 102
5.6.1 Conclusions of Biological Evaluation 103
VChapter 6
6.1.1 Hypoxia Selective Compounds 104
6.2.1 Quaternary Nitrobenzyl Compounds 104
6.3.1 Synthesis of Quaternary Nitrobenzyl Compounds 107
6.4.1 Biological Evaluation 115
6.4.2 Experimental Detail 116
6.5.1 Conclusions 116
Chapter 7
7.1.1 Other Biological Testing 118
7.2.1 Anti-Fungal Investigations 118
7.2.2 Polyamines 119
7.2.3 Selection and Synthesis of Compounds Tested for
Anti-fungal Activity 121
7.2.4 Biological Evaluation of Compounds 123
7.3.1 Tropical Parasitic Disease Investigations 125
7.3.2 Leishmania 125
7.3.3 Trichomanosis 126
7.4.1 Biological Evaluation 128
7.4.2 Experimental Detail 128
7.4.3 Selection and Synthesis of Compounds Tested for
AnibLeishmania and Ar\i\-Trichomanosis Potential 128
7.5.1 Biological Evaluation: Conclusions 131
VI
Chapter 8
8.1.1 Experimental Detail 133
8.2.1 General Methods 133
8.3.1 Experimental to Chapter 3 137
8.4.1 Experimental to Chapter 4 162
8.5.1 Experimental to Chapter 5 180
8.6.1 Experimental to Chapter 6 196
References 211
1Chapter 1
" Not people die but the worlds die within them"
-Yevgeny Yevitushenko 1
1.1.1 Cancer
cancer 1. any type of malignant growth or tumour caused by 
abnormal and uncontrolled cell division: it may spread through the 
lymphatic system or blood stream to other parts of the body. 2. 
the condition resulting from this. 3. an evil influence that spreads 
dangerously. - The Concise Oxford English Dictionary, 1996.2
Cancer is one of the most feared diseases in the modern day world!
The fight against this dreaded enemy has been an ongoing battle since well 
before the beginning of the century and is currently the concern of many research 
groups and scientists the world over. In fact, cancer was reported as early as 
classical Greek literature. A study into literature on cancerous diseases by Jacob 
Wolff reported that Atossa, the wife of Darius the Great, had been cured of cancer of 
the breast by a captured Greek physician, Democedes.3 However, this must be 
treated with caution as the difference between cancer and a lesion would not be 
known in the 5th Century BC. The difference between benign and malignant cancer 
was established more than 60 years after the first study of tumours in light of the 
tissue theory which alluded to the differences between lesions and cancer.
Many people today hear the word cancer and immediately think it is a death 
sentence and fear is instilled in them. This fear comes from the fact that the body 
has revolted against its owner, leading to destruction from within. Nowadays this is 
not always the case as there have been massive leaps made towards the 
achievement of cures for many cancers.
There has been a much greater insight into cancer as a whole and it is now 
recognised that it could also be a genetic disorder4-5 and thus we have to understand 
the causes of the disease to find cures.
2Cholera, the plague, yellow fever, tuberculosis, etc. which previously killed 
millions, have all but been eradicated. This is due to increased knowledge and 
improved hygiene during the past 150 years.6 Cancer is now one of the most 
prevalent diseases of the modern day world.
One of the main problems in the control and eradication of cancer is that it is 
not a single disease but covers over 200 different types of disease6 classed together 
as cancer. Not only are there many types of cancer (even within the same family of 
cancers) but they may be treated using different methods, thus making prognosis and 
treatment more difficult.
1.2.1 How Prominent is Cancer?
The answer to this question is that it is one of the most common diseases with 
very high mortality rates.
In the United States it is estimated that 1 in 3 will develop cancer at some 
stage in their life and that 22% of these will die from the disease.7 This makes it the 
main cause of death in the USA followed by heart disease. Cancer of the skin, lung, 
colon and rectum are the four most common cancers in the USA and account for 
over 50% of cancer mortality. Lung cancer is the largest killer accounting alone for 
28% of the deaths.7 Table 1 shows the distribution of cancer cases and deaths in the 
USA in 1990.7
Cancer Site Cases per Year Deaths per year
Lung 157,000 (15%) 142,000 (28%)
Colon/ Rectum 155,000 (15%) 61,000 (12%)
Breast 151,000(14%) 44,000 (9%)
Prostate 106,000 (10%) 30,000 (6%)
Bladder 49,000 (5%) 10,000 (2%)
Uterus 47,000 (5%) 10,000 (2%)
Lymphomas 43,000 (4%) 20,000 (4%)
Oral Cavity 31,000 (3%) 8,000 (2%)
Pancreas 28,000 (3%) 25,000 (5%)
Leukaemias 28,000 (3%) 18,000 (4%)
Skin 28,000 (3%) 9,000 (2%)
823,000 (79%) 377,000 (74%)
All Sites 1,040,000(100%) 510,000 (100%)
Table 1 Data from 1990 (American Cancer Society, Cancer Facts and Figures, 1990)7
31.3.1 What Stage of Life are you Likely to Develop this 
Disease?
Cancer can affect humans of any age but is more prevalent in the elderly. 
This is due to the fact that many malignant tumours grow quite slowly over a long 
period of time. Cancer is also responsible for 15% of childhood deaths.7
Different types of cancers are also prevalent in certain age groups. Children 
tend to suffer from cancers of the blood such as leukemias and lymphomas which 
account for 50% of childhood deaths from cancer.7 Other cancers which are 
frequently encountered in children are those of the brain, nervous system, bone and 
kidney, all of which are much rarer in adults.
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Fig 1
Fig 1 shows incidences of colorectal, breast and lung cancer. These cancers are 
most prevalent in adults over the age of 60 and practically negligible in people below 
20 years of age.7
1.4.1 What Happens when Cancer Occurs?
Cancer is a disease which is partly characterised by uncontrollable cell 
proliferation. The human body is made up of over 1014 individual cells8 which are 
subdivided into groups and classes that form various tissues and organs which are in 
themselves programmed to carry out specific allocated functions. Some cells within 
the body are apparently incapable of further division once they are formed during the 
development of the embryo or in infancy, e.g. nerve cells. Others such as the fiver
4are capable of rapid multiplication on demand, e.g. on partial destruction of the liver. 
Finally others are continuously replicating in order to replace cells that are lost or 
destroyed such as those in the blood, skin, hair etc.7 From fertilisation of the egg to 
death at an old age the human being is the product of 1016 cell divisions.9
The problem of uncontrollable cell replication generally occurs after a number 
of factors affect a cell causing it to mutate. Thus when the mutated cell replicates it 
passes on its mutation(s) to the next line of cells and gives rise to an ever-increasing 
population of unrestrained progeny cells. A well-developed tumour is made up of 
1013 cells which equates to one pound of tissue.
The word neoplasm (which literally means "new growth")7 is generally applied 
to any abnormal growth of cells and this growth can be subdivided into benign and 
malignant.
A benign neoplasm is one which remains confined to the original location and 
is usually encapsulated in a fibrous surrounding and generally grows at a much 
slower rate than that of malignant neoplasms.7
Malignant neoplasms are capable of invading adjacent tissues and organs. 
This process of invasion of other cells and formation of secondary tumours which is 
known as metastasis and once it has occurred it is generally much harder to deal 
with the cancer by surgery or other localised treatments. The process of metastasis 
in itself poses barriers to the cancer cells including the journey through the blood 
system avoiding recognition by the immune system. If the tumour is in the brain it is 
necessary for the cell to cross the blood brain barrier and attach itself to the blood 
vessel at the distant site. Only 1 in every 10,000 cells successfully establishes a 
metastatic tumour.7
Malignant neoplasms are split into three classes.9
• Carcinomas account for -90%  of all human cancers. The tumour developd from 
epithelial cells which cover the surface of the body and line the internal organs 
which are affected.
• Sarcomas are relatively rare in humans. The cancer affects the connective 
tissues such as muscle and bone.
• Leukaemias and lymphomas account for -  8% of cancers and are malignancies of 
the blood and lymph systems.
6or wound. A stimulant of these cells is the platelet derived growth factor which is 
stored in blood cells and is released during clotting. This stimulates the fibroblasts of 
the skin surrounding the clot leading to regrowth and healing of the wound.2 Different 
growth factors stimulate different cells.
1.4.3 Programmed Cell Death
Programmed cell death, otherwise known as apoptosis (which is the Greek 
word for the falling away of petals from a flower or leaves from a tree)8 is an active 
process in which cell death occurs as part of the normal developmental program of 
cells. It is critically important during embryonic development7 and is an intrinsic part 
of the developmental program of some cell types. Regulation of cell death is just as 
critical as maintaining a constant cell population as it is basically the regulatory 
control of cell proliferation. Coincident with their failure to differentiate normally, 
cancer cells generally fail to undergo apoptosis and instead continue to proliferate. 
The defective differentiation and prolonged lifespan of cancer cells is closely related 
to the capacity for unregulated cell proliferation. In many cases the progressive 
growth of malignant cells in an organism is a combined effect of the continuous 
uncontrolled cell division and the failure of the cancer cells to undergo apoptosis. 
Thus we can see that the process of programmed cell death is important in the 
growth of many cancers.8
1.5.1 What Causes Cancer?
Cancer is not caused by a single factor but is in fact a complex disease 
requiring exposure to several carcinogenic factors to initiate the faulty genetic 
program. These so called "hits" can arise from exposure to a variety of factors such 
as chemical, radiation, viral, genetic and environmental. These will be discussed 
later.
By analysing the causes we can establish that, in general, cancer could 
theoretically be cured by identifying and eliminating these initiating factors.
For cancer to develop there must be an initiating agent which alters the critical 
cell regulating genes in the body which in turn leads to abnormal cell growth. Tumour 
promotion is the second stage, when the proliferating cells increase leading to tumour 
growth. There are a variety of tumour promoters present within the body, such as
7hormones, e.g. oestrogen in endometrial carcinomas and dietary fat in colon 
carcinoma.7
1.5.2 Carcinogens
Carcinogens are the most frequently blamed agent for the initiation of cancer 
in today's society. The most commonly known intake of carcinogens is by smoking.
Since 1930 in the United States the incidence of lung cancer has increased 10 
fold which correlates closely with the increased usage of tobacco in the early stages 
of the century.7 Growth in cancer incidence is often slow as the gap between 
consumption of the carcinogen and detection of the cancer represents the multistep 
development of the cancer. Around the mid century throughout Europe it was 
actually seen to be fashionable to smoke and health warnings were ignored. This 
acts as evidence that drastic measures must be employed before a society will take 
any notice and subsequent action. After this period an increase was noted of cancer 
of the lung and larynx. An alarming statistic is that in the USA there are 27,000 
deaths per year from cancer of the lung which could possibly be avoided.7
A second carcinogenic risk is that of excessive consumption of alcoholic 
beverages. This leads to increased risk of cancers of the oral cavity, pharynx, larynx 
and oesophagus as well as cirrhosis of the liver and in turn cancer of that organ.7'9 
Fig 3 shows a selection of chemicals which are considered to be carcinogenic.7 
However, it should also be remembered that very few people handle any large 
amounts of chemicals on a daily basis apart from scientists or chemical workers.
Environmental pollution may also be considered here as much of the general 
public is under the impression that large quantities of many carcinogens are released 
by industrial pollution.7 This is actually a false belief. An example of one of the 
studies which has been performed is that of evaluation of lung cancer cases in 
Finland and Britain. Britain has a much higher degree of industrial pollution than 
Finland; however both countries have similar population and statistics for cigarette 
consumption. The findings were similar in each country verifying that industrial 
pollution in Britain was not having a detrimental effect on the number of lung cancer 
victims.7,10
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1.5.3 National Population
Examination of the epidemiology of cancers shows that there is an obvious 
factor which many people neglect to consider. The inhabitants of one country tend to 
be more prone to suffer from different types of malignancies than in another. Table 2 
shows a selection of high and low incidence rates in countries of specific cancers.
The differences in incidence rates could be due to genetic differences 
between populations or to environmental factors. The second explanation is more 
probable as studies have been completed into cancer incidence in immigrants.7,11 
This indicated that immigrants within a short period of time were showing the same 
cancer statistics as the inhabitants who had lived in that country all their lives. On 
this basis it was estimated that up to 80% of cancers may be attributable to 
environmental factors.
Cancer High Incidence Low Incidence Ratio
area area
(per 100,000)_________ (per 100,000)
Melanoma Australia (31) Japan (0.2) 155
Prostate U.S.A (91) China (1.3) 70
Liver China (34) Canada (0.7) 49
Cervix Brazil (83) Israel (3.0) 28
Stomach Japan (82) Kuwait (3.7) 22
Lung U.S.A (110) India (5.8) 19
Colon U.S.A (34) India (1.8) 19
Brain New Zealand (9.7) India (1.1) 9
Breast Hawaii (94) Israel (14) 7
Leukaemia Canada (11.6) India (2.2) 5
Table 28
91.5.4 Solar Radiation
Solar radiation in the form of ultraviolet light is the major cause of skin cancer. 
This particular type of cancer is very common but rarely is it lethal. In the USA there 
are around 600,000 cases of melanoma skin cancers (basal and squamous cell 
carcinomas) every year of which all are thought to be from exposure to sunlight. For 
comparison lung cancer has the highest cancer mortality rate in the USA. The 
incidence of lung cancer is around 160,000, which is less than 1/3 that of melanoma 
cases annually. Lung cancer accounts for a staggering 140,000 deaths per year 
whereas skin cancer accounts for 2,500 deaths per year. Thus skin cancer is 
responsible for perhaps only 1-2 % of the cancer mortality rates in the USA.7
1.5.5 Ionising Radiation
Ionisation is another form of radiation which can cause cancer. The first 
recorded case of radiation dermatitis was quoted by Haagensen in October 1902 at 
Hamburg Medical school. The patient was a worker from a factory which 
manufactured Roentgen tubes. He used his right hand as a test object in 1898. Two 
years later an ulcer developed on the irradiated area which turned out to be a 
carcinoma. The arm was amputated in 1902, but unfortunately reoccurrence of the 
cancer resulted in death in 1906.12
1.5.6 Medical Exposure
Around 250 million X-rays are performed each year in the USA, and this is a 
significant source of radiation. The average dose for diagnostic examinations is 0.5 
rem, which would relate to induction of cancer of one in one million patients. This 
accounts for 250 cancers per year.7
1.5.7 Radon and Radium
A major source of radiation exposure is from radon in the home. Radon is 
formed as a product from the decay of uranium underground which seeps into 
houses through the floorboards. Many homes which have high levels of radon gas 
have higher lung cancer incidence rates than normal. Identification and modification 
of these types of houses would dramatically reduce this risk.7
10
Radon as a source of radiation has been known for centuries. Knowledge 
dates as far back as the 16th century, in the Erzgebirge (ore mountains) which 
separate Saxony from Bohemia, and in the uranium mines of Joachimsthal and 
Scheeberg.6 Cases of lung cancer were attributed to working in an atmosphere high 
in radon.13
Radium induced cancers have also been known since 1896 with Becquerel's 
discovery. An example is that of women employed as watch dial painters who used 
luminous paint and habitually placed their brushes between their lips thus digesting 
small amounts of radium. Over a prolonged period of time this led to cases of 
aplastic anaemia, necrosis of the jaw and sarcomas.6
1.5.8 Diet
Variations in diet can increase the risk of developing some cancers as well as 
being capable of decreasing the risk of other cancers. There are many potential 
carcinogens which are found in food. But there are also many other dietary 
components which may prevent or decrease the risk of the development of certain 
cancers. This is also considered to be an environmental factor as eating habits differ 
in most countries.
Diets which are high in calories and fat have been linked to increased risk of 
cancer of the breast and colon.14 Obesity is also related to increased cancer risks of 
the uterine endometrium (epithelial lining of the uterus) which reflects a high calorie 
diet. This may be attributable to the increased levels of oestrogens produced by the 
ovaries, which act to stimulate the proliferation of endometrial cells. Fat cells also 
produce oestrogen and contribute significantly to high levels of the hormone in post 
menopausal women.7
On the other hand diets which are high in certain vitamins, selenium15 and 
compounds present in some vegetables, have been suggested to reduce cancer. 
Diets high in fresh fruits and vegetables are associated with decreased risk of many 
cancers. Diets plentiful in vitamin A and related compounds (retinoids) have been 
shown to block the development of epithelial cancers and high vitamin C diets have 
shown decreased risk of stomach cancer.7
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1.6.1 Oncogenes
Oncogenes are genes which are capable of inducing one or more 
characteristics of cancer.7 They are generally formed from proto-oncogenes during 
carcinogenesis.
Biologically active oncogenes are frequently found in carcinogenic cells and 
are absent from normal healthy cells. This would indicate that oncogenes are not 
genetically transmitted from parent to child. Instead, they are generated specifically 
in tumour cells as a consequence of genetic alterations on proto-oncogenes during 
the process of carcinogenesis. Once an active oncogene is formed it acts to drive 
abnormal cell proliferation, thus contributing to the development of the neoplasm.
The first known human oncogene was identified from a bladder tumour. The 
DNA of the bladder carcinoma was found to induce transformation of the recipient 
mouse cells efficiently, indicating that it contained a biologically active oncogene. 
Since the original discovery more than a dozen oncogene types have been identified 
in similar experiments.
The family of oncogenes which are most frequently involved in human 
carconogenesis is ras.16,17 Mutations which alter only a single nucleotide of the ras 
gene sequence suffice to convert normally functioning ras proto-oncogenes into 
potent oncogenes which efficiently induce neoplastic transformation. These 
mutations alter single amino acids at critical regulatory positions of the ras proteins, 
with the result that the ras oncogene proteins function in an uncontrolled manner. 
The ras proto-oncogenes are involved in the intracellular transmission of proliferative 
signals. Their activity within the cell is generally tightly controlled and they normally 
function as part of the response initiated by the growth factor binding to cell surface 
receptors. The proteins encoded by mutated ras oncogenes however are no longer 
properly controlled by cellular regulatory signals. Instead the oncogene proteins 
function in a continuous unregulated fashion leading to the abnormal stimulation of 
cell proliferation.
Gene amplification is a second method by which oncogenes are activated.7 It 
occurs frequently in cancer cells resulting in increasing numbers of gene copying 
which leads to the overexpression of the amplified gene. A family of genes which is 
frequently amplified is that of the myc oncogene. These genes are frequently found
12
overexpressed in a variety of tumours such as cancer of the breast and lung and 
neuroblastomas.
1.6.2 Tumour Suppressor Genes
In contrast to oncogenes which initiate the cancer process there are tumour 
supressor genes which inhibit the development of cancer.7 The function of tumour 
suppressor genes was first illustrated in experiments where normal cells and cancer 
cells were fused with each other. The resulting hybrid cells contain genes from both 
the parent cells and no longer have the full characteristics of the cancer cell. The 
tumourigenicity of the parent cancer cell is thus inhibited by the fusion of the cells 
which indicates that the genes derived from the normal parent cell act to suppress 
the tumour growth.18
An example of this type of suppressor gene is that of the p53 gene.7,8 This 
gene is found on the short arm of chromosome 17 and is frequently found as a 
mutated gene in human cancers such as brain, breast, colorectal, oesophageal, 
hepatocellular and lung carcinoma, osteosarcoma, rhabdomyosarcomas, leukaemias 
and lymphomas. The loss, mutation or inactivation of p53 has been constantly 
observed in the above cancers.19 Recently it has also been noted that inherited 
mutations of p53 are responsible for the Li-Fraumeni cancer family syndrome, which 
is associated with the development of sarcomas, breast and brain tumours and 
leukaemias.19 The inactivation of p53 has been observed in -  50% of all types of 
lung cancer and the majority of breast and colorectal carcinomas.
Now that the causes of cancer have been discussed the next chapter will be 
concerned with the treatments of the disease and physical phenomena which may be 
exploited in the employment of treatment.
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Chapter 2
2.1.1 Diagnosis
The early diagnosis of many forms of cancer will dramatically increase the 
possibility of a complete recovery without reoccurrence due to the nature of tumour 
development.
Prior to metastasis most cancers can be cured by localised treatment such as 
surgery or radiotherapy. After metastasis has occurred more dramatic treatments are 
employed in combination therapy such as chemotherapy, surgery and radiotherapy. 
Thus early diagnosis is imperative for positive prognosis.
One method for early diagnosis which is proving to be effective in certain 
cases is that of screening.
A fine example of the effectiveness of screening (if possible) is the Pap smear 
test. This was developed in the 1930s as a screening programme for cervical 
cancer. It is estimated that regular screening by Pap smear would prevent over 90% 
of deaths from cervical cancer. Such screening has in fact reduced the reported 
cases by 75% since 1940. Advantages of using the the Pap test, apart from early 
diagnosis, are that it is relatively inexpensive, safe, reliable and involves minimal 
discomfort for the patient.20
A second type of screening involving women is that for breast cancer. With 
an incidence of 150,000 cases per annum in the USA it accounts for about 30% of all 
female cancers. 1 in 10 women will suffer from this type of cancer even with 
effective mammograph screening. But it is very beneficial to catch this cancer in the 
early stages where it is likely that it could be controlled with minimal invasive 
treatments employed. The use of mammography is generally restricted to women 
over the age of 40. There are, however, a few disadvantages in the use of 
mammographs. These are the potential risk of exposure to X-rays, expense, the 
slight discomfort to the patient and the frequency of false results. The benefits 
outweigh the disadvantages immensely. Frequent physical examinations and self 
assessment of breasts are also encouraged in women of the age 40 and over to aid 
early diagnosis.21 Younger women are also encouraged to carry out self assessment 
of their breasts.
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Screening is employed in the diagnosis of colorectal cancer20 and melanoma. 
The skin is easily accessible which means that pre-existing naevia can be studied 
for malignant change. There are problems here, however, due to the lack of 
definition of who should be screened. Even restricting the screening to identifiable 
risk factors such as large numbers of common naevi, freckling tendency, history of 
severe sunburn and atypical naevi would still mean that a large proportion of the 
population would require screening. Pancreatic cancer is also screened for in cases 
where there may be an inherited predisposition, with a certain amount of success. 
Tumour markers (discussed 2.1.2) are used as a diagnostic tool in this case.
Generally annual physical examinations are recommended for people over the 
age of 40 including examination of the lymph nodes, oral cavity, prostate, testes, 
ovaries and thyroid as well as breast, cervix and colorectal cancers to aid early 
diagnosis. Unfortunately early detection may not be possible in many cases and 
symptoms may well be the first evidence of existing cancers.
The American Cancer Society has designed a method of calling attention to 
some of the early signs of many cancers which may or may not indicate the presence 
of cancers but will at least bring attention to the specific areas where symptoms exist 
and need treatment. Interestingly the symptoms spell out CAUTION!7
Change of bowel or bladder habits.
A sore that does not heal.
Unusual bleeding or discharge.
Thickening or lump in breast or elsewhere.
Indigestion or difficulty in swallowing.
Obvious change in wart or mole.
Nagging cough or hoarseness.
2.1.2 Tumour Markers
Some cancers may be detected by substances known as tumour markers. 
These are substances which are found at higher than normal concentrations in the 
blood, urine or body tissues of some cancer patients.22 A tumour marker may be 
produced by either the tumour itself or by the body in response to the presence of the 
cancerous growth. This type of phenomenon can at times be employed as a 
diagnostic tool in combination with other methods. It is not used singly due to the
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fact that many markers are found in non-cancerous patients; not every cancer has 
tumour markers; and few markers are specific to any one tumour type.
There is, however, ongoing research into the possibilities of specific markers 
for tumour types and utilising this to detect tumours before symptoms appear and 
also to follow the progression of the disease.
Carcinembryonic antigen (CEA)22 is a protein which is considered to be a 
tumour marker as more than half of the sufferers of colon, pancreas, stomach, lung 
and breast cancers have elevated CEA levels. Patients with ulcerative colitis, liver 
disease and lung infections have been shown to have elevated CEA levels but not as 
high as in the first examples.
Another tumour marker is prostate-specific antigen (PSA)22 which is produced 
by both normal and abnormal prostate cells. The levels of the antigen are useful for 
monitoring the effectiveness of the treatment over time rather than purely as a 
diagnostic tool.
Other examples are prostatic acid phosphatase, CA 125, alpha-fetoprotein, 
human chorionic gonadotrophin, lactate dehydrogenase and neuron specific enolase 
which are all used as either diagnostic or monitoring tools.
A new method which is currently employed in detection of whether a cancer 
will spread is the use of a Neoprobe detector.22 The physician uses the device to 
inject a radioactive dye into the original tumour and by placing the device around the 
tumour the sentinal lymph node, i.e. the lymph node to which a cancer is most likely 
to spread, can be detected. Thus scanning for radioactivity can identify the sentinal 
node as the one with most radioactivity. This detection system has been shown to 
be most effective in cases of melanoma and is now used in approximately 80% of 
such cases.22
2.1.3 Staging of Cancer
In order to treat the cancer it must first be established to what stage the 
cancer has developed. This is essential for determining the treatment to employ 
and likely prognosis. The concept of staging is applicable to most forms of cancer 
apart from leukaemias, since they involve the blood and are not anatomically 
localised.
16
The staging system is made up of two parts. These are grouped into four 
classes denoted by Roman numerals l-IV. Stage I cancers are usually small, 
localised and curable. Stage IV cancers are usually inoperable or have spread to be 
metastatic cancers. This definition varies from one cancer type to another and the 
prognosis will also differ, e.g. a stage II non small lung cancer will have a different 
prognosis than a stage II cervical cancer.23
The second method of staging is using the TNM system, where T stands for 
tumour, N for nodes and M for metastasis. T represents the tumour extent 0-4. T0 is 
a tumour which has not started to invade local sites. N classifies the extent of 
regional lymph node involvement. This definition depends on the cancer type. N0 
means no lymph node involvement and N4 indicates extensive involvement. M 
represents if there are metastases present, Mi, or not M0. For example T 1N1M0 is 
defined as a tumour of type Ti, Ni lymph node involvement and M0 meaning no 
metastases.7’23
A third method of cancer classification is that of the aggressiveness of the 
tumour growth. This refers to the appearance of the cells or to the percentage that 
appear to be dividing. This is graded I to IV from least to most aggressive. This is 
more important in some cancers than in others, e.g. it is very important in brain 
tumours and lymphomas.23
2.2.1 Treatments
After the cancer has been diagnosed and staged the first step on the ladder to 
recovery is to establish which is the best treatment to employ.
In general there is no one "cure” for cancer. This is because there are over 200 
different types of cancer which are treated differently depending on the type and 
stage of the cancer. A blanket "cure" has not yet been found and is unlikely to be in 
the near future.
A cancer is classed as being cured if the neoplasm recedes (or is removed) 
and does not reappear within five years of treatment. In some cases the cancer may 
redevelop but has still been classed as cured if the reoccurence is not within the five 
year limit.
There are three main types of treatment for cancer. These are surgery, 
radiotherapy and chemotherapy.7 24 These are of varying value in different situations.
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Frequently the cancer is treated by more than one, or even all three methods 
of therapy. Depending on the stage of the cancer the management may be as a 
curative or a palliative measure as many terminal patients only require treatment to 
ease pain and prolong life.
2.2.2 Surgery
Surgery is generally employed when the tumour growth is caught in the early 
stages of development. It is only successful if the neoplasm is localised and has not 
undergone metastasis and of course if it is accessible to the surgeon.
Surgery has proven to be effective in cases of malignant melanoma which is 
frequently identified early as the changes in colour of lesions etc. on the skin are 
quite noticeable. The prognosis for these patients is quite good if the growth is 
excised promptly. Unfortunately as many cancers start from inside the body it is 
often too late for this type of treatment to be successful in many patients as 
approximately 70% of cancers have already metastasised by the time of diagnosis.24
2.2.3 Uses of Surgery
Surgery is used principally as a curative treatment in cancers such as 
colorectal, breast, skin, stomach, female genital organs and prostate with a 
reasonable amount of success. It is also employed as palliative therapy in 
amputation of extremities, resection of infected, bleeding or obstructive cancers, 
severance of sensory nerve tracts and in cancers of the stomach, colorectal, lung, 
liver, pancreas and oesophagus.24 This type of therapy is more often than not used in 
combination with radiotherapy and/or chemotherapy.
2.2.4 Radiotherapy
Radiation is a DNA mutation initiator but in many cases can be used as a 
method of treatment. This is a type of treatment employed during Stages I and II of 
the disease with most success. Generally, in developed countries, around 80% of 
patients survive five years after treatment. This falls to around 20% patient survival 
rate if the disease is in the later lll-IV Stages. Similar to surgery this type of
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treatment is primarily for localised cancers but can also be used for cells which have 
spread through normal tissue beyond the scope of surgery.
A drawback of this procedure is that it is not selective to cancer cells alone but 
kills normal healthy cells, thus it may be highly toxic to the patient. This limits the use 
of such treatment.
There are five types of radiotherapy which are employed. These use photons, 
electrons, neutrons, protons and heavy nuclei.
The primary action of radiation is to damage the DNA directly or by the 
generation of chemical species such as oxygen free radicals within the cell. 
Epithelial cells are very sensitive to radiation and cause unwanted side effects such 
as anaemia, nausea, skin damage, hair loss and sterility. The extent of these 
depends on the amount of radiation and to which area of the body it is delivered.
Radiotherapy is sometimes used instead of surgery in cases such as cancer of 
the cervix, oesophagus and oral cavity where the radiation can be directed 
specifically at the tumour leaving the normal healthy cells unharmed. Hodgkin's 
disease is a form of lymphoma and is often frequently treated by direct radiation of 
the lymph nodes.24
2.2.5 Uses of Radiotherapy
Radiotherapy is used as a principally curative treatment in cancers of the 
breast, female genital organs, skin, lymphomas, primary brain tumours, prostate and 
unresectable sarcomas. Alternatively it can be used as a palliative treatment for 
bone or intracranial metastasis, control of chronic bleeding, cancer of the lung or 
reduction of elevated intracranial pressure. A factor which must also be considered 
is that cancers have varying degrees of radiosensitivity. Lymphomas and leukaemias 
have a high radiosensitivity whereas melanoma, hepatoma and other sarcomas have 
low sensitivity and respond poorly.24
2.2.6 Chemotherapy
There are a variety of different chemotherapeutic agents which are active 
against cancer via different mechanisms. These can be split into several classes
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which include alkylating agents, antimetabolites, natural products, anthracyclines and 
a miscellaneous group.
2.2.6.1 Alkylating agents
In 1962 Ross defined a biological alkylating agent as one which can replace a
hydrogen atom by an alkyl group under physiological conditions (pH 7.0 - 7.4, 37 
°C).24 25 They often have a paradoxical activity whereby they can inhibit tumour 
activity and also act as potent carcinogens.
Alkylating agents exert their anticancer action by reacting with amines, 
phosphates, sulfhydryl and hydroxy groups on crucial cellular molecules like nucleic 
acids, nucleotides and enzymes and thus inhibit their normal activity. The most 
active alkylating agents are those with two alkylating arms as they can form an 
intermolecular crosslink between different DNA strands which prevents the DNA from 
unwinding and replicating. The cell then becomes locked in the S phase and cannot 
progress through the ceil cycle which eventually leads to death of the celi.
Fig 48 shows a (3-DNA strand illustrating the major and minor grooves. The 
alkylation can take place in either of the grooves. Specific agents are selective to 
either major or minor groove which is generally dependent on size and preferred site 
of alkylation.
M ajor
g ro o v e
Mirror groove
Mnior
groove
Fig 4
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Single alkylation may lead to mispairing of bases or strand breakage which 
can also ultimately lead to cell death. The most common site of alkylation on the 
DNA is that of the N-7 position on the guanine base26 (Fig 5).
NH
NH-
GuanineDNA
Fig 5
The agents form alkyl adducts either directly or after spontaneous or metabolic 
breakdown thus inhibiting DNA replication and transcription. Steric hindrance limits 
the access of electrophiles to some nucleophilic sites whereas phosphodiester 
groups and sugar hydroxyl groups remain largely exposed to electrophilic attack. 
Some nucleophilic centres of the purine and pyrimidine bases are partially or totally 
hindered by either:
• their involvement in hydrogen bonds; or
• their position in the interior of the DNA helix and the superposition of the
electrostatic potential associated with the phosphate groups and bases
themselves which greatly reduce their nucleophilic reactivity.
This is the largest group of anticancer agents and is split into sub groups 
which are nitrogen mustards, nitrosoureas, alkyl sulfonates, triazenes and aziridines.
Nitrogen mustards generally act via an intramolecular nucleophilic substitution 
process as shown in Fig 6, forming an aziridine ring and crosslinking the DNA if the 
alkylating agent is bifunctional.
Fig 7 shows the crosslinking that can occur, i.e either inter or intra strand 
again dependent on size and preferential alkylation site sequence.
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The war gas sulfur mustard (CIChkCH^S was the first known alkylating 
agent3 originally discovered during the second world war. Examples of A/-mustards 
are mechlorethamine, chlorambucil, melphalan and lomustine. These are the most 
commonly employed group of anticancer agents.
Mechlorethamine was the first clinical chemotherapeutic agent used and is still 
in use today in Hodgkin's disease and is administered in stage IV of the progression 
of the disease.3 Other cancers where this drug is administered are of mycosis 
fungoids and malignant, pleural and pericordial effusions.3
R— N‘
Chlorambucil
Mechlorethamine
NH-
Melphalan NO
Lomustine Fig 8
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Chlorambucil is another alkylating agent in use today. This drug frequently 
encounters resistance which is attributable to cellular protective mechanisms. It is 
the phenylbutyric acid derivative of A/-mustard and is used in the treatment of 
lymphoma, ovarian cancer and breast cancer. Combined with prednisone it is 
currently a standard treatment for chronic lymphocytic leukaemia. 3
Melphalan is the phenylalanine derivative of A/-mustard which was first 
synthesised in 1953 and is employed in the treatment of melanoma, breast cancer, 
ovarian cancer and multiple myeloma.3 Finally lomustine is a rare example of an 
alkylating agent which has good activity against tumours of the brain. This is due to 
its high lipophilicity. 3
2.2.6.2 Antimetabolites
Antimetabolites are compounds with structures which are very similar to those 
of essential metabolites. They act by inhibiting the metabolising enzymes. 
Antimetabolites are taken up by the rapidly replicating cells; therefore these cells are 
selectively inhibited and antimetabolites are S phase specific. The selective toxicity 
in this case derives from a difference in rate of growth rather than a qualitative 
difference in metabolism. Antimetabolites are primarily useful in rapidly growing 
lymphomas and leukaemias rather than slower growing solid tumours.
The main metabolite analogues are the purine and pyrimidine containing 
compounds such are 5-fluorouracil, methotrexate and 6 - mercaptopurine involved in 
the biosynthesis of nucleic acids. They affect the biosynthesis of nucleic acids. This 
results in the cell being unable to produce purines or pyrimidines, thus ultimately DNA 
cannot be produced.
HN‘
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Fig 9
5-Fluorouracil3 (Fig 9) is important as it is based on biochemical rationale and 
is extensively used in breast, gastrointestinal tract, ovary, bladder, prostate, 
pancreas and hepatoma cancers.
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One mode of action of 5-fluorouracil is by the inhibition of thymidylate 
synthase (shown in Fig 10), which is essential for the biosynthesis of pyrimidines. It 
also acts by becoming fraudulently incorporated into RNA in the form of 
5-fluorouracil nucleotides and so causes confusion in base pairing during the 
transcription process.
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Methotrexate (Fig 11) is an analogue of folic acid and is effective against 
breast cancer and acute leukaemia. Its mode of action is by the inhibition of 
dihydrofolate reductase (DHFR), the enzyme which effects the reduction of folic acid. 
Without DHFR the cells are deprived of key metabolic intermediates which are 
needed to form nucleotides and ultimately nucleic acids.
Methotrexate inhibits the enzyme DHFR and since the affinity for methotrexate 
is much larger than that for dihydrofolic acid, the enzyme will preferentially bind to the 
antimetabolite. This results in the cell being unable to produce purines or 
pyrimidines, thus ultimately DNA cannot be produced.
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2.2.6.3 Natural Products
This is a group which is wide and varied in both structure and mode of action
of inhibition of cancer. The group includes doxorubicin, bleomycin, podophyllotoxins, 
the Vinca alkaloids and taxol.
Taxol (Fig 12), otherwise known as Paclitaxel, was approved for sale by the 
US Food and Drug administration in 1992 due to its significant activity in the 
treatment of patients with refractory ovarian cancer. In 1994 it was then administered 
for breast cancer. It is highly likely that it will also be approved for other cancers 
such as that of the lung.27’ 28
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Taxol is an antitubulin agent which promotes the assembly of microtubules, 
resulting in a highly stable, non functional polymer. 29"31 There is however a problem 
with the supply of this drug as a suitable industrial synthetic procedure is still in 
development. Further development of this agent may result in an important 
treatment for cancers which are not presently well controlled.
2.2.6.4 Vinca alkaloids
Vincristine and vinblastine (Fig 13) are constituents of the Madagascan 
periwinkle plant Vinca rosea and act by binding to tubulin protein which inhibits 
polymerisation. They are generally administered in stage IV and are excreted by the 
biliary tract.3
Vinblastine is used in combination chemotherapy in testicular therapy, but has 
the drawback of being highly toxic to bone marrow, Vincristine is used in childhood 
leukaemia and is toxic to the CNS. When used in combination chemotherapy 
vincristine has revolutionised the treatment of childhood leukaemia by inducing 
complete remission in 90 - 100% of cases where it is employed.
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2.2.6.5 Anthracycline Antibiotics
This group of antitumour agents has an activity spectrum which is second only 
to that of alkylating agents. They are also the most important of the natural product 
anticancer agents. 3
There are at least 5 potential mechanisms for action:
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• intercalation between DNA strands;
• membrane binding which alters the permeability of the cell and may change the 
pattern of ion transport;
• radical formation under enzymatic transformations leading to indiscriminate 
alkylation;
• chelation of metal ions, thus impairing cell function and possibly forming toxic 
organometallic compounds;
• direct alkylation.
Examples of this class are doxorubicin (Adriamycin) and daunorubicin
(Daunomycin) (Fig 14) which are isolated from different species of Streptomyces.
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Despite the wide and varied spectrum of activity of these types of agents they 
have limited use due to their toxicity and unwanted side effects.
2.2.6.6 Miscellaneous
There are several compounds which do not fit into any of the above 
classifications. Hydroxyurea is one example which acts by inhibiting ribonucleotide 
reductases. This is the enzyme that generates the deoxyribose nucleotides 
necessary for DNA synthesis.
Another example is L-asparaginase which is the enzyme which destroys 
leukaemic cells by depriving them of the L-asparagine they require for survival. 3 
Another important example is that of cisplatin (Fig 15).
Cisplatin is an example of a platinum complex which again acts by crosslinkng 
DNA . 3 It acts in four ways:
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• it binds to DNA at specific sites;
• it selectively inhibits the DNA synthesis over RNA and protein synthesis;
• it is more toxic to cells which are deficient in DNA repair;
• for equal number of DNA lesions, cisplatin inhibits the DNA synthesis to a greater 
extent than the trans -isomer which has no antitumour activity.
h3n ci
V
h3n/  ^ c i
Cisplatin
Fig 15
The podophyllotoxin derivatives, e.g. etoposide26 (Fig 16), which are extracted 
from roots and rhizomes of Podophyllum peltatum and P. emadi and are formed into 
semi-synthetic derivatives. This drug is widely used in combination with drugs such 
as cisplatin in the treatment of testicular teratoma, lymphoma, small cell lung cancer, 
leukaemia and Kaposi's sarcoma. The method of action is by O-demethylation to 
form the o/ffro-dihydroxy (catechol) derivative which may be involved in covalent 
binding to cellular macromolecules. Further reaction to form the ortho-quinone 
probably involves the formation of a semiquinone free radical which may also cause 
DNA strand breakage.
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2.2.7 Treatments by the Immune System
Biological therapies are known to use the body's immune system to fight 
cancer or to lessen the side effects which are often caused by some of the 
aforementioned treatments. The immune system itself is a complex network of 
organs and cells which work together to defend the body against any foreign invader. 
Research has proven that the immune system can recognise the difference between 
normal healthy cells and those of cancerous cells and can attempt to eliminate the 
latter. This system may, however, breakdown or become overwhelmed by these 
cells thus allowing the cancer cells to continue to proliferate.
Biological systems can be designed to repair, stimulate or enhance the natural 
anticancer function. They are often known as biological response modifiers (BRMs). 
In general they alter the interaction between the body's immune defences and the 
cancer. BRMs exist naturally in the body as cytokines and antibodies.
However, it is now possible to synthesise BRMs which can:32
inhibit tumour cell growth;
enhance the immune system against the growth;
eliminate, regulate or suppress the body response that permits cancer cell 
growth by the immune system;
make cancer cells more susceptible to destruction by the immune system; 
alter the cells growth patterns to promote behaviour similar to that of a 
healthy cell;
block or reverse the process that changes healthy cells into cancerous ones; 
enhance the ability to repair normal cell damage by other forms of cancer 
treatment;
prevent a cancer cell from spreading to other sites of the body.
These agents include a group called interferons which are a type of cytokine. 
Of the three types alpha is the most widely used in cancer treatments such as hairy 
cell leukaemia, Kaposi's sarcoma (a rare cancer of the cells lining blood vessels 
which often occurs in AIDS patients) and chronic myelogenous leukaemia. 32
Another agent class is the group of interleukins. These are made in the body. 
IL-2 (5 classes) has been studied most widely. It stimulates the activities of the 
immune cells such as lymphocytes which can destroy the cancer cells. In studies
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patients with advanced renal cell carcinoma or advanced melanoma have been 
shown to have the best response to IL- 2  therapy.32
The tumour necreosis factor (TNF) is another type of cytokine, similar to the 
previous example in that it stimulates the immune system to fight the cancer. TNF, 
however, also directly affects the tumour cells damaging them and the blood vessels 
within the cancer. Mechanisms of the action which create the damage are unclear. 
Combined with the fact that TNF is extremely toxic it has been found to act best (and 
with least unwanted toxicity) when directed at a specific tumour site rather than being 
administered throughout the body. 32
Colony stimulating factors (CSFs), sometimes called hematopoietic growth 
factors, on the other hand do not directly effect the tumour cells but encourage bone 
marrow cells to divide and develop into specialised platelets, white and red blood 
cells. Bone marrow is important to the body’s immune system because it is the 
source of all blood cells. CSFs have been found to be particularly beneficial when 
employed in combination with high dose chemotherapy. This is because the drugs 
affect the ability to make the white blood cells which are responsible for fighting the 
cancer.32
Investigations into the use of agents such as these are ongoing.
In conclusion of this section BRMs show promising developments for the 
future of treatment for many cancers in a less harsh manner than classical methods 
employed.
2.3.1 Chemoprevention
As it has now been realised that cancer is a disease which is caused by many 
factors, a simple answer would be to eradicate the possible risk areas. 
Chemoprevention may be an alternative method of cancer control.
There are a variety of methods which can be employed here. Firstly there is 
the use of diet (previously mentioned in Chapter 1).
Dietary manipulation is a chemopreventative measure which can be employed 
as diets which are high in certain foodstuffs can promote the development of cancer, 
whereas diets high in other foodstuffs can help prevent certain cancers. An example 
of this is in head, neck and oral cavity cancers which are found predominantly in 
areas where smoking levels, tobacco chewing and alcohol intake levels are high.
30
The obvious answer would be to cut out the intake of carcinogenic compounds. 
However, to alter the general public's behaviour towards activities which have been 
enjoyed for long periods of time takes much more than the cases of cancers which 
are related to such pastimes.33
If you alter the diet this may have an effect. For example, retinoids, 
carotenoids and vitamin E have all been shown to prevent the progress of chemically 
induced carcinogenesis in animal studies. 33 The mechanism of the action is as yet 
unclear but is thought to be that the retinoids affect the cell differentiation by 
stimulating cells which are depressed during carcinogenesis and by inducing 
apoptosis. They are also thought to modulate the expression of a variety of genes 
involved in growth and differentiation. G-Carotene acts as an antioxidant. It is a 
potent quencher of free radicals such as singlet oxygen as well as acting as an 
immunostimulant. Vitamin E also acts as a free radical scavenger and inhibits 
peroxidation at quite high oxygen pressure. This means that its mode of protection is 
by inhibiting lipid peroxidation and the damage caused by free radicals. Similarly to 
G-carotene it acts as an immunostimulator.
As yet altering dietary components as a strategy to prevent head and neck 
cancers is a bit premature.
A second method where chemopreventative measures are being investigated 
is in the prevention of the development of liver cancer. Liver cancer manifests itself 
mainly as hepatocarcinomas (HCCs) and ranks as the 8 th most common site for 
cancerous growths. It is a priority health problem in sub-Saharan Africa, East Asia, 
South East Asia and Melanesia. Over 90% of HCCs are related to environmental 
exposures. Chronic hepatitis, exposure to aflatoxins through food contamination and 
high alcohol consumption are though to be several of the main factors. In developing 
countries the exposure to hepatitis is thought to account for the majority of the HCC 
cases. Could this be prevented? The answer is yes, possibly through vaccination.
Oltipraz (5-2[pyrazinyl]-4-methyl-1,2-dithiole-3-thione) has been used as a 
single dose antischistosomal drug which effects the metabolism of aflatoxin B1 in 
rats. It acts by inducing the formation of glutatione S- transferase. The development 
of HCCs in rats has been shown to be inhibited with low doses of Oltripaz (0.075%  
Oltripaz with 25|ng aflatoxin B1 per oz of body weight for two weeks gave a protection 
of 100% ) . 33 This drug is in phase I and II trials to establish the safe doses and
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metabolic pathways during chronic administration. It is exhibiting some very 
promising properties as a chemopreventative agent in populations exposed to high 
doses of aflatoxins.
2.3.2 Tamoxifen
Tamoxifen, also known as Nolvadex, (Fig 17), is a drug which has been used
in clinical practice for more than 20 years.3 It is used to treat breast cancer in 
post-menopausal women in more than 100 countries. It acts by interfering with the 
activity of the female hormone oestrogen. Some breast cancer cells are oestrogen 
sensitive. The hormone binds to these cells and stimulates them to grow and divide. 
Tamoxifen prevents the binding of oestrogen. It may also benefit patients whose 
cells are not oestrogen sensitive by giving the effects of hormone replacement 
therapy. Other benefits of tamoxifen are decreased risk of osteoporosis and heart 
disease. However there are several disadvantages such as increased risk of 
cataracts, depression and cancer of the uterus.
Tamoxifen
Fig 17
Recently trials in the employment of this drug as a chemopreventative agent 
have been run. Promising results have been obtained. NCI have reported that from 
a 6  year study the use of tamoxifen has dramatically reduced the risk of developing 
breast cancer in women who are at risk by nearly half from 1 in 130 to 1 in 236.23134
Thus there appears to be great potential in the development in this area as a 
chemopreventative measure.
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2.4.1 Selectivity & Muitidrug Resistance
One of the major limiting factors in the development of chemotherapeutic 
treatment of cancer is that anticancer agents currently employed are not selective to 
cancer cells alone but kill normal healthy cells as well.
Selectivity can be encompassed on three levels, primary, secondary and 
tertiary. 38
The primary (subcellular) level is the area in cell division which is controlled by 
small molecules that initiate the processes by binding to transmembrane receptors 
which in turn pass the signal onto the growth transduction pathway to the nucleus. 
There are two broad classes of potential target molecules in this area. These are 
oncogenes (previously discussed) and their nucleic acid proteins, e.g. mRNAs, and 
secondly the protein products. The first group includes antisense oligionucleotides35, 
36 and DNA minor groove binding drugs. 3 7 ,38 The second group includes those aimed 
at selectively inhibiting protein function in the growth transduction pathway.40,41
Secondary (cellular) level is where most of the clinically used 
chemotherapeutic agents act selectively. There is still, however, very poor 
selectivity, thus their action and cytotoxicity profiles need refining. 37
On the tertiary (supracellular) level the tumours have a variety of 
microenvironments defined by the accessibility of oxygen to the cell due to limited 
vasculature networks. This leads to poor venous drainage, low pH due to increased 
glycolysis, a primitive vasculature and chronic hypoxia38,39 (discussed in 2 .6 .1 ).
A second limiting factor in the fight against cancer successfully using 
chemotherapy is that of drug resistant tumours. Many tumours may be totally 
unresponsive to certain anticancer agents. Even in tumours which are initially 
responsive a small number of drug resistant cells may be left which can proliferate 
and form another tumour which will be resistant to the original form of treatment. 
This may be due to gene amplification which occurs in many cancer cells.
Drug resistant tumours may be resistant to more than one type of agent. This 
is called multidrug resistance (MDR). An explanation for some MDR is that it results 
from expression of the gene coding of a plasma membrane protein (P-glycoprotein) 
which acts by pumping a variety of anticancer agents out of the cell before they have 
time to act, thus leading to resistance to agents such as actinomycin D, daunomycin, 
doxorubicin, vincristine, vinblastine, mitomycin C, etoposide and teniposide.
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A second area of MDR arises from alterations in topoisomerase II leading to 
resistance to daunomycin, doxorubicin, etoposide and teniposide by reacting with the 
enzyme and generating DNA breaks. Increased activity of cellular enzymes which 
repair damage to DNA can also lead to cross resistance of multiple alkylating agents.
A solution to this problem may be by combination chemotherapy, i.e. using a 
variety of different agents at once. This is useful as it is unlikely that any one cell will 
be resistant to all chemotherapeutic agents. The trick is discovering the correct 
combination of anti-tumour effects with limits on the toxicity which may be tolerated 
by the patient. A working example of this theory is the treatment of testicular cancer 
with cisplatin, bleomycin and etoposide.
2.5.1 Pharmacokinetics and Pharmacodynamics
The vast majority of conventional antineoplastic agents have a very small 
margin between the effective dose and the lethal dose, i.e. the therapeutic index is 
very low.42
The selectivity of the agents can be explained by pharmacodynamic and 
pharmacokinetic considerations.
The pharmacodynamics describe the therapeutic activity and toxicity of the 
treatment. MDR is a pharmacodynamic consideration which may be multifactorial 
and includes:42
• impaired uptake into cell or its rapid efflux by the P-glycoprotein pump;
• the utilisation of DNA repair;
• the elevation or reduction of target enzymes;
• the induction of protective mechanisms such as glutathione S- transferase.
Pharmacokinetics describes the absorption, distribution, metabolism and 
excretion of a drug. Examples of processes are :42
• the bioavailability from site of administration;
• extent of plasma protein binding;
• distribution to poorly vascularised areas or across the blood-brain barrier;
• extent and nature of biotransformation;
• rate and extent of clearance from the systemic circulation.
34
2.6.1 Hypoxia
As mentioned earlier tumour hypoxia is a phenomenon which is frequently 
found in solid tumours. If selective use of this feature can be incorporated into 
anti-tumour agents it would be a major breakthrough in the area.
2.6.2 What is Hypoxia?
Hypoxia is when cells exist in areas where the oxygen concentration is 
suboptimal for cell growth and metabolism but is high enough to maintain viability.
There are two types of hypoxia. The first of these is chronic or diffusion 
limited hypoxia. The distance at which molecular oxygen is found is limited to 150 - 
2 0 0  microns from capilliaries, thus cells this far from capillaries will become hypoxic. 
This state of hypoxia can last from hours to days. If the cells are further away than 
this we find areas of necrosis which is when the cells die due to lack of oxygen. 
Many chronically hypoxic regions are starved of glucose and other nutrients as well 
as developing a surplus of metabolic waste products.6,7< 43
Secondly we have acute hypoxia resulting from the intermittent opening and 
closing of tumour blood vessels, producing a more transient shortage of oxygen. 
This state can last from seconds to minutes. Tumour cell growth often outgrows that 
of the development of an adequate support system which may lead to the cells being 
grossly abnormal in appearance and performance.
There are several problems encountered in the existence of hypoxic regions in 
the treatment of cancer. These are the 2  - 3 fold increase in the resistance to 
radiation and also the resistance to some conventional anticancer agents, e.g. 
bleomycin and melphalan, due to the impaired vascular delivery system and the 
noncycling cell status.6 ,7 ' 43
Hypoxia may lead to the overexpression of enzymes which may affect the 
drug response.
2.7.1 Bioreducibility
A second phenomenon which can be taken advantage of to induce selectivity 
is that of the hyperexpression of reductase enzymes in solid tumours.43 Selectivity by
35
this route is called ' Enzyme Directed Bioreductive Drug Development'. The enzymes 
concerned are able to catalyse reduction of bioreducible agents. 43
Thus if we design a prodrug which will undergo metabolic reduction in hypoxic 
cells to release a toxic species which can then damage biomolecules in situ the 
selectivity would be greatly increased. These are commonly referred to as 
bioreductive or bioreducible drugs.
As different enzymes are activated to differing extents by different agents we 
could tailor agents to be activated by the reductases which are active at high levels in 
tumours and eliminate features which will be activated by enzymes which are 
predominant in normal tissues. 3
2.7.2 Bioreducible Agents
There are generally four types of compounds which are capable of undergoing 
oxygen sensitive biotransformations which are nitro, quinone, N- oxides and 
transition metal complexes.
Nitro (hetero) arenes: These are hypoxic selective cytotoxins because the
reduction of the nitro group to more toxic products (Fig 18) is inhibited by oxygen. 
This is due to reoxidation of the initial 1e' reduction product, the radical nitro anion by 
molecular oxygen. 44 This establishes a 1e' futile cycle in aerobic cells. 45 Under 
hypoxic conditions, net reduction to the hydroxylamine (4es) or amine (6 es) 
oxidation is observed. Hypoxia selective cytotoxicity requires the products of the 
nitro reduction to be more toxic than the superoxide (and other toxic species such as 
the hydroxyl radical) derived from the action of the 1 e~ futile cycle.
i e °  i  i e °
R—N02--------► R—N02-----------► R—NO
1e©
R— NH2-*— —  R— NHOH « 1e~ R— N0H
Fig 18
Quinones: The basis for oxygen selectivity is similar to that of the nitroreduction in 
that the 1 e' reduction intermediate, in this case the semiquinone, can be reoxidised 
by oxygen to inhibit net reduction in aerobic cells (Fig 19). In some cases, 
autooxidation of the dihydroquinone can also be appreciable. 46 As for the
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nitroarenes, this futile 2  e' redox cycle generates potentially active oxygen species. 47 
Since the dihydroquinones are (usually) less prone to redox cycling, they are 
substrates for conjugation. The alternative 2  e‘ reduction route is generally 
considered a detoxification pathway.
NH'
OCH
h3c
OH
OH OH
{  * DNA
W - D»A B-“
NH-
Fig 19
The reduced quinones themselves generally have low toxicity (apart from their 
propensity for reducing oxygen). Those in use usually contain potential alkylating 
functionality which is activated upon reduction. Wilson et al 49 have pointed out that 
the high reactivity of many of these quinones with thiols may be the limiting factor of 
activity in vivo.
An example of this group of compounds is Mitomycin C shown in Fig 19.
N-Oxides: (Fig 21)
Aromatic compound SR4233 has been found to be a highly selective hypoxic 
selective cytotoxin with 2 0 - 2 0 0  fold greater activity under hypoxic than aerobic 
conditions.48 In vivo activity is excellent when combined with both single dose and 
fractionated radiotherapy, and the compound is now in clinical trials. It acts by 
bioreduction as shown in Fig 2050 with oxygen inhibited reduction to the fluorescent 
triazine-1-oxide, as the major metabolite in hypoxic cells. It represents the paradigm 
for hypoxic selective cytotoxins based on the reduction of the /V-oxide.
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SR4233
1e H®
NH- Fig 20
A variety of enzymes are known to catalyse the reduction of aliphatic 
/V-oxides. The liver cytochrome P450 enzyme can reduce51 imipramine A/-oxide (Fig 
21). Reduction of aliphatic A/-oxides is easy and there is no evidence of toxic or 
reactive intermediates analogous to those generated during the reduction of nitro 
groups, quinones or aromatic /V-oxides.
Imipramine
A/-Oxide
N
/  NCH3
o
Fig 21
Transition Metals! Pt (II) complexes with nitroimadazoles have been shown to be
HSCs . 52 The nitroaromatic ligand is the active redox centre rather than the metal. 
The suggestion is that the coordination of the alkylating agents to metal through the 
nitrogen lone pair would provide the complexes in which the alkylating moiety is 
deactivated, at which point it would be reduced and could release alkylating agents. 
An example is that of the Co(lll) complex as shown in Fig 22.
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Co(lll Co(ll)l_6
H2 O
^  Co(II)(H2 0)6 + 6 L
Fig 22
1 e' reduction results in enormous labilisation of the ligands. 70 In hypoxic regions 
metabolism is possible by the displacement by water to form the stable hexa aqua 
Co(ll) species. The free ligands are now more toxic than when bound to the metal.
Fig 23 shows SN24771 as an example of this type of agent which uses 
chelating alkylating agents as ligands. However, SN24771 shows limited hypoxia 
selectivity in vitro.53 --------------------------------------------
2.8.1 Gene Targeting
The presence of oncogenes and tumour suppressor genes provides a feature
which may be exploitable. They provide a specific target for which agents may be 
developed to be specific. Is it possible to develop drugs which will interfere with the 
function of the oncogene proteins, or which will augment the activity of the tumour 
suppressor gene products? This is the main question to be asked.
A problem is posed by the fact that tumour suppressor genes and oncogenes 
are present in normal healthy cells as well as in the cancer cells. Since the products 
of the genes are critical regulators of normal cell proliferation they do not provide 
good chemotherapeutic targets. Thus the proposition is not straightforward but 
hopefully not an impossible one.
The first introduction of a recombinant gene into a human patient was on 22nd 
May 1989, at NIH in Bethesda, 54 with the purpose of marking tumour infiltrating 
lymphocytes to see where they are distributed in a patient with malignant melanoma. 
Since then there have been numerous gene marking and therapy protocols which 
have shown no serious undesirable side effects. Sustained improvement is however
SN:
Fig 23
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a problem. Gene therapy requires a considerable technical expertise and specialised 
knowledge, therefore it will not become commonplace until vectors which can be 
used as drugs can be designed.
Techniques which have made gene therapy feasible include construction of 
"designer genes", gene cloning and the ability to insert functional genes into target 
cells. Diseases for which gene targeting may be feasible include various cancers, 
AIDS, haemophilia, cystic fibrosis, various anaemias and adenosine deaminase 
deficiency.54
There appears to be a wide opportunity for the development of this area and 
investigations are currently underway.
2.8.2 Angiogenesis
Angiogenesis, the process of new capillary blood vessels formation is a 
characteristic of a number of important physiological events. New blood vessels also 
provide exits for cancer cells to spread to other parts of the body. By cutting off the 
tumours blood supply the tumour could be starved of the nutrients it needs and the 
cells would die. A drug which can cut off the tumours blood supply is known as 
angiogenesis inhibitor. As of this year there and over 300 angiogenesis inhibitors 
discovered. Some of which are established cancer drugs which have been 
“re-discovered” to have antiangiogenic properties such as taxol, 5-fluorouracil and 
interferon alpha. Work in this area is currently ongoing in many research groups.
In the next chapter work which has previously been performed in the research 
group towards the development of hypoxic selective compounds will be discussed. 
This will be followed by the discussion of our work in this area.
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Chapter 3
3.1.1 Previous Work
Previous work in the Robins research group by Dr Nicola Henderson centered 
around target compounds of 2 ,6 -disubstituted piperidine derivatives based on the 
reported anticancer activity of 2,6-bis(halomethyl)piperidines. 54,55 Compounds of this 
type could form A/-oxides, Fig 24, which should be non toxic to normal cells but under 
low oxygen conditions might be activated by reductive enzymes in hypoxic tumour 
cells to produce radicals and/or bifunctional alkylating agents.
X= Cl, Br or OCNHR
Fig 24
A/-Oxides 1 of cis and trans 2,6-disubstituted A/-methylpiperidine (Fig 24) with 
X as a carbamate or halogen were synthesised and evaluated for structure/ activity 
relationships as bioreducible prodrugs. The free bases were designed to be 
bifunctional alkylating agents active via aziridine ring formation. The c/s-isomers 
were synthesised by hydrogenation of a diester, 2, of dipicolinic acid followed by 
reductive methylation and further reduction to produce the diol, 3, then the dihalides 
and the biscarbamates were formed as shown in Scheme 1.
The trans-isomers were formed by ring closure of a dibromopimelic acid 
derivative with methylamine as shown in Scheme 2. Equilibration of the cis and 
frans-diesters 4 and 5 in acid gave exclusively the trans-diacid, from which the diol 
was obtained and converted into the dihalides and biscarbamates.
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was tested against two human carcinoma cell lines, HT29 and BE cells, under oxic 
and hypoxic conditions. HT29 cells produce high levels of DT-diaphorase, a 
reductive enzyme which favors a two electron reduction pathway, whilst BE cells 
contain no DT-diaphorase and prefer a one electron reduction pathway. The IC50 
values for this set of compounds were measured and results indicated that the free 
bases were more toxic than the /V-oxides against both cell lines. Thus the 
compounds tested were unfortunately not selective to one type of reduction pathway 
rather than the other. The reduction potentials for the /V-oxides were probably too 
high for the compounds to be reduced in biological systems.
This work was extended by the synthesis of a set of bispiperidine derivatives 
with different carbon chain lengths between the nitrogen atoms. These were 
prepared, as in Scheme 3, by esterification of DL-pipecolinic acid to give 6 , followed 
by the condensation of the free base with aliphatic diacid chlorides of varying chain 
lengths e.g. to give 7 if chain length is two carbons. This was followed by successive 
reduction of the diamide with borane-THF and the diester with lithium aluminium
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hydride to give the diester 8 and diol 9 respectively. The resulting diol was 
chlorinated using thionyl chloride, and the carbamates were formed using 
p-nitrophenyl isocyanate. The final products were obtained as mixtures of a racemic 
and meso form, as in Fig 25.
COoEt
NH'/^ ,C02Et 
R HCI
(i) Et3 N, acid chloride
(ii) B2 H6, THF ^
(iii) UAIH4
(iv) thionyl chloride's
OH
HO Scheme 3
Biological testing as before revealed that the cytotoxicity was dependent upon the 
length of the carbon bridge between the two nitrogens. The compounds with four 
carbons between the nitrogens were the most cytotoxic towards both of the human 
colon cell lines, e.g. IC50 20 pm for n = 3 and X = Cl. The sequence selectivity of 
compounds with n = 1 to 5 and X = Cl as the free bases was studied using SV40 
early promoter DNA by Professor Wakelin in Dublin and Professor John Hartley in 
London. The compounds which crosslink DNA were shown to alkylate guanines at 
the N-7 position in the major groove of DNA more selectively than melphalan. The 
bispiperidine system with two carbons between the nitrogens was the most reactive 
but it was less cytotoxic than melphalan in a human colon carcinoma cell line (IC50 
value ca. 30 pM) and in a human chronic myeloid leukaemia cell line (IC50 value ca. 
12 pM). The most cytotoxic compound was the p-nitrophenyl carbamate with an IC50 
value of 0.3 pM against the chronic myeloid leukaemia cell line. In general the 
carbamates which were tested were less efficient crosslinkers of DNA. The 
biscarbamates with n = 1,3 and 4 as free bases were tested against a panel of 
ovarian carcinoma cell lines in vitro by Dr Kelland at the International Cancer 
Research laboratory in Surrey and showed IC50 values comparable to that of
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cisplatin. Moreover none of cell lines showed cross resistance to the compounds 
tested . 56
The DNA sequence specificity of bispiperidines and their potency warranted 
further study of structure/activity relationships. This is the concern of the remainder
of this chapter. ______________________
3.2.1 Variations on the Lead Compound
In examination of Fig 26, there is a sizable set of features within the system 
which can be altered to establish structure/activity relationships and to optimise the 
selectivity and the cytotoxicity towards cancer cells.
The variables which were considered are:
• ring size;
• number of rings;
• number of carbons between the nitrogens;
• stereochemistry;
• leaving group;
• number of atoms between nitrogen and leaving group; and
• number of potential alkylating sites.
Fig 25
Fig 26
3.2.2 Ring Size
Previous compounds which have been tested have been six membered rings 
with one nitrogen present. What effect on the biological activity would reducing the
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number of atoms in the ring to five with one nitrogen have? Using the five membered 
amino acid proline as the starting material would allow us to investigate this variable.
3.2.3 Number of Rings
The previously tested compounds contained two ring systems. What effect 
would having one ring or no ring systems present have on the biological activity if the 
alkylating potential was retained in a N-C-C-CI system?
3.2.4 Number of Carbons between Nitrogens
The number of carbons between the nitrogens of the ring systems can be 
varied to find the optimum bridge length for crosslinking to occur. This also presents 
the possibility of alkylating at different sites within the major groove if the molecule is 
long and unconstrained, thus different sequence specificity may be observed.
3.2.5 Stereochemistry
Most of the previously tested compounds were mixtures of stereoisomers. If 
the compounds were enantiomerically pure would the biological activity increase or 
decrease? L-Proline is readily available and reasonably priced, which makes it a 
good starting material for the synthesis of the bispyrrolidine ring systems.
3.2.6 Leaving Group
The compounds previously tested were either chlorides or p-nitrophenyl 
carbamates. The systems synthesised in this work will have either of these two 
leaving groups or a 2,4-difluorophenylcarbamate as the leaving group. This 
derivative was chosen to avoid the possibility of radical formation from nitro groups in 
in vitro studies.
3.2.7 Number of Atoms between Nitrogen and Leaving 
Group
The mechanism of action of the previously synthesised and tested compounds 
is believed to be aziridinium intermediate formation. To provide further evidence for
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this theory compounds with three rather than two atoms between the nitrogen and 
the leaving group will be synthesised.
3.3.1 Synthesis of Analogues
3.3.2 Bispyrrolidine Derivatives
The first set of compounds synthesised in this project contained two 
pyrrolidine rings with between two and eight carbons between the two nitrogens of 
the rings. The leaving group was consistently chlorine. This changes the ring size, 
varies the bridge length and should lead to enantiomerically pure products.
OH .OCH-
NH NH
.HCI
(i) thionyl chloride, MeOH
Scheme 4
The first step in the synthesis was the formation of the methyl ester as the 
hydrochloride salt, shown in Scheme 4. This was obtained by treating L-proline in 
excess MeOH with thionyl chloride and heating at reflux.57 The product 12 was 
obtained as a white solid in high yield with spectroscopic data in agreement with 
literature values.
OCH
.OCH-
NH
.HCI
n = 0 13 
n = 1 14 
n = 2 15 
n = 3 16 
n = 4 17 
n = 5 18 
n = 6  19
(i) acid chloride, Et3 N, CHCI3
Scheme 5
The key step was to couple two of these molecules, as shown in Scheme 5, 
using the appropriate acid chloride e.g. oxalyl, malonyl, succinyl, glutaryl, adipoyl, 
pimeloyl and suberoyl dichloride to produce two through to eight carbons between the
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nitrogens of the two proline systems. The reaction was performed in chloroform with 
two equivalents of triethylamine as a base to form the proline free base in situ and to 
mop up the HCI acid formed in the reaction and hence minimise ester hydrolysis. 
The bispyrrolidine systems were obtained generally as viscous clear oils after 
purification by column chromatography. The yields were reasonably high after 
optimisation for each of the coupling experiments.
The common trends throughout these seven diester diamide compounds were the 
presence of the two carbonyl carbon peaks in the 13C NMR spectra at approximately 
5 169 and 6 172 corresponding to the amide and ester carbonyl carbons. The IR 
spectra also showed the ester and amide carbonyl stretches at approximately 1737 
and 1635 cm-1 respectively. All compounds gave satisfactory accurate mass data.
OCH OH
n = 0  2 0  
n = 1 21 
n = 2  22 
n = 3 23 
n = 4 24 
n = 5 25 
n = 6  26
n = 0 13 
n = 1 14 
n = 2 15 
n = 3 16 
n = 4 17 
n = 5 18 
n = 6  19
HO
Scheme 6(i) UAIH4 /T HF
The next step was the reduction of both the diamide and the diester to form 
the diol, shown in Scheme 6. In the bispiperidine systems previously formed54 the 
amide was reduced using borane.THF followed by ester reduction with LiAIH4 in THF  
as the solvent. Here the diester and the diamide were reduced simultaneously with 
UAIH4 in dry THF to afford the free base diols in good yields as clear viscous oils. In 
the 13C NMR spectra of the diols there was the common feature of absence of any 
carbonyl carbon peaks. The carbonyl stretches were also absent from the IR spectra 
but with the addition of new bands at approximately 3400 and 1415 cnr1 
corresponding to the hydroxyl stretch and bend. The 1H NMR spectrum showed the
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hydroxymethylene as a broad singlet at -  8 3.5. The accurate mass data were 
satisfactory.
The final step in this sequence was the conversion of the diol into the 
dichloride. This was done simply using either the diol neat or the diol in chloroform 
and neat thionyl chloride, as shown in Scheme 7. The products were obtained as 
white to light yellow solids which were recrystallised from EtOH and diethyl ether. 
The IR spectra of the dichlorides showed an absence of the hydroxyl bands 
previously observed and additional bands at ~765 cm-1 for the CH2-CI stretch. The 
13C NMR spectra also indicated the presence of the CH2-CI carbon by the CH2 signal 
at 8 55 and absence of the CH2-OH carbon signal. The accurate mass data were 
consistent with the structures.
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(i) thionyl chloride Scheme 7
Analogous compounds were prepared from DL-proline. The methyl ester 
hydrochloride salt was formed from excess MeOH and thionyl chloride as a white 
solid in acceptable yields as shown in Scheme 8. The 13C NMR spectrum showed 
the presence of the five carbons from the DL-proline and also the presence of the 
methyl ester carbon at 8 53.9. The 1H NMR spectrum confirmed the methyl ester 
synthesis by the singlet at 8 3.8 corresponding to 3 protons intensity.
The coupling of the methyl ester hydrochloride salt was again the most 
problematic step using the appropriate acid chlorides e.g. succinyl, glutaryl and 
adipoyl dichloride to obtain four, five and six carbons between the nitrogens of the 
ring systems as shown in Scheme 9.
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The yields were acceptable and the products were clear viscous oils. The 13C 
NMR spectrum showed the presence of the amide and ester carbons at 8  173.3, 
173.2, 171.3 and 171.2 for n = 2. There are two signals for each carbon as there will 
be a mixture of stereoisomers arising from chiral centres being RR, SS (racemic) and 
RS (meso). The IR spectra also confirmed the presence of two carbonyl features by 
the presence of stretches at 1735 and 1635 cm-1 which again corresponds to the 
ester and amide carbonyl stretches. The accurate mass data was satisfactory.
OCH-
OCH
NH
.HCI
n = 2 36 
n = 3 37 
n = 4 38CH30 ^ 
(i) acid chloride, EfeN, CHCI3
Scheme 9
OCH- OH
n = 239 
n = 3 40 
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HO
Scheme 10(i) UAIH4 /THF
Reduction of the diester and diamides was performed simultaneously using 
LiAlhU to afford the appropriate diol systems as oils in reasonable yields as shown in 
Scheme 10. The IR and 13C NMR spectra confirmed the structures with the absence 
of the carbonyl stretches and the carbonyl carbon respectively. The presence of 
hydroxyl stretches in the IR at -1402 and 1081 cm' 1 was observed. The final step
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was the formation of the dichloride leaving group by substitution of the alcohol by the 
chloride. This reaction was performed by stirring the diol in neat thionyl chloride at 
room temperature as shown in Scheme 11. The products were obtained as off white 
solids after recrystallisation from EtOH and diethyl ether. The IR spectra indicated 
the absence of the hydroxyl group and presence of the chloride at -  745 cm 1.
OH
n = 2 42 
n = 3 43 
n = 4 44
n = 2 39 
n = 3 40 
n = 4 41H0‘
Scheme 11(i) thionyl chloride
3.3.3 Single Ring Systems
The set of single piperidine ring systems with two and three carbons between 
the nitrogen and the leaving group were formed starting with 
/V-methylpiperidine-2-methanol and piperidine-2-ethanol. This was done to 
investigate the biological mechanism of action in single rather than two ring systems 
with different leaving groups. These will be chloride, as before, and two carbamate 
systems: p-nitrophenyl and 2,4-difluorophenyl carbamates.
The carbamates were formed because:
• they are reasonably stable which allows ease of handling;
• their ease of formation;
• carbamates are generally crystalline therefore are easily purified and 
characterised;
• the p-nitrophenyl carbamate has the potential for added cytotoxicity by the 
formation of radicals.
Starting with A/-methylpiperidine-2-methanol, which is readily available, the 
only step was the conversion of the alcohol into the chloride. This was done in the 
usual manner by stirring in neat thionyl chloride at room temperature and the product 
was recrystallised from EtOH and diethyl ether. This was achieved in reasonable 
yield to give the desired product as shown in Scheme 1 2 .
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Carbamate formation was performed using the appropriate isocyanate e.g. 
p-nitrophenyl isocyanate or 2,4-difluorophenyl isocyanate, the diol and a catalytic 
amount of dibutyltindiacetate as shown in Scheme 13. The reaction goes reasonably 
quickly and cleanly at room temperature in dichloromethane to afford the desired 
products. The mechanism is as shown in Fig 27. The 1H NMR spectrum of 47 
showed the presence of the p-nitrophenylcarbamate group by an AA'BB' system 
corresponding to the aromatic protons at 8  8.2- 7.6 and a broad singlet at 5 5.0 
corresponding to the secondary amine proton and the tertiary amine methyl singlet 
signal at 8  2.6. The IR spectrum showed the presence of a carbonyl by the stretches 
at 1739 cm 1, amine stretch at 3426 cnr1 and aromatic stretches at 1598 and 1508 
cm-1. Similarly for the 2,4-difluorophenyl carbamate compound 48 1H NMR signals at 
8  7.4- 6.7 were observed corresponding to the aromatic protons and the tertiary 
amine methyl signal at 8  2.5. The IR spectrum showed the presence of the 
carbamate carbonyl stretch at 1730 cnr1 and aromatic stretches at 1506 and 1612 
cm'1.
(i) isocyanate, Bu2 Sn (OAc)2i DCM Scheme 13
Both the p-nitrophenyl and 2,4-difluorophenyl carbamates were obtained as 
described above. The yields however were quite poor as purification by column 
chromatography on alumina was required with a large loss of product. The 
carbamate products were obtained as a yellow solid and white crystals respectively 
as shown in Scheme 13.
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In order to make compounds with three carbons between the N and the 
leaving group piperidine-2-ethanol was protected by A/-methylation using 
formaldehyde and formic acid as shown in Scheme 14. Here the use of formic acid 
is rather unusual as it is acting as a reducing agent. This is one of the few organic 
acids which can be used in such a manner. The reaction required heating to afford 
the desired product as a viscous slightly yellow oil.
OHNH‘ OH
50
(i) formic acid, formaldehyde Scheme 14
The 1H NMR spectrum for compound 50 showed the presence of the tertiary 
amine methyl by a singlet at 5 2.2 corresponding to 3 protons. The 13C NMR 
spectrum also showed the presence of this carbon by a methyl signal at 6  41.5.
The chloride 51 was obtained by stirring the A/-methylated piperidine-2-ethanol 
in thionyl chloride at room temperature as shown in Scheme 15. The resulting light 
yellow solid was then recrystallised using EtOH and diethyl ether in reasonable yield. 
The structure of 51 was confirmed by the absence of the hydroxyl stretch in the IR
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spectrum and the presence of a CH2 signal at 8  40.4 in the 13C NMR spectrum 
representing the CH2CI carbon.
(i) thionyl chloride Scheme 15
The carbamates 52 and 53 were obtained as previously mentioned using the 
appropriate isocyanates, dichloromethane and a catalytic amount of dibutyltin 
diacetate as shown in Scheme 16. They p-nitrophenyl carbamate was obtained as a 
canary yellow solid and the 2,4-difluorophenyl carbamate was obtained as white 
crystals. Again the yields were rather disappointing as alumina column 
chromatography purification was required. The structure of the p-nitrophenyl 
carbamate, 52, was confirmed by its 1H NMR and IR spectra showing carbamate 
carbonyl stretch at 1741 and aromatic stretch at 1505 and 1599 cm*1. The 
2,4-difluorophenyl carbamate 53 structure was also confirmed by the presence of 
aromatic signals at 8  7.3- 6.7 of intensity 3 protons as well as the signals of the 
original compound. The 13C NMR spectrum showed the aromatic carbons at 8  111.2 
to 8  124.1, the tertiary amine methyl at 8  39.8 and the carbonyl carbon at 8  154.2.
(i) isocyanate, Bu2 Sn(OAc)2 , DCM Scheme 16
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3.3.4 Straight Chain Systems
To examine systems without a ring in the structure and with two or three
carbons between the nitrogen and the leaving group and altering the leaving group 
the following compounds were synthesised .
OH 
2
NH \  /N H  -------- ►! 9  \
54 5 5^ >OH
(i) ethylene oxide, EtOH Scheme 17
Starting from A/,A/-dimethyl-1,6 -hexanediamine, 54, the hydroxyethyl arms of 
compound 55 were formed using an excess of ethylene oxide in EtOH by the method 
of Hancock et a l 58, as shown in Scheme 17. The structure of compound 55 was 
confirmed by 1H NMR spectroscopy showing methylene protons at 5 3.6-3.5 
corresponding to the protons next to the hydroxyl and the 13C NMR spectrum showed 
CH2 signals at 5 61.7 and 5 56.9 corresponding to the carbons of the hydroxyethyl
arms.
OH Cl
N ^ ) 2 (i)
^ >OH ^ > C I
(i) thionyl chloride Scheme 18
Again the dichloride, 56, of the diol, 55, was easily formed using excess neat 
thionyl chloride at room temperature as shown in Scheme 18. The structure of the 
product was confirmed by the absence of hydroxyl stretches and presence of CH2CI 
stretch at 619 cm' 1 in the IR spectrum. The 13C NMR spectrum showed the carbons 
of the chloroethyl arms at 5 57.2 and 5 56.6 which is much lower than those of the 
hydroxyethyl group.
The biscarbamates, 57 and 58, were formed from the diol using the 
corresponding isocyanate, dibutyltindiacetate and dichloromethane as shown in 
Scheme 19.
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(i) isocyanate, BuaSrKOAc ,^ DCM r
F
Scheme 19
R=
The structure of the p-nitrophenyl compound was confirmed by the presence 
of aromatic stretches at 1498 and 1598 cm' 1 and NH stretches at 3077 and 3365 cnrr1 
in the IR spectrum. The 1H NMR spectrum showed a AA'BB' system for the aromatic 
protons of intensity 8  protons at 5 7.9-6.5 and the methyl on the tertiary amine as a 
singlet of intensity 6  at 5 2.9. The 2,4-difluorophenyl carbamate 58 was confirmed by 
13C NMR spectroscopy showing a signal at 5 154.2 corresponding to the carbonyl of 
the carbamate system and the methyl signal at 5 39.8 corresponding to the methyl on 
the amine. The 1H NMR spectrum showed the presence of aromatic protons of 
intensity 3 at 5 7.3-6.7 and a singlet at 5 2.6 of intensity 6  protons, corresponding to 
the amine methyl protons. The IR spectrum showed the carbonyl stretch at 1734 
cm'1, the secondary amine stretch at 3441 cm' 1 and the aromatic stretches at 1526 
and 1626 cm'1.
(i) bromopropanol, acetonitrile
Scheme 20
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The hydroxy propyl groups were attached to form compound 60, on treatment 
of A/, A/-dimethyl-1,6 -hexanediamine, 59, with 3-bromopropan-1-ol in acetonitrile as 
shown in Scheme 20. The structure was confirmed by the presence of CH2 signals 
at 5 60.9, 57.6 and 35.1 in the 13C NMR spectrum corresponding to the hydroxypropyl 
group. The IR spectrum also shows the presence of the hydroxyl group with
stretches at 3642 and 1092 cnr1.
OH Cl
( [ £  60X
V- ^OH
(i) thionyl chloride Scheme 21
The dichloride, 61, was formed using excess thionyl chloride at room
temperature as shown in Scheme 21 and the structure was confirmed by the 
absence of hydroxyl stretches in the IR spectrum but the presence of the CH2-CI 
stretch at 750 cm*1. The 13C NMR spectrum showed the CH2 next to the chloride at 5 
56.7.
The biscarbamates, 62 and 63, were formed from the diol using the
corresponding isocyanate, dibutyltindiacetate and dichloromethane as shown in 
Scheme 22. The structure of the p-nitrophenyl carbamate 62 was confirmed by the 
1H NMR spectrum showing an AA'BB' system corresponding to the aromatic protons 
of intensity 8  at 5 8 .1-6.6. A broad singlet at 5 4.3 indicated the secondary amine 
proton and the singlet of intensity 6  protons at 83.05 corresponded to the methyl
groups attached to the amine. The IR spectrum showed aromatic stretches at 1508
and 1628 cm*1 as well as the carbamate carbonyl stretch at 1736 cm*1 and the NH 
stretch at 3371 and 3481 cm*1. The 2,4-difluorophenyl carbamate, 63, showed 
similar signals in the IR spectrum of 1512 and 1612 cm*1 for the aromatic stretches, 
and for the NH stretches at 3083 and 3433 cm*1 and at 1728 cm*1for the carbonyl 
stretch of the carbamate.
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3.4.1 Biological Evaluation
The compounds synthesised were tested by Professor John Hartley at 
University College London for cytotoxicity, DNA sequence specificity59 and DNA 
crosslinking60 ability against a human leukaemic K562 carcinoma cell line.
3.4.2 Sequence Specificity
A polymerase stop assay has been developed to determine the DNA 
nucleotide sequence specificity of covalent modification by antineoplastic agents 
using the thermostable DNA polymerase from Thermus aquaticus and synthetically 
labelled primers. The products of linear amplification are run on sequencing gels to 
reveal the sites of covalent drug binding. The method has previously been used to 
study a number of agents including nitrogen mustards, platinum analogues and 
mitomycin C which all agree with the sequence specificity obtained by other 
procedures. The assay is advantageous in that it is not limited to a single type of 
DNA lesion (as in the piperidine cleavage assay for guanine N-7 alkylation) , 55 does 
not require a strand breakage step and it is more sensitive than other primer 
extension procedures which have only one polymerisation cycle. In particular this 
method has considerable potential for examining the sequence selectivity of damage 
and repair in single copy gene sequences in genomic DNA from cells.
The biological evaluation was carried out as reported in the literature. 59
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3.4.3 Agarose Gel method for the Determination of DNA 
Interstrand Crosslinking
Many agents used in the treatment of cancer are bifunctional and are able to 
crosslink biological macromolecules. The most important target is DNA. The 
formation of the interstrand crosslinks may be the most relevant cytotoxic lesion. 
Such lesions are formed by an initial covalent reaction of drug with an electrophilic 
site on the DNA to form a monoadduct which can be converted into a crosslink by a 
second reaction with the other DNA strand. Not all monoadducts are converted into 
crosslinks and the "second arm" reaction is generally assumed to be slow compared 
to the initial monoadduct formation.
There are several techniques for measuring DNA interstrand crosslinking. In 
many cases they are based on the fact that covalently crosslinked DNA strands are 
prevented from complete denaturation by heat or by alkali.60 Many of these 
techniques are insensitive and time consuming. They may also require large 
amounts of DNA and drug and are generally not applicable to detailed time-course 
experiments. The method used by us is a simple highly sensitive agarose gel 
method for measuring interstrand DNA crosslinks and in particular the kinetics of 
formation of total crosslinks.
The densitometric quantitation of double and single stranded DNA within the 
same sample lane allows the extent of crosslinking to be calculated directly without 
having to take into account sample processing or loading variations. The use of 32P 
end labeled DNA makes the technique sensitive enough to measure 10 ng DNA or 
less per lane (depending on required autograph exposure). This DNA is then 
denatured by either heat or alkali. The choice of buffer may be important, in 
particular phosphate buffers should be avoided as phosphate precipitates with 
ethanol which does not then dissolve in the strand separation buffer making gel 
loading difficult.
This method is particularly applicable to detailed time-course experiments 
such as "second arm" crosslinking and compliments the technique of alkaline elution 
experiments without the influence of complicating cellular factors such as DNA repair 
and the quenching of DNA monoadducts.
The biological evaluation was carried out as reported in the literature.60
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3.4.4 MTT Based Cytoxicity Assay
Cytotoxicity tests are widely used to evaluate the effects of anticancer drugs
on different cancer cell lines. Clonogenic assays use plating efficiency, either on
plastic or on agar, as an end point such that the number of colonies relative to the 
control indicates the number of cells that survived the treatment. Also, the size of the 
colony can indicate whether the treatment was cytotoxic, cytostatic or mitogenic. 
These assays are slow and the development of microtitration assays has been of 
enormous benefit to those who screen new compounds for cytotoxic activity. The 
end point of a microtitration is an estimate of the number of cells. This can be found 
by either counts or by methods such as isotope incorporation. Use of MTT testing as 
a cell viability measure61 can be chosen at an end point.62 MTT is a yellow water 
soluble tetrazolium dye that is reduced by live, but not dead cells, to form a purple 
formazan product that is insoluble in aqueous solutions. It should be noted however 
that a number of factors can effect the reduction of M TT .63
Cells in exponential phase of growth were exposed to the cytotoxic drug of 
interest. The duration of the exposure was usually determined as the time required 
for maximal damage to occur but were also influenced by the stability of the drug. 
After removal of the drug the cells were allowed to proliferate for two to three 
doubling times in order to distinguish between cells which remain viable and are 
capable of proliferation and those which remain viable but cannot proliferate. 
Surviving cell numbers can then be determined indirectly by MTT dye reduction. The 
amount of MTT formazan produced can be determined spectrophotometrically once 
solubilised in a suitable solvent. It is important to note that the following conditions 
are met.
• MTT colour is shown to be in the linear range of dependence on the cell number;
• The colour produced is proportional to the time under MTT exposure.
3.5.1 Conclusions from Biological Testing
The four sets of compounds all underwent the above biological tests with 
results shown in Tables 3, 4 and 5.
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The results overall were rather disappointing as the activity observed for 
compounds was nowhere near as promising as in the original set of compounds.55 
However, there were several interesting conclusions.
% Crosslinking
No. IC50 pM 00.1 pM 0.1 pM 1.0 pM 10.0 pM
28 > 100 0 0 0 0
29 50 0 0 0 6.2
30 > 100 0 2 13 84
31 52 0 0 10.4 56.2
32 >100 0 0 4 41
33 > 100 0 2 2 52
Table 3
% Crosslinking
No. IC50 pM 0.01 pM 0.1 pM 1.0 pM 10.0 pM
61 > 100 0 0 0 0
62 5 0 0 0 0
63 30 0 0 0 0
56 > 100 0 0 44 -
57 21 0 0 0 0
58 > 100 0 0 0 0
Table 4
% Crosslinking
No. IC50 pM 0.01 pM 0.1 pM 1.0 pM 10.0 pM
46 > 100 0 0 0 0
47 30 0 0 0 0
48 > 100 0 0 0 0
51 > 100 0 0 0 0
52 > 100 0 0 0 0
53 > 100 0 0 0 0
Table 5
Chlorambucil IC50 45 pM 
Melphalan IC50 8.5 pM
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3.5.2 Leaving Groups
From the IC5o values of compounds 62 at 5 pM, 57 at 2 1  pM and 47 at 30 pM 
we observe that the most cytotoxic compounds were the ones containing the 
p-nitrophenyl carbamate functionality. The difluorophenyl carbamate is the second 
most cytotoxic leaving group and chlorides were the least in these compounds. This 
could be explained by the possibility of the lone pair on the nitrogen attacking the 
carbonyl group and expelling the amine ring with the nitro group still attached as 
shown in Fig 28. It could also be suggested that the nitro carbamates are more 
cytotoxic than the difluorocarbamates by the formation of radicals from the nitro 
groups.
Fig 28
3.5.3 Ring Systems and Linker Length
It was also obvious that compounds with two ring systems were more active 
than the single piperidine or straight chain systems independent of leaving group 
featured. Compound 31 with the six carbon unit between the ring systems appears 
to be the best compound tested with IC50 value of 52 pM and crosslinking of 10.4 % 
at 1.0 pM and 56.2 % at 10.0 pM.
The single piperidine ring systems behaved as expected and there was no 
crosslinking activity observed as there is only one site for alkylation. There was also 
very little cytotoxicity shown in the piperidine ring system apart from 47 with ICso 
value of 30 pM which was for the p-nitrophenyl carbamate system.
Reasonable crosslinking values were obtained from the bispyrrolidine systems 
with five and eight carbon linker units showing crosslinking at concentrations as low 
as 0.1 pM.
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3.5.4 Ring Size and Stereochemistry
The bispiperidine systems were generally found to be better crosslinkers and 
more cytotoxic than the bispyrrolidine systems. Thus the conclusions are that the six 
membered ring systems were preferable to the five membered rings. It should be 
remembered, however, that the bispiperidine compounds were tested as a mixture of 
distereoisomers whereas the bispyrrolidine were tested as single ll enantiomers thus 
no conclusions can be drawn about the effect of stereochemistry on the biological 
activity observed. Results from testing of diastereoisomers of the bispyrrolidine 
systems were inconclusive due to solubility problems encountered by the tester.
62
Chapter 4
4.1.1 Macrocyclic Alkylating Agents
The main concern of this chapter is to discuss the progress from the synthesis 
of monofunctional and bifunctional alkylating agents to the design and synthesis of 
novel alkylating agents which contain a variable number of sites capable of 
alkylation.
The use of linear and branched polyamines in the treatment of cancer has 
previously been reported,64,65,66 thus an alternative strategy would be the development 
of cyclic polyamines. An area which is, as yet, unexplored is that of multifunctional 
macrocyclic alkylating agents.
This chapter is concerned primarily with the formation of azamacrocycles as 
alkylating agents, i.e. cyclic systems with nitrogen as the only heteroatom present 
within the ring structure. These systems have been designed to incorporate a 
selection of structural variations in an attempt to establish structure/ biological activity 
relationships within the series.
4.2.1 History of Macrocycles
The basic defintion of a macrocycle is that it is a heterocyclic ring, comprising
of nine or more atoms, of which at least three are non-carbon atoms such as 
nitrogen, oxygen, sulfur, phosphorus etc.67
Why should there be an interest in the synthesis of azamacrocycles? 
Macrocycles and their metal complexes have been of great chemical and biological 
interest for many years. Macrocyclic ligands which contain heteroatoms are 
important complexing agents for cations, anions and neutral molecules. The 
presence of similar compounds in many fundamental biological processes has 
stimulated their study. Such compounds include porphyrins and corrins which play 
an important part in the biological process of transporting oxygen in mammals and 
photosynthesis in plants, respectively.67 [Other examples of biological processes 
involving macrocycles are reported by Hosseini and Lehn 1987,68 Lehn 198569 and 
Yohannes et al. 198570.]
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In particular azamacrocycles have undergone intensive investigation since 
their discovery over a hundred years ago when Bayer in 1886 prepared 
tetraazaquatren71 (Fig 29).
Fig 29
Azamacrocyles were established well before the discovery by Pedersen of the 
oxygen containing ligand 18-crown-6 in 1967.72
Properties of such compounds are determined by the fact that the nitrogen 
has a much stronger association with transition metal ions than oxygen. Oxygen is 
also more electronegative therefore the electron pair in nitrogen is more available for 
complexing purposes. This is an interesting phenomenon in this study as the 
potential for hypoxic selectivity could be exploited in the alkylating agent by the use of 
metal complexes which could be bioreduced in the body as mentioned previously. 
Azamacrocycles have properties which are intermediate between oxygen crown 
ethers, which strongly complex alkali and alkaline metal earth ions, and those of 
aza-oxa crowns which strongly complex heavy metal ions. Thus there is a wide 
scope for the development of azamacrocyclic alkylating agents.
4.3.1 Nomenclature
There are a variety of methods which are currently in use for naming 
macrocycles. In the method of Busch and co-workers67 the size of the macrocycle is 
given in brackets followed by the number and types of heteroatoms present within 
the system. For example, cyclam (Fig 30), which is one of the more commonly 
known azamacrocycles, is written as [14]N4. This, however, does not explain exactly 
where the nitrogens are positioned within the ring system. Therefore, in this thesis a 
variation on this theme will be employed. The structure will be written fully, by 
numbering the systems from the heteroatom with the highest atomic number as in 
Journal of Chemical Society papers listed in references. Cyclam will be written as
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1,4,8,11-tetraazacyclobutadecane. Also shown in Fig 30 are cyclen:
1,4,7,10-tetraazacyclododecane and tacn: 1,4,7-triazacyclononane which are both 
well known azamacrocycles. This means we are stating exactly what heteroatoms 
are positioned where within the macrocyclic systems.
NHNH HN.
NH
NH4 NH HN'
Cyclam
4.3.2 Methods of Synthesising Azamacrocycles
Generally there are two main commonly employed methods of synthesising
macrocycles. These are by template synthesis and by high dilution techniques.
The first reported synthesis of a macrocycle was by Baeyer in 1886.71 He 
used the condensation of pyrrole and acetone in the presence of mineral acid and 
achieved a 88% yield. Following this there were numerous attempted and 
successful syntheses of a wide variety of macrocycles. These are too numerous to 
mention and many are described in the review from a historical viewpoint by 
Newkome and coworkers.67 The following workers have made considerable 
contributions in the area: E. Blasius (polymer-containing macrocyclic ligands); A. V. 
Bogatskii and I. G. Lukyanenko (prepared hundreds of aza-oxa macrocycles); D. H. 
Busch (template synthesis of aza-oxa macrocycles); J. M. Lehn (biological-like 
aza-oxa macrocycles); M. Okahara (ring closure of diols with tosyl chloride); P. 
Paoletti (complexing properties of aza-oxa macrocycles); J. E. Richman and T. J. 
Atkins (tosylamide ring closure reactions) and H. Stetter (first prepared macrocyclic 
diamides) all of which are discussed by Newkome.67
4.3.3 Synthesis Using Templates
There has been a wide and varied array of methods employed in the synthesis 
of macrocycles over the past 20 years. They have been in the main unsuccessful
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and highly wasteful due to low yields of the desired product; use of large volumes of 
solvent; and competing side reactions which may occur.
The first reported synthesis of a macrocycle by employing template cyclisation 
techniques was in 1907 during the synthesis of phthalimide in a ferrous ion complex 
of phthalocyanine.73 The metal ion acts as a template. Alternatively they may act in 
less obvious ways by masking or by activating individual functional groups or they 
may influence the reaction in other ways which are related to the more readily defined 
steric influences in the reaction sequence.
In general, the generation of the macrocyclic product is controlled by the 
presence of a metal template ion which interacts with the heteroatoms inducing the 
desired cyclic product. The main concern, to effect the cyclisation, is the orientation 
of the reactive sites to give the macrocyclic product rather than the linear polymer.
In the synthesis of medium to large rings (upwards of 13 members) there is an 
unfavourable entropy term to the overall free energy change. This leads to 
limitations in the temperatures which can be used in the reaction, as heating gives 
rise to an even more unfavourable TAS term and the competing reactions e.g. 
oligomerisation may be favoured at the expense of the desired cyclised product. 
These effects may be eradicated if an ion can be used as a template for the 
cyclisation step. Generally the metal can then be removed by either adding acid or 
by ligand exchange processes, e.g. by adding CN', sulfide or EDTA, or following 
reduction of the metal if it has a suitable redox couple.
The first reported template synthesis for polyazamacrocycles was by Curtis74 
in the reaction of [Ni(1,2-diaminoethane)]2+ with dry acetone to give the 14-membered 
system with four aza constituents as shown in Fig 31. The carbon nitrogen double 
bond can then be easily reduced with borohydride.
An alternative approach involving the cleavage of a common bond between 
two or more smaller rings, e.g. 5 or 6-membered, may also be employed. This is a 
well established method for medium to large ring synthesis. It is regarded as a 
template method wherein a tertiary or quaternary carbon serves as the template. An 
example is that of the synthesis of tricyclic orthoamides by the alkylation of 
bicycloguanidines.75-78 The intermediates may be hydrolysed to give the free base 
triazamacrocycle or the opportunity may be taken to alkylate the nitrogens selectively 
(Fig 32).
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Fig 31
Today there are many similar methods for the synthesis of not only aza 
macrocycles but aza-oxa and aza-thia-macrocycles.
1. NaH, THF
2. 1,3-Dibromopropane
3. BF4-
 ►
1. UAIH4
Fig 32
4.3.4 High Dilution Synthesis
The first non-template synthesis of a macrocycle was reported in 1954 by 
Stetter and Roos.79 This involved the condensation reaction of terminal halides with 
bissulfonamide sodium salts under high dilution conditions to afford macrocyclic 
sulfonamides in moderate yields. Over a prolonged period this method has been 
honed and optimised for many macrocyclic compounds, each of which may require 
different conditions for the best results for the individual reactions to afford 
acceptable yields.
High dilution techniques take advantage of the fact that two groups can react 
forming the start of a linear chain and the remaining reactants are so dilute that the
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two functional groups on each end can react together to form the cyclic product 
rather than encountering another open chain reactant. In large volumes of solvent it 
is statistically easier for the two ends of the short chain to find and react with each 
other than to find other short chain molecules. Also the functional groups at the ends 
of the short chains are reactive towards each other, while only half of the times the 
two separate chains meet will the groups be mutually reactive.
The reaction generally takes place in a dipolar aprotic solvent such as 
dimethyl formamide (DMF) and is now most commonly effected by the reaction of the 
dianion of a bistoluenesulfonamide with a ditosylate or dimesylate in dry DMF. The 
dianion of the toluenesulfonamide salt may be generated prior to the cyclisation step 
by employing sodium hydride in DMF or sodium in dry EtOH or alternatively the 
reaction can occur in DMF in the presence of caesium carbonate generating the 
anion in situ. Fig 33 shows the general synthetic approach. Note that the tosylate 
group acts in two ways. Firstly it acts as a protecting group for the nitrogen and 
secondly as an activating group. It makes the secondary NH proton sufficiently 
acidic that the salt formation will occur under mild conditions. The sulfonamide group 
can then be removed by a variety of methods which will be discussed in section 4.4.1 
to leave the azamacrocycle as the free base.
NH NH NH2 Ts= CH so
TsN NTs
HTsN NTs NTs NTsH
NTs NTs
TsO OTs
TsN NTs NTs NTs
Fig 332Na
A second cyclisation method using a direct condensation may also be 
employed. The reaction of an ester or an acid chloride with linear polyamines will 
afford the cyclic amide. The amide can then be reduced, generally with lithium
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aluminium hydride, to give the desired free base product as shown in Fig 34. This 
method employs more vigorous forcing reaction conditions than high dilution 
techniques.
NH NH NH NH NH
NH(i) EtOH
(ii) LiAIH4 , THF
NH
NH-
Fig 34
4.4.1 Sulfonamide Cleavage
The cleavage of sulfonamide groups from nitrogen is notorious for its difficulty, 
unpredictability, low yields and unreliability from one compound to the next.
There are several methods for sulfonamide removal reported in the literature. 
The most common ones are acid hydrolysis with concentrated sulfuric acid; reductive 
cleavage with hydrobromic acid and glacial acetic acid; reductive cleavage with 
lithium aluminium hydride; and electrochemical reduction.
• Acid hydrolysis using 90 - 97% concentrated sulfuric acid at high temperatures for 
a prolonged period is one of the most common sulfonamide cleavage methods. 
This is followed by treatment with base to give the free base product. This 
method may be unsatisfactory as some aza and oxa-aza compounds decompose 
under strongly acidic or basic conditions. The high temperatures and long 
reaction times along with difficulty in isolating the desired product also make this 
method unfavourable. It is, however, preferred for aza compounds giving 
acceptable yields, e.g. 98% sulfuric was used to give TACN in 90% yield by 
Searle and Geue in 1984,80 McAuley et aI in 198481 obtained 90% yield and 
Ciampolini et al in 198682 deprotected [14]N4 -3Ts in 90% yield. A more recent 
publication by Lazaar in 199583 reports rapid detosylation of sulfonamide 
compounds on heating at 180 °C in concentrated sulfuric acid for 8 minutes.
• The use of hydrobromic acid and glacial acetic acid is also a common method 
employed in amine detosylations. Phenol is often used in the reaction as a 
bromine scavenger but it is not a necessity to the success of the reaction. This 
method allows the product to be obtained as the hydrobromide salt on addition of
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large volumes of organic solvents such as diethyl ether. Thus isolation of the 
product is easier than in the use of concentrated sulfuric acid. Yields obtained 
using this method are in general acceptable e.g. 30% HBr/CH3C 0 2H gave [9]N20  
in 92% yield reported by Thom et al in 1986,84 40% HBr/CH3C 0 2H /phenol gave 
[5]N5 in 94% yield by Osvath et al in 198785 and 33% HBr/CH3C 0 2H /phenol gave 
[32]N6 in 92% yield by Hosseini and Lehn in 1986.86 Thus this method is 
applicable for small to large sized macrocyclic rings.
• Reductive cleavage of the sulfonamide group with lithium aluminium hydride is a 
convenient reasonably clean route to isolate the desired product. However, if 
there are any carbonyl moieties within the structure they will also be reduced. 
Examples of employing this method in cleaving sulfonamide moieties are the 
formation of [18]N40 2 in 95% yield by Buhleier et al. in 197787 and [19]N20 4 in 
85% yield by Pietraszkiewicz and Jurczak in 1984.88
• Electrochemical methods may be used to cleave tosylate groups. In general the 
yields are not as high as in other cleavage techniques. Examples of this 
technique being employed are yields of 92% of dibenzo-[15]N20 2 and 52% for 
cyclen both by Kossai et al in 1979.89
There are several other methods which have been used in sulfonamide
cleavage such as the use of sodium with naphthalene.90
The most recent development in the area is that of reductive cleavage using 
Gilman's phenyldimethylsilyl lithium at 0 °C which selectively reduces secondary over 
primary amines.91 This will be discussed later.
4.5.1 Results and Discussion
The first set of compounds which were synthesised consisted of alkylating 
agents containing only nitrogen.
This set of compounds was made to investigate the effect of:
• altering the number of alkylating arms by changing the number of nitrogens within
the system;
• the size of the ring by changing the number of carbons between the nitrogens; 
and
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• alkylation at different sites on the DNA strand.
4.6.1 Synthesis of Macrocyclic Compounds
There were three major routes employed in the synthesis of the
azamacrocyclic alkylating agents in this chapter:
• use of readily available macrocycles to form the alkylating agents;
• high dilution techniques; and
• cyclisation using condensation techniques.
4.6.2 Available Starting Materials
There are a very limited number of azamacrocycles which are available at a 
reasonable cost. The alkylating agents were formed by the reported method of 
Hancock et a l 92 and Boeyens et a l 93 using ethylene oxide in EtOH followed by 
chlorination with thionyl chloride as shown in Scheme 23 and Scheme 24.
(i)
OH 
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(i) thionyl chloride
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Scheme 23
The first product synthesised was /V-choloroethylaziridine. This was formed 
from /V-hydroxyethylaziridine, 63, which was available from Aldrich, and thionyl 
chloride. The chloride was recrystallised from EtOH and diethyl ether after 
continuous stirring in thionyl chloride for 48 h, as shown in Scheme 23. The IR 
spectrum of 64 showed a C-CI stretch at 779 cm-1 and CH stretches at 2850 and 
2981 cm 1. The 13C and 1H NMR spectra showed the presence of three carbon 
signals at 5 55.1, 48.8 and 27.1 and the absence of the hydroxyl proton in the 1H 
NMR spectrum.
A/,A/’-Di(chloroethyl)piperazine, 67, was formed from piperazine firstly forming 
the diol 66 and chlorination using thionyl chloride, as shown in Scheme 24. Product 
67 was recrystallised from EtOH and diethyl ether in good yield as a white solid. Diol
66 showed stretches in the IR spectrum corresponding to the hydroxyl at 1282 and
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3421 cm*1. The 13C NMR spectrum showed the three carbon signals at 8 59.6, 58.9 
and 52.1 and the accurate mass spectrum in El+ mode showed the mass of 66 to be 
175.1447 amu with the required mass being 175.1446 amu. The target compound 
showed the absence of hydroxyl stretches in the IR spectrum but the presence of a 
C-CI stretch at 751 cm*1.
HO.
OHHN NH
(i) ethylene oxide, EtOH
(ii) thionyl chloride Scheme 24
The third compound, A/,A/’-di(chloroethyl)-1,4-diazacycloheptane, 70, formed 
as shown in Scheme 25, increases the ring size by one carbon. Diol 69 was formed 
from 1,4-diazacycloheptane 68 and ethylene oxide in EtOH. The diol showed the 
presence of the hydroxyl proton in the 1H NMR spectrum at 5 4.05. The 13C NMR 
spectrum showed five methylene carbons and the IR spectrum showed hydroxyl 
stretches at 1251 and 1052 cm*1. The target compound 70 was formed by 
continuous stirring of compound 69 in thionyl chloride for 24 h as a beige solid which 
was recrystallised from EtOH and diethyl ether in good yield as an off-white solid. 
The IR spectrum showed the presence of a C-CI stretch at 751 cm*1 and the absence 
of the hydroxyl stretches. The 1H NMR spectrum confirmed the absence of the 
hydroxyl proton.
HO.
OHHN NH
(i) etheylene oxide, EtOH
(ii) thionyl chloride
Scheme 25
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The tetraol compound 72 was formed from cyclen 
(1,4,7,10-tetraazacyclododecane) 71 with ethylene oxide in the usual method. The 
target compound 73 was formed by stirring 72 in neat thionyl chloride as in Scheme 
26.
r ~ \NH NH
\
NH NH' 
71
HO
V OH
(i)
HO'
\ r A /
.N K
:n n:
\_y
(ii)
y
72
Cl
‘OH
V
Cl
(i) etheylene oxide, EtOH
(ii) thionyl chloride
Scheme 26 Cl
Y~V
:n n;
j
73
‘Cl
The 1H NMR spectrum for compound 72 showed signals at 5 2.16-2.23 with 
intensity 24 protons corresponding to the methylenes next to the nitrogens, 8 
3.27-3.31 of intensity 8 protons representing the methylenes adjacent to the hydroxyl 
groups and finally the hydroxyl protons at 8 4.87. The corresponding tetrachloride 
compound 73 showed C-CI stretches in the IR spectrum at 727 cm 1. The 
microanalysis showed acceptable percentages for carbon, hydrogen and nitrogen.
74 H0‘
(i) ethylene oxide, EtOH
(ii) thionyl chloride Scheme 27
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Tetrachloro compound 76 also has four potential alkylating sites contained 
within a macrocycle which has two carbon atoms more than compound 73 in the ring.
Tetraol 75 was obtained in excellent yield as a viscous oil and gave spectroscopic
data as in the literature.93 The chlorinated compound 76 was obtained by stirring in 
thionyl chloride, as shown in Scheme 27, followed by recrystallisation from EtOH and 
diethyl ether in 74% yield. The IR spectrum showed a C-CI stretch at 765 cm 1 and 
the absence of any hydroxyl stretches.
HO OH Cl,
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HO OH
(i) ethylene oxide, EtOH
(ii) thionyl chloride Scheme 28
By increasing the macrocyclic unit by one carbon another test compound 79
can be formed after alkylation of 77 using ethylene oxide followed by chlorination 
using thionyl chloride, as shown in Scheme 28. 79 was obtained in reasonable yield 
as an off-white solid. The tetraol 78 had an accurate mass spectrum found and 
required of 391.3284 amu in Cl+ mode. The 1H NMR spectrum of 78 showed signals 
at 8 3.2-3.0 representing the eight methylene protons alpha to the hydroxyl group. 
The tetrachloride 79 had an accurate mass of 463.1929 amu found and required. 
The 1H NMR spectrum also showed a shift in the position of the methylene protons 
alpha to the terminal chloride group of the alkylating arms.
By the inclusion of a diamide feature we can easily form a bifunctional 
alkylating agent 82 by alkylation of 80 using ethylene oxide in EtOH followed by 
chlorination using thionyl chloride as shown in Scheme 29. Starting with
1,4,8,11-tetrazacyclotetradecane-5,7-dione the diol 81 was formed which showed a 
13C NMR spectrum signal at 8 168 corresponding to the amide carbonyl carbon, and 
five signals between 8 63 and 53 corresponding to the carbons alpha to the amines 
and the carbons adjacent to the hydroxyl group. The target compound 82 showed
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the absence of any hydroxyl stretches in the IR spectrum but the presence of a 
CH2-CI stretch at 752 cm 1, along with the amide carbonyl stretch at 1686 cm'1. The 
accurate mass spectrum showed the found mass to be acceptable.
(i) ethylene oxide, EtOH
(ii) thionyl chloride Scheme 29
These are the only compounds which were formed from readily available 
starting materials.
4.6.3 High Dilution Synthesis
As discussed earlier high dilution techniques are an appropriate method to 
employ in the formation of macrocyclic compounds.
The general synthesis of this type of compound is by the protection and 
activation of the amine systems by a tosylate and activation of the alcohol to facilitate 
cyclisation.
HO OH -------- ► TsO OTs
83 84
(i) p-toluenesulfonyl chloride
DCM, sodium hydroxide sol., TEBA
________________________ Scheme 30
To form the macrocyclic compound 88, cyclisation with the bistosylated 
compound 84 was carried out as shown in Scheme 31. The ditosylated alcohol 84 
was formed from 1,2-ethanediol, 83, p-toluenesulfonyl chloride, DCM, sodium 
hydroxide solution and TEBA in a two phase reaction as shown in Scheme 30. This 
reaction went in excellent yield to afford compound 84 as a white solid (all tosylated 
compounds were recrystallised before use in cyclisation reactions). The disodium salt 
87 was formed by dissolving the tosylate in EtOH and adding blocks of sodium. The
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macrocyclic product 88 was obtained in good yield as a white fluffy solid. 
Spectroscopic data agreed with those reported and good analytical data were 
obtained.80
,NH'
:nh
NH,
(i)
,NTsH
;nts
‘NTsH
(ii)
©
.NTs
;NTs (iii)
85 86
.2Na
"'NTs
©
87
©
NTs
NTs^  
88
NTs
(i) p-toluenesulfonyl chloride, Et2 0 , sodium hydroxide sol.
(ii) EtOH, Na
(iii) DMF, 84 Scheme 31
The trisulfonamide 88 was detosylated as discussed in section 4.4.1 to afford 
the free base 1,4,7-triazacyclononane 89 as a white solid. The 1H NMR spectrum 
showed a singlet of intensity twelve protons at 5 2.47 corresponding to the NCH2 
protons and 8 1.75 of intensity 3 protons corresponded to the secondary amine 
protons. The 13C NMR spectrum showed only one signal at 8 47.0. This material 89 
was then alkylated to afford the triol 90, which was chlorinated on stirring in neat 
thionyl chloride overnight as shown in Scheme 32. The 1H NMR spectrum of the triol 
90 showed signals at 8 1.14-1.16 intensity 9 protons, 8 2.41 intensity 18 protons and 
8 3.71-3.90 with intensity 3 protons corresponding to the methyl, methylene adjacent 
to the nitrogen and the methine protons, respectively. The chloride 91 showed 
acceptable microanalysis results and IR stretches at 780 cm'1 representing the C-CI 
stretch.
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HO'(i) H2S04
(ii) (S)-propylene oxide, EtOH
(iii) thionyl chloride Scheme 32
The next two compounds were synthesised similarly to the last compound. 
A/,/\/',/\/”-Tri(p-toluenesulfonyl)-1,4,7-triazacydodecane 94 was formed using the 
trisulfonamide 87 and the ditosylated compound 93 as shown in Scheme 34.
Tosylated 1,3-propane diol compound 93 was obtained, as shown in Scheme 
33, using p-toluenesulfonyl chloride, DCM, sodium hydroxide solution and TEBA as a 
white solid in good yield. Spectroscopic data were in agreement with the literature 
values.80
OH OH (i) OTs OTs 
 ►
92 v  93
(i) p-toluenesulfonyl chloride,
DCM, sodium hydroxide sol.,
TEBA Scheme 33
TsN87 + 93
NTs
(i) DMF
Scheme 34
A/,A/',A/”-Tri(p-toluenesulfonyl)-1,4,8-triazacyclounadecane 95 was prepared 
from /V,/V'/\f-tri(p-toluenesulfonyl)-dipropylenetriamine and 0 ,0 ’-di(p-toluenesulfonyl) 
-1,2-ethanediol as shown in Scheme 35. The accurate mass, 1H and 13C NMR 
spectra were all acceptable for these compounds.
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4.6.4 Linear System Formation Before Cyclisation
An alternative method which can be employed in the formation of medium to 
large sized macrocylic compounds is that of forming linear amine systems before the 
cyclisation reaction.
Two linear polyamine systems which are readily available are those of 
spermine, 103, and spermidine, 96. Spermidine, 96, has three nitrogens in the 
system with spacer lengths of three and four carbons. This allows us to form 
macrocycles where the spacer lengths between the carbons in the macrocycle are 
different from the previously mentioned compounds.
Spermidine was tritosylated using the usual amine tosylation method with 
p-toluenesulfonyl chloride, sodium hydroxide solution and diethyl ether at 0 °C as 
shown in Scheme 36.
HTsN
,2Na
(i) p-toluenesulfonyl chloride, Et2 0 , sodium hydroxide sol.
(ii) EtOH, Na
(iii) DMF, 93 Scheme 36
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The tritosylsulfonamide compound 99 was obtained on cyclisation of the 
disodium salt of 98, with 93 and obtained as a white solid after dropwise addition of 
93 in dry DMF to the tosylated amine at 100 °C, as shown in Scheme 36.
—
HO N OH (j) TsO NTs OTsv_y w — v_y w  
100 101
(i) p-toluenesulfonyl chloride, DCM, 
sodium hydroxide sol., TEBA Scheme 37
Tritosylation of diethanolamine 100 afforded 101 in good yield as a fluffy white 
solid as shown in Scheme 37. Spectroscopic data were in accord with the 
literature.94 Compound 101 was reacted with the disodium salt of the tosylated
spermidine compound 98, as shown in Scheme 38, in dry DMF to afford the
tetratosylsulfonamide 15-membered ring as a light yellow powder.
NTs TsN
98 +101
NTs TsN
102(i) DMF
Scheme 38
The longer spermine chain allows us to have carbon spacer lengths between 
the nitrogens in the ring systems of three, four and three respectively. The final 
spacer length between the terminal nitrogens is dependent on the tosylated alcohol 
employed in the cyclisation step.
As previously the amine must be protected by tosylation. The tetratosylated 
compound 104 was formed in the usual manner with p-toluenesulfonyl chloride and 
sodium hydroxide solution in diethyl ether. The yield of the white solid was poor but 
acceptable. The nineteen membered tetratosylsulfonamide compound 105 was 
obtained on the cyclisation of the tosylated spermine 104, with the tritosylated 
diethanolamine 86, formed as shown in Scheme 39, by the usual manner, in DMF 
again utilising caesium carbonate to form the anion in situ as in Scheme 39.
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(i) p-toluenesulfonyl chloride, 
DCM, sodium hydroxide sol., 
TEBA
(ii) Cs2C03 DMF, 8 6  .
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Scheme 39
In a similar manner linear chains of varying lengths can be built up from readily 
available starting materials such as 1,2-diaminoethane and 1,3-diaminopropane as 
shown in Scheme 40. This allows larger macrocycles containing additional nitrogen 
atoms to be formed.
The synthesis of /V.AM.B.H.IS-hexaO^-toluenesulfonyl^.B.H.ie-tetraaza 
octadecane-1,20-diamine from 1,2-diaminoethane was performed in a similar manner 
to reported, as shown in Scheme 40.95 The linear hexaamine 109 was prepared as 
the acyclic form of the macrocyclic hexaamine product desired. Symmetrical 
elongation of diethylamine by tosylation, Michael condensation with acrylonitrile 
followed by reduction with borane gave rise to compound 108. This was subjected to 
the same sequence of reactions to afford compound 110.
Compound 107 was formed using the literature method95 as shown in Scheme 
41 in good yield as white crystals. The 1H NMR spectrum showed a doublet of 
doublets at 8 7.72-8.39 corresponding to the aromatic AA’BB’ system, a singlet at 8
2.4 corresponding to the methyl group attached to the aromatic moiety, a broad 
singlet, of intensity 2 protons, at 8 5.53 representing the amine proton and a singlet 
of intensity 4 protons corresponding to the methylene groups alpha to the nitrogen 
atoms. The elongation of the compound proceeded by adding acrylonitrile in excess 
dropwise to a stirring mixture of compound 108 in DMF as reported.95
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Characterisation of the white needles obtained in good yield, showed the 
presence of a nitrile stretch in the IR spectrum at 2250 cm*1 and the nitrile carbon in 
the 13C NMR spectrum at 5 118.2. Compound 108 was reduced using borane to 
afford the primary terminal amine. The IR spectrum showed the absence of the 
nitrile stretch and the presence of broad N-H stretches at 2258 cm'1. The terminal 
nitrogens were singly tosylated as before. This linear tetraaza compound was further 
elongated using the previous method. Again the nitrile carbon appeared in the 13C 
NMR spectrum at 8 118.1 cm-1. Compound 110 was obtained on reduction using 
borane and tosylation as before as a white solid in acceptable yield. The IR 
spectrum again showed the absence of nitrile stretches and the presence of primary 
amine N-H stretch at 2270 cm*1. The 1H NMR spectrum showed two singlets of 
intensity 12 and 6 protons at 5 2.36 and 2.33 corresponding to the internal and 
terminal methyl groups, with a doublet of triplets at 8 1.85-1.70 of intensity 8 protons 
and a broad singlet at 8 3.21 of intensity 2 protons corresponding to the secondary 
amine protons. The aromatic region was a complex multiplet of doublet of doublets 
corresponding to the AA’BB’ aromatic systems of the sulfonamide groups.
The disodium salt of the linear hexaamine 110 was formed in EtOH using 
sodium, to afford a white solid which was not characterised but cyclised using high
dilution techniques, with O.O’-ditosylpropanediol 93, to afford the tosylated analogue
of the desired product as a biege solid in good yield. The tosylated 1,3-propanediol 
compound was synthesised as described.95 The cyclisation of 93 and 111 afforded 
compound 112.
NH
(i) p-toluenesulfonyl chloride, DCM, 
sodium hydroxide sol., TEBA
(ii) acrylonitrile, DMF
(iii) borane/ THF107 HTsN.
NTsH
NTs
NO
Scheme 40
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Compound 113 was synthesised in the same manner as compound 112 
starting from 1,3-propanediamine. Characterisation of intermediates agreed with 
data reported.95
NTs NTsNTs NTsH TsN-
NTs!NTs NTs
TsN-
TsN© NTs TsNNTsHTsNNTs
.2NaNTsNTs
112111110
(i) EtOH, Na
(ii) DMF, 93 Scheme 41
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4.6.5 Condensation cyclisations
The use of condensation reactions between esters and amines is a convenient 
method for the synthesis of macrocyclic amines which may or may not contain other 
heteroatoms such as oxygen or sulfur. This procedure involves neither the use of 
high dilution techniques nor the protection and deprotection of amines to afford the 
free bases desired.
In compound 115 two of the nitrogens present in the ring system are protected 
as a direct consequence of the cyclisation technique employed as shown in Scheme 
42. The condensation of esters with linear polyamines in EtOH generally gives the 
diamide cyclisation product. From this point selective alkylation of the unprotected 
nitrogens is possible or reduction of the amides to afford the free base. Two aza
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macrocyclic compounds, 115 and 117, were formed in this manner using literature 
procedures.9697
,NH-
Eto-
:NH NH HN
EtO-
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Scheme 42
NH- 114
(i) EtOH
Compound 115 was formed by vigorously heating diethylenetriamine and 
diethyl malonate in EtOH refluxing for 5 days as reported.97115 showed a doublet of 
triplets in the 1H NMR spectrum at 8 3.24-2.64 and signals at 8 170 corresponding to 
the carbonyl carbon, and 8 47.2 and 39.2 corresponding to the other carbon types 
present. The diamide was reduced to afford the free base in very low yield. The 13C 
NMR spectrum showed the absence of the carbonyl carbon and an additional signal 
at 8 52.7.
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■NH ,NH HN.
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117 
Scheme 43(i) MeOH
The diamide 117 was formed from triaminodipropane and diethyl malonate in 
MeOH as in the literature and is shown in Scheme 43. 1H and 13C NMR signals 
corresponding to the literature.97
The final diamide prepared was 1-oxa-4,7,10-triazacyclododecane-3,11-dione 
119 formed from diethylenetriamine 85 and the methyl ester 118 derived from 
diglycolic acid as shown in Scheme 44.98 The 13C NMR spectrum showed the 
presence of the amide carbonyl carbon at 8 172 and three other signals at 8 70.4,
47.4 and 38.3 representing the remaining carbons.
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Unfortunately the diamides were mainly resistant to reduction by borane or 
LiAIHU. 13C NMR spectra indicated starting material by the presence of a signal at -  8 
170. The biological evaluation of the target compounds is discussed at the end of 
the next chapter.
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Chapter 5
5.1.1 Heterocyclic Alkylating Agents
The previous chapter was concerned with the synthesis of alkylating agents 
containing only nitrogen as the heterocyclic atom. This chapter will, however, be 
concerned with the synthesis of alkylating agents containing atoms other than 
nitrogen (such as oxygen and sulfur) within the macrocycle.
Variations in the size of macrocycle, number and type of heteroatoms, and 
number of alkylating groups will be made.
5.2.1 Synthesis of Oxa, Aza Macrocyclic Alkylating Agents
The first set of oxa, azamacrocyclic alkylating agents which were synthesised 
were formed similarly to some of the azamacrocycles in Chapter 4.
5.2.2 Available Starting Materials
There are a very limited number of oxa, and azaoxamacrocycles which are 
readily available from chemical companies which are reasonably inexpensive. This 
limited availability reflects the difficulties which are generally encountered in the 
synthesis of macrocycles of this type. There are a few, however, which have been 
developed into alkylating agents for biological evaluation in this work.
The first compound formed was A/-chloroethyl-1-oxa-4-azacyclohexane 122 as 
shown in Scheme 45. 1 -Oxa-4-azacyclohexane 120 was successfully alkylated
using ethylene oxide in EtOH to give the alcohol 121 as a light yellow oil in good 
yield. The accurate mass spectrum in El+ mode showed the found mass as 132.1024 
amu and the required mass was 132.1025 amu. The alcohol 121 was stirred in 
thionyl chloride to afford the chloride, compound 122 as a cream coloured solid in 
high yield. The IR spectrum showed the presence of the C-CI stretch at 659 cm'1. 
The accurate mass spectrum in Cl+ mode was again acceptable. The found mass 
was 150.0685 amu with a required mass of 150.0686 amu.
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(i) ethylene oxide, EtOH
(ii) thionyl chloride Scheme 45
Compound 125 was formed from 1,7-dioxa-4,10-diazacyclododecane. This 
was treated with ethylene oxide to afford the diol 124 which was treated with thionyl 
chloride to give the target compound as shown in Scheme 46. The diol 124 was 
obtained as an orange oil in good yield. Target compound 125 was obtained as a 
light beige solid in acceptable yield. The 13C NMR spectrum of 125 showed the 
presence of four carbons at 5 67.4, 60.3 corresponding to the carbons next to an 
oxygen atom and signals at 6 57.7 and 53.4 corresponded to the methylene carbons 
adjacent to the nitrogen atom.
(ii) ci.HO.
NH
OH
123 (i) ethylene oxide, EtOH
(ii) thionyl chloride
125124 Scheme 46
The third target compound which was formed from readily available starting 
material was compound 128. This was obtained when 1,4,10,13-tetraoxa- 
7,16-diazacyclooctadecane was treated with ethylene oxide followed by thionyl 
chloride as shown in Scheme 47. The dichloride was obtained as a viscous orange 
oil. The diol 127 was obtained in high yield and its 1H NMR spectrum showed signals 
at 5 2.58-2.63 as a multiplet corresponding to the methylene protons adjacent to the 
nitrogen atoms. Signals at 5 3.35-3.53 corresponded to the protons next to the 
oxygen atoms within the system. The hydroxyl protons were observed as a broad 
singlet at 5 4.78. In the 13C NMR spectrum the shift of the signal of the methylene 
carbon next to the terminal atom from 8 59 in the diol to 39 supports the substitution 
of the hydroxyl for the chloride.
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The dichloride compound ty/V’-dKchloroethylHAIO .IS-tetraoxa^.ie- 
diazacyclooctadecane 128 was formed similarly to the previous target molecule, 
using the usual chlorination methods. The 13C NMR spectrum of 127 showed two 
signals at 5 68.7 and 67.7 corresponding to the methylenes next to the oxygens and 
signals at 8 58.1, 58.0 and 53.5 corresponded to the carbons next to the nitrogen and 
hydroxyl atoms. The dichloride was obtained in acceptable yield and showed a shift 
of the methylene next to the terminal atoms to 5 42.7 supporting the substitution of 
the hydroxyls by the chlorides.
,OH
130129
NH NH
131132
(i) 1,2-dibromoethane, sodium hydroxide sol., EtOH
(ii) 1,3-diaminopropane, MeOH
(iii) borane/THF Scheme 48
Compounds containing a benzyl moiety have previously been shown to have 
significant biological activity against malaria parasities by Dr Lindsay Slater, who was 
previously a member of the research group." The presence of benzyl groups 
increases the lipophilicity of the compounds. The synthesis of
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A/,/\/’-di(hydroxyethyl)-5,6:14,15-dibenzo-1,12-diaza-1,4-dioxacyclopentadecane, has 
been reported.100
132
OHHO'
133 134
(i) ethylene oxide, EtOH
(ii) thionyl chloride Scheme 49
The aldehyde 130 was formed as in the literature by Williamson condensation 
from salicylaldehyde 129 and 1,2-dibromoethane in a 2 to 1 ratio with 
characterisation as in the literature.101 Imine 131 was formed on treating the aldehyde 
130 with 1,3-diaminopropane as a fluffy beige solid in low yield. The imine was 
reduced using an excess of borane in THF to afford the secondary amine 132 as a 
white solid in acceptable yield, as shown in Scheme 48. Characterisation of 
compounds was in accord with the literature data.101 The free base 132 was alkylated 
in the usual manner with ethylene oxide and chlorinated using thionyl chloride as 
shown in Scheme 49 to afford /V,A/’-di(chloroethyl)-5,6:14,15- 
dibenzo-1,12-diaza-1,4-dioxacyclopentadecane 134 as a white powder with 
spectroscopic data in agreement with those of Lindoy et a/.102
5.2.3 High Dilution Synthesis
There are a wide variety of macrocyclic alkylating agents which could be 
synthesised.
Using high dilution techniques it is relatively straightforward to form 
macrocyclic structures which contain sulfonamide moieties. In this work variations 
were made in the size of the macrocycle; the number and type of heteroatom; and 
their spacing within the macrocycle.
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5.2.4 Diaza Macrocyclic N-Tosylated Compounds
W e chose to start by forming a small aza-oxa macrocyle compound 137 using 
high dilution techniques. 1,3-Ethylenediamine was tosylated as previously to give 
compound 107. Dipropylene glycol was tosylated as shown in Scheme 50, to afford 
compound 136 ,103 i.e. using p-toluenesulfonyl chloride, DCM, with sodium hydroxide 
solution acting as a base and TEBA as catalyst. The tosylated alcohol, 136, was 
obtained as fluffy white needles in high yield. Spectroscopic data agreed with those 
of the literature.104 The disodium salt of the tosylated amine was formed by adding 
sodium to a solution of the secondary amine compound 107 in EtOH. The cyclised 
product was obtained by dropwise addition of the tosylated alcohol 136 in dry DMF to 
a solution of the salt of the tosylated amine in dry DMF at 100 °C and the 
temperature was maintained over night. The ditosylated product was obtained as an 
off white solid in acceptable yield. Characterisation was in agreement with that of the 
literature.105
(i) p-toluenesulfonyl chloride, DCM,
sodium hydroxide sol., TEBA Scheme 50
/ “ XNTs )
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(i) CS2 CO3 , DMF \  /
Scheme 51
An alternative method would be to use two equivalents of caesium carbonate, 
in dry DMF along with the tosylated amine and tosylated alcohol compounds as 
shown in Scheme 51. The deprotonated tosylamide is formed in situ. The caesium 
ion does not play an active role in these types of reactions but acts as a means of 
solubilising the carbonate in the solvent. The tosylated alcohol was slowly added 
over a period of several hours and stirred overnight. This reaction involves a [1+1] 
Richman Atkins type co-condensation of the AMosylated compound 107 with the 
linear ditosylate ester. The product was obtained on crystallisation from hot toluene. 
The yield from this method was very poor. Thus the former method was preferred.
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(i) p-toluenesulfonyl chloride, DCM,
sodium hydroxide sol., TEBA Scheme 52
Compound 139 is very similar to the previous compound formed but contains 
two carbons less. Diethylene glycol was tosylated as shown in Scheme 52, using 
p-toluenesulfonyl chloride, DCM, sodium hydroxide solution and TEBA, as a white 
solid in good yield. The cyclic product was obtained by using caesium carbonate in 
dry DMF to facilitate the ring closure as shown in Scheme 53. However the yield of 
the white solid was very poor. Spectroscopic data were in agreement with those 
reported.106
.NTsH
(i) EtOH, Na (ijj)
(ii) 139, DMF
(iii) CS2C03, DMF Scheme 53
By extending the number of oxygens in the ring to two we can form medium 
sized macrocycles. The ditosylated alcohol 143 was formed from triethylene glycol, 
sodium hydroxide solution and TEBA in DCM as shown in Scheme 54.103 The 
macrocycle contains two nitrogens, as shown in Scheme 55, using caesium 
carbonate to generate the salt in situ. Again this method leads to poor yields. 
Characterisation agreed with that in the literature.107
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(i) p-toluenesulfonyl chloride, DCM, sodium hydroxide sol., TEBA
Scheme 54
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Scheme 55
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Finally the ditosylsulfonamide macrocyclic compound 147 was formed, as 
shown in Scheme 57, with three oxygen atoms in the ring. The disodium salt of 
107, was used along with ditosylated tetraethylene glycol compound 146 which was 
formed from tetraethyleneglycol, TEBA, sodium hydroxide and DCM in the two phase 
system shown in Scheme 56.103 Spectroscopic data were in agreement with those in 
the literature.108 The white solid macrocyclic product was obtained in good yield by 
this method and characterised data agreed with those reported.109
HO 0 0 0 OH m TsO O O O OTs
v _ / w v _ y v _ y
145 146
(i) p-toluenesulfonyl chloride, DCM, sodium hydroxide sol., TEBA Scheme 56
107+146
(i) DMF
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147Scheme 57
5.2.5 Triaza Macrocyclic W-Tosylated Compounds
Incorporating three nitrogen atoms into the macrocycles allows us to extend 
the number of possible alkylation sites. It also increases the size of the macrocycle.
As in the previous section (5.2.4) the number of oxygens within the ring 
systems was increased stepwise. Compound 148 was formed from the 
tritosylsulfonamide 86. The tosylation of diethylenetriamine was carried out as 
described in Chapter 4 to afford compound 87 which formed the disodium salt also 
as in Chapter 4. The cyclisation occurred as before by the slow addition of the 
ditosylated alcohol 139 in dry DMF to the amine salt in dry DMF at 100 °C with 
vigorous stirring as shown in Scheme 58. Characterisation agreed with that in the 
literature.110
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(ii) DMF, 139
Scheme 58
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Compound 149 was synthesised from the tritosyl salt 87 and the ditosylated 
triethylene glycol 143. The cyclisation occurred using the sodium salt, as shown in 
Scheme 59, to afford a white solid in acceptable yield.
NTs
(i) EtOH, Na
(ii) DMF, 143 NTs
149Scheme 59
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(i) EtOH, Na
(ii) DMF, 146 NTs
Scheme 60 150
The trioxa, triaza compound 150 was synthesised from the tritosyl salt 87, and 
the ditosylated tetraethylene glycol 146, as shown in Scheme 60. The cyclisation 
was carried out as for the previous compound and afforded 150 as a white solid in 
good yield.
5.2.6 Tetraaza Macrocyclic N-Tosylated Compounds
The incorporation of a fourth nitrogen atom into the macrocycles allows us to 
extend the number of possible alkylation sites. In the compounds formed we are also 
altering the positioning of the nitrogen atoms relative to one another.
Compound 151 was previously formed in the synthesis of compound 141 as a 
[2+2] Richman Atkins type addition also takes place, i.e. two molecules of each of the 
tosylated amine and alcohol form the product as shown in Scheme 61. As with the 
smaller compound a very low yield was obtained.
NTs TsN.
107 + 139
NTs TsN-
Scheme 61 151
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The final tetraaza macrocyle was synthesised in a similar way as shown in 
Scheme 62. As before low yields were obtained.
(i) / \ /
107 + 143--------- ► NTsS' 0 0 TsN
(i) Cs2 CC>3 , DMF
NTs 0 0 TsN
\ / \ _y v_y
Scheme 62 152
5.3.1 Synthesis of Thia, Aza Macrocyclic Alkylating Agents
5.3.2 Available Starting Materials
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Scheme 63
As for the previous rings formed, there are very few cyclic starting materials 
from which we can work. 1,4,10,14-Tetrathia-7,17-diazacyclooctane 153, is readily 
available. Using chloroacetyl chloride with triethylamine, the nitrogens were alkylated 
to afford compound 154, by the method of Lehn, Parker et a/.111 The diamide was 
reduced using a solution of borane in THF, as shown in Scheme 63, to afford the 
target molecule 155 as an off white solid in good yield. The IR spectrum showed the 
absence of hydroxyl stretches and the presence of a CH2-CI stretch at 750 cm-1.
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5.3.3 High Dilution Synthesis
For comparison of biological activity a sulfur analogue of a previously prepared 
compound 125 was made.
Compounds 157 and 158 were formed as shown in Scheme 64 from 
diethanolamine, which was tosylated in the usual manner to afford the tosyl 
compound 101. The formation of two carbon to sulfur bonds proceeded using 
thiourea to afford compound 156,112 which was reacted with 1,2-dibromoethane in the 
usual manner with caesium carbonate to afford compounds 157 and 158, with the 
[1+1] product as the major and the larger [2+2] product as the minor component.
^OTs
^NTs
^OTs
101
(i)
(ii)
,SH
:nts
kSH
156
(iii) '  1
157
NTs S
(i) CS(NH2 )2 , EtOH
(ii) NaHC0 3 , H20 \
(iii) 1,2-dibromoethane, Cs2 C0 3 , DMF
Sy v
^ 15 8
S.
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Scheme 64
5.4.1 Detosyiation Attempts on Sulfonamide Macrocycles
The process of removing tosylate groups from nitrogen atoms is one which is 
well documented as being very problematic. There are numerous methods as 
previously mentioned in Chapter 4 which can be utilised for this process. However, 
none of these reactions are universally applicable. Thus each individual compounds 
formed as a sulfonamide macrocycle must be examined to decide an appropriate 
route for detosyiation. There are numerous literature references to the difficulties 
encountered in successful performances of this reaction, relating to each of the 
different cleavage methods which can be employed.
5.4.2 Concentrated Sulfuric Acid Method
One of the most commonly employed techniques in detosyiation of amines is 
that of heating in concentrated sulfuric acid.
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The reported temperature and times involved vary depending on the 
compound and author employing the method. The solution was then generally 
cooled and EtOH added cautiously. The aqueous solution was basified using 
sodium hydroxide pellets or solution and extracted using chloroform. This was the 
method reported by Lazaar113, Hay and Norman114 and Meunier et al. 115
Variations of this method were employed for a selection of the sulfonamide 
macrocyclic compounds formed in Chapter 4 and Chapter 5.
The only compound where complete detosyiation occurred using this method 
was the tritosylated tacn 88 as shown in Scheme 65. Spectroscopic data of 89 
agreed with those in the literature.116
Compound 93 was heated at 160 °C for 8 h in concentrated sulfuric acid 
before cooling and addition to EtOH and diethyl ether which was stirring vigorously. 
A beige precipitate formed which was taken up in water and 47% hydrobromic acid 
was added. No precipitate occurred indicating that the hydrobromide salt of the 
triaza compound did not form.
The same technique, apart from heating at 180 °C was employed with 
compound 94. 1H NMR spectra indicated the precipitate was starting material 
obtained in low yield.
The penta aza compound 105 was treated with concentrated sulfuric acid and 
formation of the HBr salt was attempted. However, no precipate was observed on 
the addition of large volumes of diethyl ether.
Using the same method on oxa, aza compounds 151 and 152 heating the 
sulfuric acid solution at 190 °C for 1-2 h resulted in a small amount of precipitate of 
the detosylated salt. On analysis this was shown to be 75% detosylated. Thus this 
method looked promising for use on other oxa, aza compounds if the correct 
temperature and timing could be found. Further experiments using this method 
varying time and temperature of heating proved to be unfruitful; frequently cleavage
(i) cone H2 SO4
(ii) NaOH Scheme 65
NH
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of the ether linkage was observed. Either starting material was recovered or an 
inseparable mixture of tosylated products and open ring compounds was obtained. 
This is not surprising due to the harsh conditions of the reaction. Compounds 144, 
148 and 152 were all investigated by this technique, but to no successful conclusion.
The thia, aza compounds 157 and 158 were also subjected to treatment with 
concentrated sulfuric acid, but the compounds broke down.
5.4.3 Hydrobromic and Glacial Acetic Acid
This method of detosyiation is also a frequently employed technique. 
Literature reports have shown a varied level of success using this technique from 
very low yield to virtually quantitative. The HBr salt was generally obtained from 
heating the sulfonamide compounds at reflux in 47% aqueous hydrobromic acid and 
glacial acetic acid. Alternatively prolonged stirring at room temperature sometimes 
facilitates the cleavage.117 Phenol is frequently used as a bromine scavenger in this 
reaction, but is not necessary in all cases. The salt of the detosylated product was 
generally obtained on the addition of large volumes of organic solvents such as 
diethyl ether.
The N,N ’,A/”-tri(p-toluenesulfonyl)-1,4,7-triazacyclononane 88, was subjected 
to this method of reductive cleavage using literature methods.117,118 with starting 
material being recovered.
The tosylate 99 formed from spermidine was stirred with a solution of phenol, 
HBr and glacial aetic acid. The major product obtained was phenol, without any 
recovery of the starting macrocyclic material.
The tetraaza, tetraoxa tosylate 152, was subjected to this cleavage method. 
No salt was formed and no starting material were recovered.
5.4.4 Lithium Aluminium Hydride Reduction Method
This is one of the less vigorous methods of sulfonamide cleavage. It is also 
generally a clean and high yielding reductive technique. The products often prove 
difficult to isolate. At least 2.5 equivalents of lithium aluminium hydride are used per 
sulfonamide group, refluxing in THF for varied periods of time before basic work 
Up 119.120 yhjS method was used for the detosyiation of A/,A/',A/”-tri
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(p-toluenesulfonyl)-1,4,7-triazacyclononane 88, using 2.5 equivalents of lithium 
aluminium hydride for each of the sulfonamide groups present. This method failed, 
affording a very small amount of white solid which was very impure starting material.
The treatment of the diaza, trioxa tosylate 147, gave a similar result. However 
when the triaza, dioxa compound 142 was treated with 3.2 equivalents of the 
reducing agent a small amount of detosyiation was observed, but the majority of the 
recovered material was starting material.
5.4.5 NaI Liquid Ammonia Reduction Method
The use of liquid ammonia and lithium / sodium is a useful method for 
reductive cleavage of sulfonamides.117 In literature reports this system has varied 
success and again has to be evaluated against each individual tosylate. It is carried 
out by adding sodium to a solution of liquid ammonia and the sulfonamide until a 
blue colour appears followed by quenching with ammonium chloride.
This method117 was used in an attempt to detosylate 
A/,A/,,A/”-tri(p-toluenesulfonyl)1,4,7-triazacyclononane 88. The product obtained was 
not that of the free base desired but an intractable mixture of starting material and 
impurities. There was no sign of detosyiation. The reaction was repeated several 
times with no success.
5.4.6 Sodium/ Naphthalene Reduction Method
Reductive cleavage in this manner is useful in certain cases.117,121'22 The 
tosylated compound was added to a sodium naphthalide solution and DME at low 
temperatures. The product was generally obtained with naphthalene still present and 
purified by column chromatography.
This technique was employed to cleave reductively the 
/V,A/,,/\f-tri(p-toluenesulfonyl)-1,4,7-triazacylononane 88 using the method of 
Heathcock and Blumenkopf.123 This compound was chosen again as it was formed 
on a larger scale than that of the other macrocyclic compounds. Limited success 
was again observed with this technique as a viscous yellow oil was obtained which 
on analysis still showed the tosylate signals to be present in the 1H NMR spectrum as 
well as signals for ring opened products.
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5.4.7 Phenyldimethylsilyl Lithium Method
The use of Gilman’s reagent (phenyldimethylsilyllithium) is one of the most 
recently employed techniques in sulfonamide cleavage, being pioneered by Dr Ian 
Fleming of Cambridge University. He admits that this, as with all of the other agents 
which can be employed in sulfonamide cleavage, has its limitations and 
incompatibilities since it is a powerful nucleophile which reacts with a wide range of 
electrophiles. This compound is suitable to afford secondary amines but not primary 
amines.
Gilman’s reagent124 is formed at 0 °C from lithium and phenyldimethylsilyl 
chloride by slow cleavage of the Si-Si bond of 
1,1,2,2-tetramethyl-1,2-diphenyldisilane after the rapid formation of the disilane as 
shown in Scheme 66.125 It was found that two or more molar equivalents were 
necessary for the cleavage as the by product from the cleavage, which was probably 
phenyldimethylsilyl sulfinate, reacts rapidly with the second equivalent of the 
silyllithium reagent.91
PhMe2SiCI— - — PhMe2SiLi  -------»» PhMe2SiSiMe2Ph
Li Scheme 6 6
The idea behind the use of this reagent as a sulfonamide cleaving agent is 
that on treating diphenyl sulphone with phenyldimethylsilyl lithium the organic layers 
from the work up were not organic products derived from the diphenyl sulfone but the 
hydrolysis products from the silicon reagent. This suggested that the lithium reagent 
had attacked the sulfur to give the silyl sulfinate ester, displacing phenyllithium as 
shown in Scheme 67. The ester will further react and form the lithium salt which will 
stay in the aqueous layer.
so.
SOJJ
(i) 2 equ. PhlVU^SiLi, THF
(ii) CO2 Scheme 67
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This cleavage method was applied to several of the macrocyclic sulfonamide 
compounds synthesised, including both aza and aza, oxa systems of varying ring 
sizes and heteroatom content.
The tri(p-toluenesulfonamide) 88 was treated with phenyldimethylsilyl lithium.91
This technique showed some potential as partial sulfonamide cleavage was 
observed. Possibly a larger excess of the reagent could improve the reaction.
Using the same sized ring but replacing a sulfonamide group with oxygen, 
compound 141, was also treated with this reagent for 6 h at 0 °C. No success was 
achieved as starting material was recovered.
The triazatrioxa compound 150 with a larger ring size was partially detosylated 
(50-60 %). This was carried out using 3.5 equivalents of the reagent per sulfonamide 
group as shown in Scheme 68. The yield of the oil, however, was very poor and 
there were also a larger percentage of impurities and also the original starting 
material was present. The mixture could not be separated by column 
chromatography.
fNTs O \
(i)
rNH \ /O \
‘NTs
V
NTsy v
150
0 ^  NH NH O'
y  (i) PhMe2 SiLi, THF v _ v ^ /
160
Scheme 68
A similar observation was found on the treatment of the diaza,trioxa 
compound 147 with the reagent. Detosyiation appeared to increase to 70% to afford 
160 in this instance (Scheme 68).
Finally the triaza.dioxa compound 149, was also treated with the 
phenyldimethylsilyl lithium reducing agent with 3.5 equivalents for each tosyl group. 
Surprisingly the 1H NMR spectrum showed no detosyiation had taken place. 
However the mixture which was obtained contained impurities as in previous cases 
which were inseparable from the starting material.
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NHNTs
NHNTs
(i) PhMe2 SiLi, THF 161147
Scheme 69
This technique was the final one employed in the attempted detosyiation of 
the sulfonamide macrocyclic systems. It was the one which showed the most 
potential for development.
5.4.8 Detosyiation Conclusions
The sulfonamide cleavage methods attempted proved to be fruitless and in the 
majority of cases a waste of starting materials as the recovery of pure starting 
compounds by column chromatography yielded very small amounts.
The above attempts and different methods represent a long period of time and effort 
as the materials which were subjected to the detosyiation techniques required to be 
resynthesised many times to allow further investigation into the different methods and 
conditions tried for the sulfonamide cleavage.
In hindsight it may have proved to be more beneficial if a different route for 
formation of the macrocyclic systems could have been attempted. Different nitrogen 
protecting groups such as mesyl groups may be used or further investigations carried 
on condensation reactions with acid chloride or ester moieties. These methods, 
however, afford different problems as the yields in the cyclisation step using mesyl 
groups are much lower than when using tosylate groups. Vigorous conditions and 
long periods are required for crab cyclisation techniques.
5.5.1 Biological Evaluation of Macrocyclic Compounds
As with the previous biological evaluation described in Chapter 3, it was 
performed against the P562 leukaemic cell line by Professor John Hartley at 
University College London. The cytotoxicity of the compounds was examined 
against the cell line. The DNA sequence specificity, crosslinking ability and single 
strand Taq stop assay were also studied.5960
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5.5.2 Results of Biological Evaluation of Aza Macrocyclic 
Alkylating Agents
Chlorambucil was run in parallel with the test compounds as a positive 
reference. It was also the control compound when examining sequence specificity.
The selection of compounds tested incorporates a variety of ring sizes from a 
three membered single alkylating agents through bis, tris and tetra aza compounds of 
up to fifteen atoms within the cyclic system. The results are shown in Table 6 .
On examination of the cytotoxicity the lowest IC50 values were observed for 
the tri and tetra functional alkylating agents 76, 73 and 91 with cytotoxicity values of 
7.5, 1 0  and 13 pM respectively. These three compounds showed cytotoxicity values 
much lower than that of chlorambucil, which is a drug commonly used in 
chemotherapy, and about the same as melphalan (another drug used in 
chemotherapy). Although compound 79 is very similar structurally to compound 76 it 
appears to have a much lower cytotoxicity value which was rather unexpected.
The mono and bifunctional alkylating agents 67 and 64 showed very little 
cytotoxicity towards this cell line.
Compound
No.
IC50 pM % Cross 
-linking
Ranking
0.01 pM 0.1 pM 1.0 pM 10 pM
64 > 1 0 0 2 2 1 0
'
6
67 > 1 0 0 4 7 23 51 5
91 13 32 1 0 0
' '
3
73 1 0 64 1 0 0
'
2
76 7.5 16 94 1 0 0 1
79 < 1 0 0 77 1 0 0 4
Chlorambucil has an IC 5 0  value of 45 pM 
Melphalan has an IC 5 0  value of 8.5 pM 
Table 6
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The cytotoxicity results were mirrored by the activity levels in the DNA 
crosslinking experiments apart from compound 79 which had the best crosslinking 
value of 77% at 0.01 pM and 100% crosslinking at 0.1 pM. The second best 
crosslinker was compound 73 with 64% crosslinking at 0.01 pM and 100% 
crosslinking at 0.1 pM. 91 was slightly less efficient at crosslinking with 32% at 0.01 
pM and 100% crosslinking at 0.1 pM. The final tetra alkylating agent 76 showed 
100% crosslinking at ten times the concentration as the other three tri and tetra 
functional compounds.
The three compounds 73, 79 and 91 were described by Professor Hartley as 
“being amazing crosslinkers and amongst the most potent that he has passed 
through this specific screen”. They are at least four logs better at crosslinking than 
chlorambucil.
Although the compounds 73, 79 and 91 gave clear reactivity at 1 pM for 
crosslinking this was not reflected in the overall covalent binding. They produced 
much higher crosslinker to mono adduct ratio than the others tested such as 64, 67 
and 76. This was expected because of the multiple levels of chloroethyl groups 
present giving rise to increased chance of crosslinking.
76 revealed extensive covalent binding in the Taq stop assay. Stop sites are 
those of guanine bases with sequence specificity similar, but not identical to that of 
chlorambucil. The other compounds which were efficient crosslinkers gave good 
bonding patterns. However, they were not very sequence specific. Only at lower 
doses was there any evidence of sequence specificity similar to that of chlorambucil. 
There were also small differences in the intensity of some bands, but this was not 
very striking.
The pattern of alkylation of compounds 64, 67 and 79 was again somewhat 
different from that of chlorambucil.
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5.5.3 Results of Biological Evaluation of Aza, Oxa and Aza, 
Thia Macrocyclic Alkylating Agents
Compound
No.
IC50 pM % Cross 
-linking
0.01 pM 0.1 pM 1.0 pM 10 pM
122 > 100 0 1 4 5 4
125 > 100 0 1 5 4 3
134 2.7 3 43 100
‘
1
155 > 100 0 0 4 49 2
Table 7
In general the biological results, shown in Table 7, for the above compounds 
were very disappointing for all but one compound.
The IC s o  values for compounds 122, 125 and 155 were all above 100 pM 
which was rather disappointing. However, the most impressive compound tested 
overall was that of 134 which had a cytotoxicity IC 5 0  value of 2.7 pM. This value is 
much lower than that of chlorambucil and melphalan. It also showed very good 
crosslinking values, but not quite as efficient as some of the aza alkylating agents in 
Table 6, but still showing evidence of good activity. Similarly to the aza compounds 
tested above, compound 134 gave stop sites in the Taq stop assay of guanine and 
was similar but not identical in sequence specificity to chlorambucil.
Compounds 67 and 79 showed no evidence of covalent bonding nor produced 
significant stops in the polymerase assay at the doses used.
The only other compound which showed any evidence of crosslinking was the 
thia, aza agent 155. Neither of the oxa, aza compounds showed much evidence of 
crosslinking. A similar observation was noted in the Taq stop assay and sequence 
specificity.
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5.6.1 Conclusions of Biological Evaluation
On consideration of the results obtained from the biological evaluation the 
agents with most potential for anti-cancer development were those of the aza tri and 
tetra chloroethyl compounds, 73, 76 and 91 which showed excellent cytotoxicity and 
crosslinking values. The only compound containing heteroatoms other than nitrogen 
in the system which showed good potential was 134. This was the compound 
containing benzyl moieties and shown in the other biological evaluation in Chapter 6 
and Chapter 7 to have a range of biological activities.
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Chapter 6
6.1.1 Hypoxia Selective Compounds
As the body of evidence for the presence of hypoxic regions126 in many 
tumours grows so does the possibility of developing drugs which will be selective to 
cancer cells alone. The phenomenon of hypoxia could be extensively utilised in 
designing features within drug systems to be activated in regions of low oxygen 
levels.127
Many hypoxic regions have been implicated128 in the emergence of drug 
resistance and metastatic phenotypes. Rice et al reported an amplification of the 
dihydrofolate reductase and P-170 glycoproteins genes with increased resistance to 
methotrexate and adrianamycin.129 Young and Marshall reported that hypoxia 
resulted in the emergence of clones with markedly enhanced metastatic potential.130 
These data indicate that hypoxic cells can negatively impact the effect of tumour 
treatment making them important targets for novel compounds which may eradicate 
tumour cells in the hypoxic environment.
Previously this idea has been investigated in a variety of areas such as in the 
development of metal complexes of current active prodrugs which could be 
bioreduced in the body thus liberating the active moiety from the prodrug. Also 
quaternisation of A/-mustards could be employed. The quaternisation of tertiary 
amines with suitable leaving groups which could be utilised in biological systems was 
thought of as far back as the 1950s131 as these compounds would increase the water 
solubility of the drugs being employed.
6.2.1 Quaternary Nitrobenzyl Compounds
Hypoxic selective cytotoxins (HSCs) are generally capable of undergoing 
selective metabolism (usually reductive) under hypoxic conditions to generate a 
much more toxic species. Conceptually they consist of three domains:132 a "trigger", 
which undergoes activation on hypoxic selective reduction, followed by the "effector" 
which is activated on the reduction of the "trigger"; and finally the "linker" which 
connects the other two domains and communicates the change.133
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One set of compounds which have been extensively studied by Denny et al in 
New Zealand are nitrobenzyl halides.132133
Nitrobenzyl quaternary compounds are known to undergo fragmentation after 
one electron reduction as shown in Fig 35 using mechlorethamine 159 as an 
example.
The mechanism of the activity of compounds of this type is thought to be that 
of a one electron reduction to form the radical anion which in turn undergoes 
intramolecular transfer and decomposes to the radical anion and the halide ion. 
Evidence for the initial radical anion and the subsequently formed nitrobenzyl radical 
have been proven by the difference in intensity of absorption spectra between radical 
compounds and non radical starting materials. Thus the rates of transfer from 
starting material to radical anion can be measured; for example p-nitrobenzyl 
chloride, bromide and iodide are 4 x 103, 1.7 x 105 and 5.7 x 105 s"1 respectively.
i©
NO-
ch j-'' \  
159
Fig 35
Fig 35 is shown as in the literature.132,133,139
Evidence also indicates that the o-derivative decomposes much more rapidly 
than the meta. The pKa of the p-nitrobenzyl bromide anion radical is 2.8 and the 
protonated form is found to undergo intramolecular transfer around 60 times more 
slowly than the anion radical. The reactivity of the various radical anions is 
rationalised in terms of spin density and charge distribution at the various positions 
on the ring and in terms of electrophilicities.134 Thus o- or p- is preferred for a faster 
reaction.
Many of the compounds which have been synthesised contain a nitro aromatic 
moiety. This is because the compound must be highly activated to release the 
alkylating agents under hypoxic conditions in neoplastic cells. Nitrobenzyl halides are
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regarded as prototypes in this area of nitroreductase catalysed bioreductive alkylating 
agents.
Under aerobic conditions o- p- and m-nitrobenzyl chloride radical anions 
reduce oxygen to superoxide as is demonstrated by oxygen consumption and spin 
trapping of the superoxide with 5,5- dimethyl-1 -pyrroline-A/-oxide. At low oxygen 
conditions the o- and p-nitro radical anions undergo intramolecular electron transfer 
and decompose to nitrobenzyl radicals which can be spin trapped with f-nitrobutane. 
The radical adducts are characterised by a nitrogen hyperfine splitting of 16.5 G and 
two equivalent p hydrogen hyperfine splittings of 1 0 . 6  G . 135
Some nitrobenzyl halides have been evaluated as HSCs and shown evidence 
of selective killing of hypoxic EMT6  cells. This evidence has been reviewed. 136,137
It has been found that quaternary ammonium salts are more stable than those 
of the corresponding chlorides. 132,135,138,139 Analogues, such as 
o-nitrobenzylmethylamine have shown high selectivity for hypoxic cells in vitro1 3 3 ,136 
and in v/'vo133 along with greater cytotoxicity against intact rather than dissociated 
EMT spheroids. The m-nitro isomer was found to be less cytotoxic than either of the 
o-, or p-nitro isomers which is consistent with the previous literature134 on the subject 
which indicates that the rates of fragmentation are lower for the m-isomer. The 
fragmentation can therefore be controlled by appropriate structural changes allowing 
the fragmentation to be competitive with the back oxidation process in particular 
oxygen concentrations. To some extent the toxicity is also dependent on the 
complete reductive activation of the nitro heterocyclic drugs by the enzymes within 
hypoxic systems.
A seperate factor which can be varied in the compounds is that of reduction 
potentials. Generally speaking the desired reduction potential for HSCs is between
-300 and - 450 mV. The large positive Hammett substitutent parameter (a  o,p) of the 
quaternary function equates to -330 mV for the p-isomer which is within the desired 
range. Thus control of this factor can be maintained within the design of the 
compound. Mechlorethamine shows very high selectivity for hypoxic EMT6  cells in 
culture, rising to several thousand fold after 4 h. This is an unusual time dependance 
for which the reasons are unknown but may be due in part to the slow kinetics of 
release and subsequent build up of mechlorethamine within the hypoxic cultures. 139
107
There are several advantages of these systems such as the cationic charge 
on the quaternary salts which ensures water solubility; control of the lifetimes of 
radicals; control of the reduction potential and rates of fragmentation of the nitro 
benzyl moeity. A disadvantage is that the cellular uptake of the compounds within 
the biological systems is slow.
For these reasons this type of anticancer agent merits further investigation.
6.3.1 Synthesis of Quaternary Nitrobenzyl Compounds
In an attempt to develop prodrugs which are hypoxic selective a selection of 
twelve novel quaternary nitrobenzyl nitrogen mustards were synthesised. The test 
compounds were synthesised from alkylating agents which had previously been 
synthesised and had undergone biological testing against either the human HT29 
and BE cell lines or the human P562 leukaemic cell line and had shown promising 
results.
The compounds synthesised were either o- or p-nitro substituted derivatives, 
and not m- as the previously reported compounds which were m-nitrobenzyl 
alkylating agents were either inactive or much less active than the corresponding o- 
or p- derivatives. The influence of having different potential for alkylation has also 
been investigated by the incorporation of from one to four different alkylating sites in 
the molecule.
Compound 160 has previously been tested against the human colon 
carcinoma cell line HT29 and was found to be four times more toxic in Walker rat 
tumour cells under hypoxic conditions.54 This, however is not as selective as nitromin, 
Fig 36, which operates by a one electron reduction intermediate. The nitrogen anion 
radical has been proposed to explain the DNA strand breakage observed in addition 
to DNA crosslinking in cells treated with this compound. 140
Nitromin
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Compounds 162a and 162b were synthesised starting from the readily 
available piperazine (1,4-diazacyclohexane). 1,4-Bis(2-hydroxyethyl)piperazine 6 6  
was obtained as a white solid on treatment of piperidine with ethylene oxide in EtOH 
according to literature,58 in good yield. The o- or p-nitrobenzyl moiety was attached 
on treatment with o-nitrobenzyl chloride or p-nitrobenzyl bromide, respectively, in 
acetonitrile under reflux conditions as a white solid for the o-derivative and as a beige 
solid for the p-derivative. The target compounds 162a and 162b were formed as 
chlorides by substitution reaction in thionyl chloride and recrystallised from EtOH and 
diethyl ether as white solids.
HO
HO.
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OH 0 -NO2  X=CI(a; 
P-NO2  X=Br(b;
(i) o-nitrobenzyl chloride, 
p-nitrobenzyl bromide, 
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(ii) thionyl chloride
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Scheme 70
Synthesis of the diol has previously been discussed in Chapter 4. The IR 
spectrum for the o-nitrobenzyl derivative, compound 161a, showed hydroxyl 
stretches at 3387, 2924 and 2853 cm-1 with hydroxyl bending at 1316 cm*1. Also 
present were aromatic stretches at 1609 and 1526 cm'1. The nitro group stretches 
were shown at 1577 and 1344 cm-1. The 13C NMR spectrum showed four CH carbon 
signals in the aromatic region as well as two quaternary carbon signals from 5 
138.5-125.6. The benzyl CH2 carbon was observed at 8  58.2 and the signals for the 
carbons of the CH2 adjacent to the nitrogen were observed at 5 47.5 and 8  38.0.
The p-nitrobenzyl derivative, 161b, showed stretches in the IR spectrum at 
1525 and 1608 cm' 1 for the aromatic vibrations. The hydroxyl stretches were 
observed at 3418, 2981, 2914 and 1350 cm 1. The 13C NMR spectrum showed only 
eight signals due to the symmetry within the compound. Four signals occurred in the 
aromatic region at 8  150.1, corresponding to the carbon with nitro group attached and
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5 135.4, 132.6 and 125.4 representing the remaining carbons in the aromatic moiety 
and the AA’BB' system. The benzyl CH2 group carbon was observed at 5 58.4 and 
the CH2 adjacent to the hydroxyl group occurred at 5 55.4. The 1H NMR spectrum 
clearly showed the AA'BB' system at 5 8.13-8.08 and 8  7.51-7.42 as a complex 
signal. The methylene protons alpha to the nitrogen were shown as a broad singlet 
at 5 2.28 and the benzyl CH2 protons at 5 3.70 as a singlet and finally the protons of 
the CH2 group alpha to the hydroxyl group are represented as a singlet at 5 3.53.
The chlorides 162a and 162b were synthesised by general methods. The IR 
spectra showed the absence of the hydroxyl stretches and the addition of a stretch at 
approximately 750 cm'1. In the 1H NMR spectrum the signal for the carbon next to 
the chloride group occurred at 8  38.
The previously synthesised compound 160 was chosen to develop into a 
quaternary nitrobenzyl alkylating agent due to the initial promising crosslinking activity 
and cytotoxicity values observed on biological evaluation of 160 as an anticancer 
agent. 54
Compound 10 (Fig 26 in Chapter 3) was synthesised similarly to the route 
and methods employed by Dr Nicola Henderson starting from DL-pipecolinic acid 
forming the methyl DL-pipecolinate hydrochloride salt 164 using MeOH and thionyl 
chloride instead of 2 ,2 -dimethoxypropane and concentrated hydrochloric acid 
previously used in the synthesis of this compound. Two of these molecules were 
coupled using succinyl dichloride in chloroform with two equivalents of triethylamine 
as a base to form the piperidine base in situ and to mop up the hydrochloric acid 
formed to minimise ester hydrolysis to give 165. The amide and ester were reduced 
in one step using lithium aluminium hydride in good yield, as shown in Scheme 6 6  to 
afford the desired compound 1 0 .
Compound 165 showed signals at 8  170.9 representing the ester carbonyl and 
at 8  57.5 representing the chiral centre carbon in the 13C NMR spectrum. The rest of 
the signals in the 13C and the 1H NMR spectra were as reported by Henderson et al.55
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(i) MeOH, thionyl chloride
(ii) malonyl chloride, Et3N, CHCI3 NH^^^COoH
(i)
(iii) LiAIH4, THF 163
.HCI
NHX^ "C 0 2CH3 
164
J 10
OH
(iii)
(ii) n=2
Scheme 71
,, C02Et
X
165
The chlorides 167a and 167b were obtained by substitution reaction on stirring 
in neat thionyl chloride and recrystallised from EtOH and diethyl ether as a white solid 
167a and an off white solid 167b, respectively, as shown in Scheme 72. Diols 166a 
and 166b were isolated and immediately chlorinated without full characterisation 
other than 1H NMR spectra. The final products 167a and 167b showed the absence 
of hydroxyl stretches and the addition of CH2-CI stretches at approximately 750 cnrr1 
in the IR spectra with the aromatic and nitro stretches as mentioned previously.
.OH NO- OH
n=2
N 0 2^ —HO' NO' 2XHO'
166
©N- o- NO2  X= Cl (a) 
p- NO2  X=Br (b)
N02 ,2X
(i) o-nitrobenzyl chloride or p-nitrobenzyl bromide, 
acetonitrile
(ii) thionyl chloride Scheme 72
The third set of o- and p- substitued nitrobenzyl compounds were those shown 
in Scheme 73. These compounds are only capable of single alkylation. Compound 
46 as previously mentioned in Chapter 3 was tested against the P562 leukaemic cell 
line. Treatment of A/-methyl-piperidine-2 -methanol 45 with o-nitrobenzyl chloride or
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p-nitrobenzyl bromide in acetonitrile gave the quaternary salts, 168a and 168b, as 
white solids. Both the o- and p- substituted compounds showed hydroxyl stretches at 
3200 to 3500 and -1050  cm' 1 in the IR spectra. Also observed were the aromatic 
stretches at 1518 and 1604 cm 1 and C -N 0 2 stretches at 1330 cm-1. On treatment 
with thionyl chloride the chlorides, 169a and 169b, were obtained and recrystallised 
from EtOH and diethyl ether as white crystals, in acceptable yields. The IR spectrum 
showed the absence of the hydroxyl stretches and the presence of a CH2-CI stretch 
at 750 cnrr1.
(i) o-nitrobenzyl chloride ^  ^  
or p-nitrobenzyl bromide^'sj:^ 
acetonitrile
(ii) thionyl chloride
o- NO2  X= Cl 
p- NO2  X= Br Scheme 73
Quaternary nitrobenzyl chloride, 171, was formed from the diol 3 which had 
been reported in Chapter 3 . 141 Dipicolinic acid was refluxed with thionyl chloride for 
48 h before the acid chloride which was formed was reacted with EtOH to give the 
diester 2. Hydrogenation of the ester and methylation of the nitrogen was carried out 
using the method of Feldkamp et a / . 142 The hydrogenation of the pyridine ring was 
carried out in aqueous acetic acid using Adams’ catalyst. The isolation of the 
unmethylated product was unnecessary as N- methylation could proceed in the same 
solution using a reductive methylation procedure. This was completed by 
exchanging the platinum catalyst for palladium on charcoal and adding a slight 
excess of aqueous formaldehyde. The diester was then hydrogenated to afford the 
methylated product. This was the preferred method of methylation. The non 
aromatic cyclic compound was obtained as white crystals. This diester 2 was 
reduced using lithium aluminium hydride in THF to afford the diol product 3, as shown 
in Scheme 1 in Chapter 3.
The quaternisation of the nitrogen was performed in acetonitrile using the 
appropriate halogenated nitrobenzyl derivative to afford compound 170. The test 
compounds were obtained by chlorination of the quaternised diol compound 171
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using thionyl chloride. These compounds were recrystallised from EtOH and diethyl 
ether, as shown in Scheme 74.
CH
.Br
171170
(i) p-nitrobenzyl bromide,] 
acetonitrile
(ii) thionyl chloride
N02 
Scheme 74
NO-
The quaternised diol 170 was synthesised in reasonable yield. The IR 
spectrum showed vibrational stretches in the aromatic region and nitro stretches as 
in the previous p- nitro benzyl compounds. The final test compound 171 was also 
obtained in acceptable yield. The IR spectrum showed the absence of hydroxyl 
stretches. The presence of a CH2-CI stretch was observed at 704 cm-1. The 13C 
NMR spectrum showed four carbon signals for the aromatic moiety between 8  159.4 
and 8  124.9. The rest of the signals observed were three CH2 carbons, one methyl 
carbon and one quaternary carbon signal which corresponds to the remainder of the 
structure.
Compound 134 had previously been synthesised and had undergone 
biological evaluation against the P562 human leukaemic cell line by Professor John 
Hartley at University College London. The observed IC50 value of 2.5 pM was much 
lower, than that of chlorambucil or melphalan.
Compound 132 was formed following the method of Lindoy and Armstrong101 
using Williamson condensation between 1,2-dibromoethane and salicylaldehyde in 
good yields. This was followed by a condensation reaction or Schiff base cyclisation 
to afford the macrocyclic imine 131. Reduction with borane THF afforded the free 
base 132 as shown in Scheme 48 in Chapter 5. Structures of these compounds 
were confirmed by comparison of spectral data with those of Lindoy and 
Armstrong. 101
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Diol 133 was formed on reaction of 132 with ethylene oxide in EtOH in a 
reasonable yield. As before the quaternary nitrogen was formed on reaction of diol 
133 with p-nitrobenzyl bromide in acetonitrile and the product 172 was chlorinated by 
substitution reaction in neat thionyl chloride to afford 173 as a light green solid in 
good yield as shown in Scheme 75. The diol was not fully characterised before 
chlorination.
172133
,N© ®N.
OH HO' OHHO'
.2Br
173
©N.
Cl (i) p-nitrobenzyl bromide, acetonitrile 
(ii) thionyl chloride
2Br
Scheme 75
NO- NO-
Cyclen is a readily available starting material and presents the potential for 
introducing four alkylating arms thus increasing the possibilities for crosslinking if this 
compound was developed into an multifunctional alkylating agent.
The tetraalcohol 76 was formed on reacting cyclam with an excess of ethylene 
oxide in EtOH as reported by Hancock and co-workers using general methods.58 On 
attempting the formation of the quaternary amines only one quaternisation reaction 
occurred leading to 174. The tetraol was then converted into the desired chloride 
product 175 as shown in Scheme 76.
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OH HOHO- •OH Cl
HO- -OH HO -OH Cl
.NO- NO-
.Cl(i) o-nitrobenzyl chloride, acetonitrile
(ii) thionyl chloride 175 Scheme 76
Product 175 was obtained as an off white solid which was recrystallised from 
EtOH and diethyl ether. The IR spectrum showed CH2-CI stretching at 744 cm*1. 
The nitro group showed stretching at 1546 and 1350 cnr1 and aromatic vibrations at 
1526 and 1628 cm'1.
A variation from a cyclam type would be the incorporation of an amide group, 
as in compound 177. This presents the possibility of developing bifunctional 
alkylating agents as the nitrogen lone pairs on the amides are delocalised and not 
available for alkylation. The free base nitrogens reacted with the ethylene oxide to 
form the diol 81, which was in turn converted into the quaternary amine using 
o-nitrobenzyl chloride in acetonitrile to form compound 176. The chlorination 
occurred as before using neat thionyl chloride to yield the desired product 177 as 
shown in Scheme 77. The IR spectrum of the target compound showed CH2-CI 
stretches at 749 cm-1, the carbonyl stretch was present at 1685 cm'1 and aromatic 
stretches at 1529 and 1605 cm'1.
.NH HN. NH HN..NH HN.
HO'
OH
■OH Cl
HO'
NO- 176
(i) o-nitrobenzyl chloride
(ii) thionyl chloride .2CI
Scheme 77
Continuing the formation of multifunctional alkylating agents a system with 
three alkylating arms was synthesised from 1,4,9-triazacyclononane (tacn), as shown 
in Schemes 31 and 32 in Chapter 4. The synthesis of 1,4,9-triazacyclononane is
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well documented and proceeds under high dilution conditions as described in 
Chapter 4. The tosylated macrocycle was obtained as a white solid in reasonable 
yield. This underwent deprotection using concentrated sulfuric acid and sodium 
hydroxide to leave the free base as a white solid. The yield was very poor but was 
sufficient to carry on as in Scheme 78. As before the alcohol 178 was formed from 
ethylene oxide and quaternised in acetonitrile with the benzyl halide to give 179. 
Finally the chloride 180 was obtained using neat thionyl chloride as an off white solid.
The 13C NMR spectrum of the quaternised triol 179 showed signals at 8 144.8, 
129.8, 127.6 and 8 123.51 representing the aromatic carbons. Signals were also 
observed at 8 58.6 58.0, 49.9 and 30.9 corresponding with the remaining carbons. 
The 1H NMR spectrum of the chloride 180, showed singlet signals at 8 3.37, 4.44 
and 4.48 and doublet signals at 8 7.47-7.52 and 8.12-8.17 representing the 
methylene groups adjacent to the nitrogen, the methylene next to the aromatic 
moiety, the chloride and finally the AA'BB' aromatic system. The IR spectrum 
showed the presence of CH2CI stretches at 730 cm*1 along with the aromatic 
stretches at 1524, 1606 cm*1 and the nitro group stretch at 1349 cm*1.
HO
HO
■OH
®  N:© N :
“OH
180179178
•3Br k U  NO-Scheme 78
(i) p-nitrobenzyl bromide
(ii) thionyl chloride n o 2
6.4.1 Biological Evaluation
The compounds synthesised above were tested by Professor Ian Stratford 
from the School of Pharmacy and Pharmaceutical sciences at the University of 
Manchester.
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6.4.2 Experimental Detail
Selective toxicity to hypoxic A549 cell lines was determined using the MTT 
assay as reported by Stratford and Stephens,143 and also Jaffarr et al .144 
The cells were treated with the drug for 3 hours at 37 °C under aerobic or hypoxic 
(N2) conditions. The drug was then removed and the cells allowed to proliferate for 
three days prior to the MTT assay.
The results of the biological testing are presented in Table 8. IC50 (air) values, 
the concentrations required to kill 50 % of aerobic cells under the conditions of the 
assay, are divided by the IC50 (N2) values, the concentrations required to kill 50 % of 
hypoxic cells, to give the hypoxic cytotoxicity ratio. These values enable quantitative 
comparisons of bioreductive cytotoxicities of the drugs. The aerobic and hypoxic 
toxicities of selected compounds against this cell line were described by Robertson et 
a/.145
Compound
Number
ICso(air)
mM
IC50 (N2) 
mM HCR
175 0.097 ± 0.026 0.075 ±0 .016 1.3
173 0.031 ± 0.027 0.027 ± 0.005 1.1
180 6.61 ± 1.73 5.77 ± 1.09 1.1
171 0.864 ±0 .172 0.80 ± 0.11 1.1
169b 1.50 ± 0.196 1.23 ±0.151 1.2
Table 8
6.5.1 Conclusions
Only the five compounds listed in the table were actually tested. This was due 
to Professor Stratford having limited time and the initial tesing indicating that the 
remainder of the testing would be of limited value.
In all cases the compounds had marginally lower cytotoxicity values under 
nitrogen atmosphere than in the aerobic environment. The most active compound 
was compound 173 followed by 175 according to the lowest cytotoxicity values rather 
than differences between the two enviroments.
There can be no conclusions drawn about the activity being related 
preferentially towards either the 0 - or p-nitrosubstituted compounds as the 
compounds tested were all p-nitro substituted compounds.
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Indications were that the best activity would be obtained by bifunctional agents 
rather than trifunctional agents as 180, which was the trifunctional compound has 
the lowest activity. However, conclusions as to preferential activity by single or 
bifunctional agents is unclear as the second most active compound is a single 
functionality cyclam derivative. However, on comparison of compounds 171 and 
169b which are very similar compounds in structure, the bifunctional compound 171 
is slightly more cytotoxic than the single functional compound 169b. Thus indicating 
that bifunctional molecules have more potential than structurally similar single 
functionality agents.
The results found on biological evaluation of the above compounds were very 
disappointing and on examining the error margins on the values there is no 
significant differences in activity between the aerobic and hypoxic conditions. It was 
therefore decided that research in this area within the group would be brought to a 
close.
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Chapter 7
7.1.1 Other Biological Testing
Occasionally compounds which are found to be active in one biological system
can be active in a different biological environment. Two sets of compounds which 
have previously been synthesised and undergone anti-cancer biological evaluation 
have been selected to undergo a seperate biological evaluation process as potential 
anti-fungal or anti-parasitic agents (here we are going to examine action against 
Leishmania and Trichomanosis which are two parasitic tropical diseases).
7.2.1 Anti-fungal Investigations
Fungi are eukaryotic organisms which differ from plants in that they cannot 
photosynthesise food and therefore have to consume resources from dead matter as 
parasites on living organisms or in symbosis with another living being.
There are over 64,000 different species of fungi but due to difficulties in 
taxonomy there may be many more which have as yet not been discovered.146 Of 
these species over 13,000 exist as lichens. This type of fungal species is 
widespread and varies from simple moulds, yeast and rusts to larger members of the 
family such as toadstools.
The family is split into five groups: zygomycotina, mastiyomycotina, 
ascomycotina, basidiomycotina and deuteromycotina. The classes are distinguished 
by distinctive sexual and developmental differences.
Plant pathogenic fungi adopt a parasitic lifestyle, i.e. they eat living plants, and 
form a parasitic symbiosis in which only the fungi benefit. Some fungi only grow in 
association with a living host, i.e. obligate parasites. Others can only exist away from 
the host, i.e. saprotrophs which live on dead matter. Parasitic fungi can also be 
described according to their modes of nutrition. Nectrophoic fungi kill cells in the host 
before eating them whereas biotrophs consume only living cells.
Fungicides act by killing the development of fungal species (seeds) or mycelium 
(feeding system). There are generally two types of fungicides which are classified
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according to their uptake and mobility in the plants, protectant systems and 
eradication fungicides.
Protectant systems are a form of prophylaxis, i.e. treatment which prevents a 
disease. They are applied directly to an area of possible infection. They are 
incapable of penetrating plant tissues. Eradicant systems are applied after infection 
has occurred and have limited penetrative action. Both of these classes are 
non-systemic, i.e. not penetrative of living plants.
Chemical treatment is split into three forms: direct activity; toxic inactivation; or 
enhancement of resistance in the host plant.
Chemicals which act by killing or inactivating a fungus are directly acting. 
Those which prevent toxic secretions are inhibitory acting and those which enhance 
the resistance of the plant by altering its metabolism fall into the final category.
7.2.2 Polyamines
Polyamines are found in many forms throughout nature. They are found in 
every cell in the human body and play crucial but ill-defined roles in cell division and 
growth, e.g. putrescine, NH2(CH2)3NH2; cadaverine NH2(CH2)5NH2, spermidine 
NH2(CH2)3NH(CH2)4NH(CH2)3NH2; spermine NH2(CH2)3NH(CH2)4NH2 and ornithine 
NH2C H C 02H(CH2)3NH2. Spermine and spermidine are synthesised from putrescine 
which is synthesised from ornithine in fungi. Plants are also capable of synthesising 
putrescine from arginine as shown in Scheme 79.
ODC
ADC
OrnithineNH
Arginine
NH'NH'
NH
Agamatine
NH' NH-
N-carbamoyl putrescir^
NH NH'
Putrescine
Scheme 79Putrescine
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1. Arginine decarboxylase, 2. Agmatine iminohydrolase, 3. A/-caramoyl putrescine 
amido hydrolase, 4. Ornithine Decarboxylase.
Ornithine decarboxylase (ODC) is a 5'-pyridoxal phosphate (PLP) dependent 
enzyme and is a dimer of 80000- 82000 amu and a recent X-ray has shown ODC to 
exist as doughnut shaped dodecamers.147
PLPFig 37
PLP, Fig 37, has a high specificity for ornithine and decarboxylates it to 
putrescine, but it can also catalyse the decarboxylation of lysine to cadaverine. As 
fungi can only use the ODC route to produce putrescine whereas plants can use both 
routes there is the possibility of blocking ODC formation which would effect the fungi, 
i.e. the fungal growth can be curtailed by inhibiting ODC leaving host plants to use 
the ADC route. There are three classes of ODC inhibitors, the most significant class 
being suicide inhibitors, including DMFO (Fig 38) which has previously been shown 
to have anti-fungal and anti-cancer activity.148
F
© I p
0 2C
h3n^
^ nh2
Fig 38 DMFO
The second class is that of ornithine and putrescine analogues which are 
competitive inhibitors. This is the main area of interest of our research group in 
anti-fungal compounds. The final set of compounds are those which are capable of 
interacting or combining with PLP.
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7.2.3 Selection and Synthesis of Compounds Tested for 
Anti-fungal Activity
After examining the biological evaluation results on all of the compounds
synthesised and tested against the human leukaemic P562 cell line, the following 
small selection was submitted for further biological evaluation as potential anti-fungal 
agents to examine if they are active by inhibiting ODC.
The best anticancer activity was observed with the macrocyclic systems. Thus 
the majority of the compounds tested for anti-fungal activity are macrocyclic 
compounds with the exception of compound 30. The leaving group throughout the 
selection was maintained as chloride, to allow for comparison. All compounds were 
tested as the hydrochloride salts.
The first compound which was chosen was the bis alkylating agent, 29, which 
has the pyrrolidine system, formed from two L-proline rings, joined with a four carbon 
spacer length. The compound was synthesised as discussed in Chapter 3. The 
reason for choosing this particular compound was that it was shown to have 
reasonable activity against the human leukaemic P562 cell line.
The second compound chosen for testing against fungi was 82, which is the 
diamide bisalkylating system formed from cyclam. The potential of bisalkylation is 
maintained. The compound was synthesised as described in Chapter 4.
The third compound examined was the compound 128. The alkylating potential 
is bifunctional. The incorporation of oxygen into the system may show a marked 
difference from the aza systems. The compound was formed as described in 
Chapter 4.
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Compound 155 with bifunctional alkylating potential was also synthesised to 
investigate any effects the inclusion of sulfur into the systems would have on the 
activity. Thus the previous compound, 128, and this one can be compared as they 
differ only with respect to the heteroatom included. Although sulfur and oxygen are 
both Group VIA (16) elements they show large differences in character. They are 
both 2e‘ away from a noble gas configuration with essentially nonmetallic nature 
discussed in Chapter 5. 155 was synthesised as shown in Chapter 5.
The potentially tri alkylating compound 91 was formed as described in Chapter 
4. 91 was chosen to examine the effect of increasing the number of nitrogens 
present within the system and also increasing the number of alkylating sites present.
ci-
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The final alkylating compound contained the potential of tetra functionality. 
Compound 76 was formed from cyclam as in Chapter 4.
7.2.4 Biological Evaluation of Compounds
The fungicidal activity of the compounds was examined on infection of barley 
seedlings with the powdery mildew fungus Erysiphe graminis f.sp.hordei Marchal by 
Dr Dale Walters at the Scottish Agricultural College, Auchincruive. The effects were 
determined as in the literature.149(preprint)
The effects of compounds on growth and polyamine biosynthesis of 
Pyrenophora avenae were also examined. Growth of the Pyrenophora avenae was 
as in literature publication150 as is the determination of the formation of polyamines 
from radiolabelled ornithine in the fungus.
Radial growth was measured after five days; the % leaf area covered with 
powdery mildew was assessed ten days after inoculation. Compounds were applied 
to seedlings two days after inoculation and all compounds were used at 25 pM.
All compounds were tested as the hydrochloride salts.
Compound Radial Growth, mm % leaf area infected
control 3.7 ± 0.03 48.8 ± 4.48
29 3.7 ± 0.03 39.1 ±2 .9 6
76 3.1 ±0 .02 33.2 ±2 .1 5
82 3.4 ± 0.03 26.0 ±2.21
128 3.3 ± 0.02 21.3 ± 1.90
91 3.1 ±0 .03 38.8 ± 2.95
155 3.8 ±0 .03 33.8 ± 5 .9
Table 9
Table 9 shows the results of the two tests performed on the compounds. The 
first was the in vivo test on Pyrenophora avenae and the second was the in vitro test 
with powdery mildew. As in the previous chapter the error margins are significant.
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None of the tested compounds had any significant activity against the 
Pyrenophora avenae as the radial growth measured in mm was only slightly below 
that of the control. On the other hand significant activity was observed against the 
powdery mildew. All of the tested compounds had at least 9% less infected leaf area 
than the control. Two of these compounds were active, compounds 82 and 128. On 
examination of the structures of these compounds there did not appear to be any 
obvious similar features which would be responsible for the activity. The only 
similarities between compounds 82 and 128 is that they are both bifunctional 
alkylating agents containing oxygen atoms within the system and that they contain 
medium sized macrocycles. 91 was nearly inactive. This was surprising as it 
contains three alkylating moieties which would be expected to confer activity. As 
compound 29 showed very little activity in either of the tests the indication was that 
pyrrolidine systems do not possess the potential of anti-fungal activity, whereas 
certain multifunctional macrocyclic alkylating agents posess some anti-fungal activity.
Compound Radioactivity in poiyamine (dpm mg protein-1)
Putrescine Spermidine Spermine
control 29.2 ± 3.48 30.4 ±3.78 65.9 ± 3.14
29 36.5 ± 1.91 53 .214 .81 7 9 .8 1 6 .5 5
76 16 .6±0 .57 5 .7 1 0 .7 3 44 .3 15 .81
82 5.7 ± 0.63 4 .9 1 0 .5 3 6 1 .2 1 7 .2 8
128 5.3 ± 0.39 4.9 1 0.56 26 .213 .81
91 3.1 ±0 .38 22 .6 1  1.97 11 .812.91
155 10 .010 .90 5 1 .0 1 4 .8 0 2 2 .01  1.80
Table 10
Table 10 shows the effect on the flux of the label from ornithine into the 
polyamines. Compounds 82, 128, 91 and 76 reduce the levels of putrescine 
dramatically. This is a very positive result as it indicates that the ODC levels would 
also be reduced. The spermidine levels were comparable to that of putrescine apart 
from one anomally. 155 gave conflicting results where the levels increased by 10 
fold to that of putrescine. This may be misleading as you require putrescine to form 
spermidine. The spermine levels then drop back to 22.0 dpm mg protein1. 
Experimental error may be to blame for this inconsistency. The spermine levels for 
the other compounds were comparable to the control apart from 128 and 91 which 
were much lower.
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Thus overall 128 was the best compound in vitro against powdery mildew and also in 
in vivo tests againt Pyrenophora avenae.
7.3.1 Tropical Parasitic Disease Investigations
There are now over 30,000 named species of protozoa of which 10,000 are 
parasitic invertebrates and they exist in almost every species of vertebrate. Thus it is 
not surprising that man and most domesticated pets act as hosts to these parasites. 
The diseases which are caused by these parasites are out of proportion for the 
number of species involved. The protozoa which infect humans range from forms 
which are never fatal to those which cause diseases such as malaria, sleeping 
sickness, Chaga's disease and leishmaniasis, which are now regarded as being 
major diseases in tropical countries and together threaten over one quarter of the 
population of the world.
Parasitic protozoa lie between the prokaryotic and higher eukaryotic organisms 
and share some of the characteristics of each. They are usually small, have short 
generation times, high rates of reproduction and have a tendency to induce immunity 
to reinfection in those hosts that survive.
7.3.2 Leishmania151'152'153
One such tropical disease which is caused by parasitic protozoa is that of 
leishmaniasis. This is a very unpleasant disease which causes blistering and lesions 
on the skin. The typical infection is cutaneous but may invade subcutaneous or 
deeper tissues causing hideous and permanent disfiguration in man. Leishmaniasis 
in man is known to be caused by a complex of six species and fifteen or sixteen 
subspecies. Cutaneous leishmaniasis is caused by Leishmania tropica and visceral 
leishmaniasis is due to Leishmania donovani. Some are self healing dermal forms 
such as L. tropica and L. mexicana whereas others such as L. donovani are found 
effectively to be non-healing visceral forms. L. donovani infection frequently 
progresses to fatal conclusions over a number of years. Approximately only one 
quarter of patients with visceral leishmaniasis will recover.
Cutaneous leishmaniasis is an infection of the skin and includes three distinct 
clinical entities: tropical sores; mucocutaneous leishmaniasis and disseminated 
anergic cutaneous leishmaniasis.
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After inoculation into the skin leishmaniasis parasites multiply by binary fission 
within histocytes which eventually rupture and release the parasites which enter other 
histocytes. The vector for this very unpleasant disease is that of the common 
bloodsucking sandfly. After ingestation by the insect vector the leishmania parasites 
change into flagellated leptomanads which multiply in the fly’s gut, giving rise to huge 
numbers of organisms. The fly then bites and regurgitates the organisms into the 
next host. Tropical sores then develop where the sand fly bites, often on hands, 
arms, legs, face and ears. The incubation period can be anything from two to eight 
weeks to as long as three years. Biopsy specimens reveal that many organisms are 
found both in histocytes and free in tissue. As immunity develops the overlying 
epithelium becomes hyperplastic and necrosis of the dermis causes ulceration. Later 
there is a shift from a pure histocytic reaction to a granulamatus reaction, which is 
characterised by increasing numbers of lymphocytes and plasma cells. As this 
occurs the organisms become reduced in numbers and are finally impossible to find. 
Healing proceeds when granulation tissue and scar tissue fill the crater. Lesions of 
mucocutaneous leishmaniasis are characterised by a necrotizing granulomatus 
reaction with many inflammatory cells with very few organisms. These lesions of 
mucocutaneous leishmaniasis are resistant to treatment.
In anergic cutaneous leishmaniasis there are many large histocytes in the 
dermis which contain the cutaneous leishmaniasis. Necrosis does not occur nor do 
granulomas form, but the parasites continue to multiply with increasing numbers of 
histocytes which accommodate them.
Diagnosis is generally by smears or biopsy specimens. Leishmania parasites 
are recognised by their shape, size and staining characteristics. Treatment for 
tropical sores within the first year with anti-malarials remains the most effective way 
of dealing with the disease.
7.3.3 Trichomanosis151152153
Trichomanosis is another protozoan parasitic tropical disease. There are three 
species which are common in humans throughout the world. These are 
Trichomanosis hominis in the caecum and large intestine, Trichomanosis tenax in the 
mouth and Trichomanosis vaginalis in the vagina and urethra of women and seminal 
vesicles and prostate of men. T. tenax is harmless whereas T.vaginalis is often
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harmless but may cause inflammation and discharge and is an increasingly important 
venereal disease infecting an estimated 180 million people worldwide. None of the 
Trichomanosis species form cysts but have rounded resistant stages. This means 
that the organism can survive in an external environment. T.tenax and T. vaginalis 
are both transmitted by direct contact. T. vaginalis infection in males rarely lasts 
more than four weeks as it is limited whereas in women it may persist for up to 
several years.
The genus Trichomanosis comprises flagellates that have three to five anterior 
flagella, an undulating membrane, an axostyle, and usually a cytosme.
These parasites are widely spread and effect nearly every mammal associated 
with man. T. vaginalis is the largest and most robust and is the only pathogen, 
although it had been suggested that heavy infections with T. hominis may cause 
diarrhoea.
7. vaginalis is a colourless pyriform flagellate. Its habitat is the vagina of the 
female and the urethra, epididymis, and prostate of the male. Hence it is frequently 
found in the urine. Reproduction takes place by binary longitudinal fission, with 
mitotic division of the nucleus. The trophozite is one of the most resistant parasitic 
protozoa. The incidence of infection is 10 to 25 % women, and higher in groups 
where hygiene is deficient. Only about 1/7 of the infected women get symptoms, 
although the vaginal secretions are invariably altered. There are several modes of 
transmission. Sexual intercourse, especially of asymptomatic infected males is 
probably the most important. However since young virgins are found infected, it 
appears that direct contact with infected females, contaminated toilet articles and 
toilet seats will transmit the infection. 7. vaginalis is the causative agent of persistent 
vaginitis. The flagellate is responsible for low grade inflammation. The bacterial flora 
and physiological status of the vagina, including pH, are among factors which 
determine infection. Clinical diagnosis is based on symptoms of burning, a frothy 
creamy discharge, and punctuate lesions and hyperemia of the vagina. The 
microscopic examination of a drop of saline for motile trichomonads of a fresh vaginal 
discharge is the most practical method of diagnosis. Prostatic secretions following 
prostatic massage and urine of the male should be examined. The most effective 
drug for treatment for both sexes is metronidazole. Because the drug is carcinogenic 
and mutagenic under experimental conditions it has been recommended only if the
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infection is severe and other measures have failed. Other drugs which have been 
applied with varying success to the vaginal mucosa by insufflation or by suppository 
are silver pictrate, furazolidone or iodochlorohydroxyquin. Attention to personal 
hygiene is the most important preventative measure and the detection of infected 
males could help in reducing infections.
This is an area where further development of the treatment could be 
exceedingly helpful to a large number of people.
7.4.1 Biological Evaluation
The biological evaluation was carried out by Professor Coombes at the 
University of Glasgow in the Parasitology department as follows.
7.4.2 Experimental Detail
The compound was dissolved to approximately 40 mg ml"1 in water (ideally) then 
dilutions of 1000, 500, 250, 100, 50, 25 and 10 pg ml"1 were made. 20 ml of the 
above dilutions were added to 180 pi culture at 105 pi"1 which means that the final 
drug concentrations were 100, 50, 25, 10, 5, 2.5 and 1 pg ml'1. The cultures were 
initiated at 105 ml"1 and incubated for about 24 h anaerobically at 37 °C for 
Trichomonads and 120 h aerobically at 25 °C for Leishmania promastigates.
Controls, i.e. no drug, were run in tandem and the cultures and drugs were cultivated 
in 96 microlitre plates. 5 ml of the 40 mg ml'1 stock and 195 ml of water were 
combined to give 1 mg ml"1 in 2.5 % DMSO. The remaining dilutions were also made 
up in 2.5 % DMSO. The procedure was then followed as above to have final 
concentrations of 0.25 % DMSO which did not affect the growth of the organism.
At the end of the incubation period, the cultures are first assessed by eye 
(microscope) and assigned arbitrary indications of cell growth.
7.4.3 Selection and Synthesis of Compounds Tested for 
Anti-Leishmania and Anti-Trichomanosis Potential
The compounds which were synthesised for testing against the two diseases 
were chosen to cover a selection of variables such as:
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• number of alkylating arms;
• number of atoms in heterocycles;
• number of nitrogens within the systems;
• other heteroatoms within the system;
• functional groups;
• number of quaternary nitrogens; and
• ortho and para substituted nitrobenzyl derivatives.
The compounds were all alkylating agents and tested as quaternary (either o- or 
p-substituted) nitrobenzyl salts. Most of the compounds tested were developed from 
compounds which had previously undergone biological evaluation against the 
leukaemic P562 cell line or BE29 or HT cell lines as described in Chapter 6 and had 
shown some promising cell selectivity or/ and cytotoxicity.
The synthesis of the first compound, 169b, was previously described in 
Chapter 6
CH
Br
169b
N02
The second and third compounds 162a and 162b were synthesised to study 
anticancer activity against HT29 and BE carcinoma cell lines as the free bases. 
They incorporate bifunctional alkylating potential within a small azamacrocycle. They 
also investigate if there are any differences in biological activity between o- 
substituted, 162a, and p- substituted, 162b, nitrobenzyl substituted compounds.
Their synthesis was discussed in Chapter 6.
©N ©N© N ©N
NO;
.2CI.2Br
162b 162aNO-
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Compound 10, was previously synthesised as the free base by Dr Henderson 
and showed promising anticancer activity against HT29 and BE carcinoma cell lines. 
The compound was synthesised as reported.54
NO-
©N. 2X
NO-
NO2  o X= Cl 167a 
NO2  p X= Br 167b
Product 10 showed a level of anti-cancer activity thus meriting further biological 
evaluation. The synthesis of the free base was as described in Chapter 5 followed 
by quaternisation, with both o- and p- derivatives, as discussed in Chapter 6 to 
afford 167a and 167b.
©N
NH HN
u
The penultimate bifunctional alkylating agent is compound 173. This is a large 
macrocyclic compound with four nitogen atoms within the cycle with two alkylating 
arms and incorporation two aromatic rings functionality. The nitrobenzyl groups 
attached are p- substitiuted. Compound 173 was synthesised and characterised in 
Chapter 6.
The diamide cyclam derivative 177 offered a bifunctional alkylating potential and 
incorporated the amide functionality. The o-substituted quaternary nitrogen 
compound 177 was chosen for testing.
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.Br
175
NO-
Potentially tetra alkylating agent 175 was synthesised as in Chapter 6. This 
compound is a large aza macrocycle quaternised with an o-substituted nitrobenzyl 
group. As stated in Chapter 6 the compound only had one nitrobenzyl moiety 
attached.
7.5.1 Biological Evaluation: Conclusions
The compounds were tested against the Leishmania and Trichomanosis and 
Table 11 shows the results of this testing.
Leishmania Trichomanosis
MLC LD50 MLC LD50
176 >25 >25 >25 10
162a >25 >25 >25 10
167a >25 >25 >25 >25
177 100 50 >100 25
173 50 10 >100 10
167b >100 >100 >100 >100
175 >100 50 >100 25
162b >100 >100 >100 >100
169b >100 >100 >100 >100
Table 11
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None of the results were particularly promising against either of the parasites.
There were, however, similarities in comparing the two sets of data.
The most active compounds against Leishmania were 162a, 167a, 173 and 
175. Thus indicates that bifunctional alkylating agents were preferential for activity. 
The p-nitrosubstituted compounds appeared to have limited biological activity. The 
most active compounds were of varying sizes thus no conclusions can be drawn 
about size preference. An interesting fact is that the most active compounds are 
those that contain nitrogen as the only heteroatom.
The most active compounds against Trichomanosis were again 162a, 176 and 
167a followed by 177 and 173. This indicates that the o-nitrosubstituted compounds 
had better activity than compounds which were p-nitrosubstituted. The bifunctional 
alkylating agents were also those preferred for biological activity. Again the size of 
the most active compounds varies thus no conclusions can be drawn for preferential 
activity. Finally the most active compounds against Trichomanosis were those 
containing nitrogen as the only heteroatom within the cyclic system
This information indicates that the macrocyclic aza compounds are consistently 
the ones which show the most promise for further development.
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Chapter 8
8.1.1 Experimental Detail
Reagents were purchased from Aldrich Chemical Company (Gillingham, UK) 
or Lancaster Synthesis (UK) and were used without further purification. Organic 
solvents were obtained from Rhone-Poulenc-Rorer and were dried, as necessary, 
using the procedures of Perrin and Armarego. Melting points, m.p., were determined 
in open capillaries using Gallenkamp apparatus and are uncorrected. 1H and 13C 
NMR spectra were obtained on a Bruker AM200-SY spectrometer operating at 200 
MHz and 50 MHz respectively. 13C NMR spectra were assigned with the aid of 
Distortionless Enhancement by Polarisation Transfer (DEPT) edited spectra. The 
numbering schemes do not refer to the system of nomenclature but to the assigned 
carbon numbers in the diagrams in the experimental. Mass spectra (MS) were 
recorded on an updated AE1 MS 12 or MS902 spectrometers; percentile figures refer 
to relative intensity as a percentage of the base peak. MS were obtained using 
electron-impact ionisation (El) mode or if stated, chemical ionisation (Cl) mode or fast 
atom bombardment (FAB). Infra-red (IR) spectra were obtained on a Perkin Elmer 
PU 9800 FT-IR spectrophotometer. Retention factors (Rf) were obtained by 
analytical Thin Layer Chromatography (TLC) on Merck aluminium backed silica 
plates of 0.25 mm thickness or Merck aluminium alumina backed plates of thickness 
0.2 mm; chromatograms were visualised using UV conditions at 254 nm or by 
staining with iodine. All column chromatography was carried out on silica gel (particle 
size 70-230 mesh) or alumina (particle size 150 mesh). Micro analysis were 
performed by the department micro analyst.
8.2.1 General Methods
General method (a):
Methyl prolinate hydrochloride salt 12 in chloroform (30 ml) was added to a 
round bottomed flask along with triethylamine (two equivalents) under nitrogen. The 
solution was stirred for 10 min before being cooled to between -5 and -10 °C. The 
acid chloride (0.5 equivalents) was slowly added dropwise. The reaction mixture was
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allowed to return to room temperature and stirred overnight. The solvent was 
removed under reduced pressure and the residue was taken up in water and 
extracted with ethyl acetate (4 x 50 ml). The combined organic extracts were dried 
over M gS 04> filtered and concentrated. The products were purified by column 
chromatography on alumina.
General method (b):
The diester diamide was taken up in dry THF and slowly added to a solution of 
LiAIH4 (4.5 equivalents) in dry THF under nitrogen at 0 °C. The reaction mixture was 
allowed to warm to room temperature and stirred overnight. The flask was then 
cooled to 0 °C and water THF (1:1) was added dropwise followed by water to 
quench the reaction completely. The solvents were removed under reduced 
pressure and to the resulting white solid was added DCM. The solution was stirred 
for 30 min before filtering and concentration of the filtrate to leave the required diol.
General method (c):
The alcohol was slowly added to neat thionyl chloride (20-30 ml) at room 
temperature (if a vigorous reaction occurred and the alcohol was taken up in 
chloroform and the thionyl chloride was cooled to 0 °C before addition). The reaction 
stirred at room temperature before any solvent and excess thionyl chloride were 
removed under reduced pressure. The resulting solid was taken up in EtOH and 
recrystallised on the addition of diethyl ether.
General method (d):
A mixture of the diol, isocyanate (quantities shown for individual compounds) 
and 3 drops of dibutyltindiacetate were stirred together in DCM at room temperature 
and the reaction was monitored by TLC until complete. The solution was then 
concentrated to leave a solution which was purified by column chromatography.
General method (e):
As in literature method58 with further purification by taking the residue up in 
water and extracting with chloroform. The desired alcohol was obtained on 
concentration of the extracts in vacuo.
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General method (f):
For A/,A/’-di(p-toluenesulfonyl) diethylenetriamine, diethylenetriamine (41.3 g, 
0.4 mol) in distilled water (250 ml) was added to a three necked flask. NaOH pellets 
(48.0 g, 1.2 mol) were slowly added keeping the temperature below 40 °C. The 
solution was cooled to 15 °C and diethyl ether was added (250 ml) with vigorous 
mixing. p-Toluenesulfonyl chloride (229.0 g, 1.2 mol) was added keeping the 
temperature below 20 °C. The solution was cooled to 0 °C and stirring was 
maintained for 1 h. The white solid was filtered off and washed with diethyl ether 
(250 ml). The product was recrystallised from chloroform.
General method (g):
/V,N'/V”-Tri(p-toluenesulfonyl)diethylenetriamine (31.0 g, 55.0 mmol) was 
suspended in dry EtOH (250 ml). Sodium metal (4.5 g, 0.2 mol) was added, whilst 
keeping the temperature between 60 and 70 °C. After the last of the sodium was 
added the solution was clear and on cooling the disodium salt precipitated. After 
refrigeration overnight the product was filtered off and oven dried at 120 °C for 
several hours.
General method (h):
To a solution of p-toluenesulfonyl chloride (42.0 g, 0.2 mol) in DCM (50 ml) 
was slowly added 1,3-propanediol (7.61 g, 0.1 mol) in DCM (75 ml) at 0 °C followed 
by benzyltriethylammonium chloride (TEBA) (0.92 g, 4.0 mmol) then sodium 
hydroxide (8.0 g, 0.2 mol) in water (50 ml) at 0 °C with vigorous stirring. The solution 
was allowed to return to room temperature and stirring was maintained for 1 h. The 
solution was then poured into water (100 ml). The organic layer was removed and 
washed with water (3 x 150 ml). The solvent layer was dried over MgSCX, filtered 
and concentrated in-vacuo followed by several hours on a vacuum line to remove any 
trace of solvent to leave the product as a fluffy white solid.
General method (i):
A /,0 ,0 ’-Tri(p-toluenesulfonyl)diethanolamine (0.70 g, 1.2 mmol) in dry DMF 
(50 ml) was added dropwise via a pressure equalised dropping funnel over 4 h to a 
solution of caesium carbonate (0.2 g, 0.6 mmol) and
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/V,/V'/V”/V”’-tetra(p-toluenesulfonyl)spermine (1.0 g, 1.2 mmol) in dry DMF (50 ml) 
heated to 100 °C and stirring was maintained for 12 h. The solvent was distilled off 
to leave a white solid which was taken up in water (20 ml) and DCM (20 ml). The
organic layer was removed and washed with water (3 x 20 ml). The organic layer
was dried over M gS04, filtered and concentrated in vacuo. The residue was taken 
up in minimal hot toluene and the desired product crystallised. The larger [2+2] 
Richman Atkins product precipitated at room temperature and the smaller product on 
refrigeration. On further cooling the Richman Atkins [1+1] product was obtained.
General method (j):
The disodium salt of A/,/V,,A/”-tri(p-toluenesulfonyl)diethylenetriamine (15.95 g, 
26 mmol) was dissolved in dry DMF (100 ml). The mixture was heated to 100 °C 
and O ,0 ’-bis(p-toluenesulfonyl)-1,2-ethanediol (9.68 g, 26 mmol) in dry DMF (100ml) 
was added dropwise with vigorous stirring at 100 °C and this was maintained for 12 
h. The solution was cooled to room temperature and slowly added to ice water (750 
ml) with vigorous stirring. The precipitate was filtered off and washed with water (5 x 
200 ml). The product was oven dried at 120 °C overnight before recrystallisation 
from minimum hot chloroform and the addition of three times the volume of EtOH. 
The crystallisation occurred after cooling to 0 °C. The precipitate was filtered and 
washed with EtOH.
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8.3.1 Experimental to Chapter 3
Methyl L-Prolinate hydrochloride 12
,OCH-
NH
.HCI
Ester 12 was prepared as in the literature56 with L-proline (15.00 g, 0.13 mol) 
in methanol (125 ml) and thionyl chloride (18 ml) as a white solid, (19.0 g, 88 %); Umax 
(KBr disc) 1747 and 2738 cm 1; 5 H (200 MHz, C D C I a )  1.82-2.36 and 3.1 (6H, m, ring 
C H 2) ,  3.31 (3H, s, C H 30 ) ,  3.35-3.41 (1H, m, C H N ) ;  8C (50 MHz, C D C I a )  22.1 (C-4),
26.9 (C-3), 44.3 (C-5), 51.9 (C-8), 57.8 (C-2), 167.6 (C-6).
M,N(-(1,2-Dioxo-1,2-ethandiyl)bis(2S-2-methoxycarbonylpyrrolidine) 13
OCH
Bispyrrolidine 13 was prepared using general method (a) with L-prolinate 
hydrochloride 12 ( 2 . 0 0  g, 1 2  mmol) in chloroform ( 3 0  ml), dry triethylamine ( 3 . 0 4  g, 
3 0  mmol) and oxalyl chloride ( 0 . 7 6  g, 6  mmol) which had been freshly distilled. The 
product was obtained as a light yellow coloured solid ( 1 . 4 2  g, 7 6  %); i w  (KBr disc) 
1 1 9 2 ,  1 4 2 9 ,  1 6 3 2 ,  1 7 3 7 ,  2 8 8 2 ,  2 9 8 8  and 3 0 1 9  cm 1; 5 H ( 2 0 0  MHz, C D C I 3 )  1 . 9 0 - 1 . 9 7  
( 8 H ,  m, ring C H 2) ,  2 . 1 4 - 2 . 2 5  ( 4 H ,  m, ring C H 2) ,  3 . 6 9  ( 6 H ,  s, C H 3) ,  4 . 4 4 - 4 . 4 8  ( 2 H ,  dd, 
C H N ) ;  6C ( 5 0  MHz, C D C I a )  2 4 . 4  ( C - 4 ) ,  2 9 . 2  ( C - 3 ) ,  4 7 . 2  ( C - 5 ) ,  5 2 . 4  ( C - 9 ) ,  5 7 . 7  ( C - 2 ) ,
1 6 9 . 1  ( C - 6 ) ,  1 7 1 . 8  ( C - 7 ) ;  m/z ( C l +)  3 1 3 . 1 5  (M H \ 100% ) ,  3 3 0 . 1 7  ( M+NH4\  6 5  % )  
(found: M+ 3 1 2 . 1 3 1 9 ;  C ,  5 3 . 8 9 ;  H ,  6 . 4 1 ;  N ,  8 . 8 3  %. C u H s o N z O e  requires 3 1 2 . 1 3 2 1 ;  C ,  
5 3 . 8 4 ;  H ,  6 . 4 5 ;  N ,  8 . 9 7 % ) .
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/V,N’-(1,3-Dioxo-1,3-propanediyl)bis(2S-2-methoxycarbonylpyrrolidine) 14
Bispyrrolidine 14 was prepared by method (a) using 12 ( 2 . 0 0  g, 1 2  mmol) in 
chloroform ( 3 0  ml), dry triethylamine ( 3 . 0 4  g, 3 0  mmol) and malonyl chloride ( 0 . 7 6  g, 
6.0 mmol) which had been freshly distilled. The product was obtained as a light 
yellow oil ( 1 . 4 2  g, 7 6  %); i w  (thin film) 1 1 6 2 ,  1 4 3 5 ,  1 7 5 0 ,  2 8 8 0 ,  2 9 4 8 ,  2 9 5 8  and 
3 0 1 7  cm*1; 8H ( 2 0 0  MHz, C D C I a )  1 . 6 8 - 2 . 1 7  ( 8 H ,  m, C h k C H N ,  C J ± > C H 2 N ) ,  2 . 6 0 - 2 . 9 5  
( 4 H ,  m, N C H 2) ,  3 . 5 9 - 3 . 7 6  ( 2 H ,  m, N C O C H 2) ,  3 . 6 0  ( 6 H ,  s, C H a )  and 4 . 3 6 - 4 . 4 5  ( 2 H ,  m, 
C H N ) ;  8 C ( 5 0  MHz, C D C I a )  2 4 . 6  ( C - 4 ) ,  2 9 . 3  ( C - 3 ) ,  4 1 . 8  ( C - 8 ) ,  4 7 . 6  ( C - 5 ) ,  5 2 . 2  ( C - 1 0 ) ,  
5 8 . 9  ( C - 2 ) ,  1 6 8 . 3  ( C - 6 ) ,  1 7 2 . 4  ( C - 7 ) ;  mfo ( C l /  Isobutane) 3 2 7 . 2  (MH+, 1 0 0  % ) ,  3 4 4 . 2  
(M+NH4\  5 % )  (found: MH* 3 2 7 . 1 5 5 1 .  C i s H z a N z O e  requires 3 2 7 . 1 5 5 6 ) .
N,N'-( 1,4-Dioxo-1,4-butanediyl)bis(2S-2-methoxycarbonylpyrrolidine) 15
OCH
Bispyrrolidine 15 was prepared using method (a) using 12 (2.00 g, 12 mmol) in 
chloroform (30 ml), dry triethylamine (3.04 g, 30 mmol) and freshly distilled succinyl 
chloride (0.93 g, 6.0 mmol). The product was obtained as a light pink oil (1.57 g, 78 
%); IW  (thin film) 1169, 1636, 1738 and 2882 cm*1; 8H (200 MHz, C D C I a )  1.7-2.09 
(8H, m, CH2CHN, CH2CH2N), 2.36-2.85 (4H, m, CH2), 3.61 (6H, s, CH3), 3.56-3.61 
(4H, m, NCOCH2), 4.36-4.58 (2H, m.CHN); 8C (50 MHz, C D C I a )  26.4, 29.1 (C-3 ),
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(C-4), 31.2 (C-8), 46.8 (C-5), 52.1 (C-10 ), 58.6 (C-2), 170.8 (C-6), 172.7 (C-7); m/z 
(Cl+/ NH3) 341.2 (M H \ 100 %) (found: MH+ 341.1706 CiehfesNzOe requires 341.1713).
tf,N-(1,5-Pentanediyl)bis(2S-2-m ethoxycarbonylpyrrolidine) 16
Bispyrrolidine 16 was prepared by method (a) using 12 (2.00 g, 12 mmol) in 
chloroform (30 ml), dry triethylamine (3.04 g, 30 mmol) and glutaryl dichloride (1.01 g,
6.0 mmol) which had been freshly distilled. The product was afforded as an off white 
solid (1.44 g, 68 %); I W  (KBr disc) 1199, 1636, 1747, 2935, 2955 and 2988 cm 1; 8 H 
(200 MHz, CDCI3) 1.90-2.15 (10H, m, CH2CHN, ChfeCHzN, COCH2CH2), 2.33-2.45 
(4H, m, CH2N), 3.40-3.69 (4H, m, COCH2), 3.65 (6H, s, CH3) and 4.38-4.43 (2H, m, 
CHN); 8c (50 MHz, CDCh) 19.7, 24.7 29.2 (C-3), (C-4), (C-9), 33.0 (C-8), 47.0 (C-5),
52.2 (C-11), 58.6 (C-2), 171.7 (C-6), 172.5 (C-7); m/z (El+) 355.2 (M H \ 100 %) 
(found: M* 354.1790; C.57.46; H, 7.52; N, 7.82 %. C iy H ^ O e  requires 354.1791; C, 
57.61; H, 7.40; N, 7 .92% ).
N,/V-(1,6-Dioxo-1,6-hexanediyl)bis(2S-2-methoxycarbonylpyrrolidine) 17
OCH
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Bispyrrolidine 17 was prepared using method (a) with 12 (2.00 g, 12 mmol) in 
chloroform (30 ml), dry triethylamine (3.04 g, 30 mmol) and freshly distilled adipoyl 
dichloride (1.09 g, 6 mmol). The product was obtained as a white oil (1.92 g, 87 
% ) ; o m a x  (thin film) 1173, 1431, 1632, 1730 and 2882 cm 1; 8H (200 MHz, C D C I 3)
1.50-1.65 (4H, m, COC^Chb), 1.79-2.02 (8H, m, CifeCHN, ChbCH2N), 2.06-2.19 
(4H, m, CH2N), 3.38-3.59 (4H, m, COCH2), 3.54 (6H, s, CH3) and 4.27-4.32 (2H, m, 
CHN); 8c  (50 MHz, C D C I 3)  22.4, 24.6, 29.0 (C-3), (C-4), (C-9), 34.0 (C-8), 46.9 (C-5),
52.0 (C-11), 59.2 (C-2), 171.7 (C-6), 172.7 (C-7); m/z (Cl+) 369.2 (MH+, 100 %) 
(found: MH+ 369.2026. CisH^NjA* requires 369.2026).
/V,N’-(1,7-Dioxo-1,7-heptanediyl)bis(2S-2-methoxycarbonylpyrrolidine) 18
Bispyrrolidine 18 was prepared by method (a) using 12 (2.00 g, 12 mmol) in 
chloroform (30 ml), dry triethylamine (3.04 g, 30 mmol) and freshly distilled pimeloyl 
dichloride (1.18 g, 6.0 mmol). The product was obtained as a yellow oil (2.24 g, 98 
%); omax (thin film) 1173, 1438, 1639, 2882, 2951, 2981 and 3020 cm*1; 5H (200 MHz, 
CDCI3) 1.18-1.36 (2H, m, COCHzCHzChh), 1.54-1.63 (6H, m, ChhCHN, COCH2CHh), 
1.83-2.10 (6H, m, CJ±>CHN, CH2CH2N), 2.18-2.26 (4H, m, CH2N), 3.50-3.64 (4H, m 
COCH2), 3.68 (6H, s, CH3) and 4.38-4.43 (2H, m, CHN); 8C (50 MHz, CDCI3) 22.4, 
24.1,24.6, 29.1 (C-3), (C-4), (C-9), (C-10) 34.0 (C-8), 47.0 (C-5), 52.1 (C-11), 58.2 
(C-2), 172.1 (C-6), 172.8 (C-7).
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A/,A/-(1,8-Dioxo-1,8-octanediyl)bis(2S-2-methoxycarbonylpyrrolidine) 19
OCH-
Bispyrrolidine 19 was prepared by method (a) using 12 (2.00 g, 12 mmol) in 
chloroform (30 ml), dry triethylamine (3.04 g, 30 mmol) and freshly distilled suberoyl 
dichloride (1.27 g, 6 mmol). The product was afforded as a clear oil (2.16 g, 91 %); 
Umax (thin film) 1177, 1438, 1639, 1738, 2882, 2950, 2980 and 3026 crrr1; 5 H (200 
MHz, CDCIa) 1.25-1.32 (4H, m, CH2 chain), 1.53-1.57 (4H, m, CH2 chain), 1.89-2.16 
(8H, m, CH2 ring), 2.17-2.29 (4H, m, CH2 ring), 3.40-3.60 (4H, m, NCOCH2), 3.64 
(6H, s, CH3) and 4.40-4.58 (2H, m, CHN); 5C (50 MHz, CDCb) 24.3, 24.6, 28.6, 28.9 
(C-3), (C-4), (C-9), (C-10), 34.1 (C-8), 46.9 (C-5), 52.0 (C-11), 59.0 (C-2), 171.9 
(C-6), 172.8 (C7); m/z (Cl+) 396.2 (M*, 100 %).
/V,/V-(1,2-Ethanediyl)bis(2S-2-hydroxymethylpyrrolidine) 20
.OH
HO
Diol 20 was synthesised using method (b) with 13 (1.40 g, 4.5 mmol) in dry 
THF (25 ml) and lithium aluminium hydride (0.94 g, 27 mmol) in dry THF (20 ml) as a 
clear oil (0.37 g, 36 %); umax (nujol) 1044, 1419 and 3000 (broad) cm-1; 5 h  (200 MHz, 
CDCI3)1.16-1.46 (4H, m, CH2CH2N), 1.63-1.87 (4H, m, ChfcCHN), 2.24-2.32 (8H, m, 
NCH2), 3.28-3.51 (6H, m, CFhOH, CHN) and 4.81 (2H, bs, OH); 8C (50 MHz, CDCI3)
25.3 (C-4), 27.2 (C-3), 46.0 (C-5), 55.9 (C-7), 64.5 (C-2), 65.4 (C-6); m/z (Cl+) 
229.21 (MH+, 100%) (found: MH+ 229.1913. Ci2H25N20 2 requires 229.1914).
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N ,N -(1,3-Propanediyl)bis(2S-2-hydroxymethylproline) 21
OH
HO
Diol 21 was obtained using method (b) with lithium aluminium hydride (0.50 g, 
13 mmol) in dry THF (25 ml) and 14 (1.0 g, 3.0 mmol) in dry THF (20 ml) as a light 
yellow oil (0.27 g, 37 %); i w  (thin film) 1063, 1431, 3376 and 3627 cm 1; 8H (200 
MHz, CDCb) 1.45-2.51 (10H, m, C H 2C H 2 N  ring, C h h C H N ,  C H 2 C H 2C H 2 N  chain), 
2.64-3.35 (4H, m, N C H 2 chain), 3.38-3.44 (2H, m, C H N ) ,  3.46-3.78 (8H, m, C H 20 ,  
C H 2 N  ring) and (2H, bs, O H ) ;  8 C (50 MHz, CDCI3) 24.0, 27.0, 27.2 (C-3), (C-4), (C-8), 
54.5 (C-5), 55.3 (C-7), 64.7 (C-2), 65.8 (C-6); m/z (Cl+) 243.0 (M H \ 100 %) (found: 
MH+ 243.2071. C 13H 27N 2O 2 requires 243.2073).
N'N'-tf ,4-Butanediyl)bis(2S-2-hydroxymethylpyrrolidine) 22
OH
HO
Diol 22 was synthesised using general method (b) with 15 (1.50 g, 4.4 mmol) 
in dry THF (20 ml) and lithium aluminium hydride (0.75 g, 20 mmol) in dry THF (25 
ml) as a clear oil (0.73 g, 82 %); i w  (thin film) 1074, 1397, 3422 and 3612 cm'1; 8 h  
(200 MHz, CDCI3) 1.46-1.64 (10H, m, CH2CH2 chain, CI±>CHN ring, CH2CH2N ring),
2.06 (4H, m, CH2N chain, CH2CH2N ring), 2.46 (4H, m, CH2N ring and chain), 
2.71-2,80 (2H, m, CH2N ring), 3.07-3.13 (2H, m, CHN), 3.33-3.67 (4H, dd and dd, 
CH2OH) and 4.27 (2H, bs, OH); 8C (50 MHz, CDCI3) 23.1, 26.6, 27.2 (C-3), (C-4),
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(C-8), 54.2 (C-5), 54.9 (C-7), 63.0 (C-2), 65.5 (C-6); m/z (Cl+) 257.0 (MH*, 100%) 
(found: MH+ 257.2226. C14H29N2O2 requires 257.2229 ).
N,N'-{ 1,5-Pentanediyl)bis(2S-2-hydroxymethylpyrrolidine) 23
.OH
HO
Diol 23 was synthesised using general method (b) with 16 (1.40 g, 4.0 mmol) 
in dry THF (25 ml) and lithium aluminium hydride (0.90 g, 26 mmol) in dry THF (20 
ml) as a yellow oil (0.83 g, 75 %); i w  (thin film) 1071, 1404, 3429 and 3627 cm*1; 8 h  
(200 MHz, CDCI3) 1.25-1.41 (4H, m, CH2CH2CH2N chain), 1.61-1.86 (8H, m, 
CH2CH2N ring and chain), 2.07-2.23 (2H, m, ChfcCHN), 2.33-2.46 and 2.58-2.72 (4H, 
m, CH2N chain), 3.06-3.12 and 3.30-3.36 (4H, m, CH2N ring) and 3.37-4.40 (8H, m, 
CH2OH, OH, CHN); 5 c  (50 MHz, CDCI3) 23.6, 25.5 (C-4), 27.5, 28.5 (C-3), (C-8), 
(C-9), 54.1, 54.6 (C-5), (C-7), 62.2 (C-6), 64.9 (C-2); m/z (Cl+) 271.26 (M H \ 100%) 
(found: MFT271.2382. C15H31N2O2 requires 271.2386).
N ,N ’-{ 1,6-Hexanediyl)bis(2S-2-methoxycarbonylpyrrolidine) 24
OH
HO
Diol 24 was formed using general method (b) with 17 (1.85 g, 5.0 mmol) in dry 
THF (25 ml) and lithium aluminium hydride (0.84 g, 23 mmol) in dry THF (25 ml) as a 
yellowish oil (1.07 g, 75 %); i w  (nujol) 1074, 1408, 3422 and 3627 cm 1; 5H (200 
MHz, C D C I 3)  1.25-1.63 (8H, m, C H 2 C H 2 N ,  C H 2 C H 2C H 2 N  chain), 1.64-1.89 (8H, m,
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ChfcCHN, CH2CH2N ring), 2.06-2.46 (4H, m, CH2N chain), 2.58-2.68 and 3.05-3.12 
(4H, m, CH2N ring), 3.30-3.36 (2H, m, CHN) and 3.49-3.55 (4H, m, CthOH), 3.74 
(2H, bs, OH); 5C (50 MHz, CDCI3) 27.1, 27.5, 28.7, 32.6 (C-3), (C-4), (C-8), (C-9),
54.1 (C-5), 54.7 (C-7), 62.1 (C-6), 64.9 (C-2); mfz (Cl+) 285.23 (M H \ 100 %) (found: 
MH* 285.2539. Ci6H33N20 2 requires 285.2542).
N,N-(1,7-Heptanediyl)bis(2S-2-hydroxym ethylpyrrolidine) 25
.OH
H0‘
Diol 25 was synthesised via general method (b) using 18 (2.24 g, 5.9 mmol) in 
dry THF (20 ml) and lithium aluminium hydride (1.40 g, 37 mmol) in dry THF (20 ml) 
as a clear oil (1.47 g, 84 %);8H (200 MHz, CDCI3) 1.09-1.45 (6H, m, CH2CH2CH 2 N 
chain), 1.48-1.73 (6H, m, CIH2CH2N chain), 1.95-2.06 (6H, m, Ci±>CHN, CH2 ring), 
2.15-2.29 (4H, m, CH2N chain), 2.44-2.48 and 2.48-2.58 (4H, CH2N ring), 2.89-2.93 
(2H, m, CHN), 3.17-3.36 (4H, m, CH2OH) and 3.92 (2H, bs, OH); 5C (50 MHz, CDCh)
27.3, 27.4, 29.1, 32.5 (C-3), (C-8), (C-9), (C-10), 54.1 (C-5), 54.9 (C-7), 62.5 (C-6),
65.1 (C-2); m/z (Cl+) 299.3 (MH+, 100 %), 341.3 (M+ C 3H 7, 65 %) (found: MH+ 
299.2698. C i7H35N20 2 requires 299.2697).
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JV,Nf-(1,8-Octanediyl)bis(2S-2-hydroxymethylpyrrolidine) 26
,0H
HO'
Diol 26 was produced using general method (b) with 19 (2.16 g, 5.4 mmol) in 
dry THF (20 ml) and lithium aluminium hydride (0.91 g, 25 mmol) in dry THF (20 ml) 
as a clear oil (1.39 g, 82 %); i w  (thin film) 1116, 1385, 3440 and 3627 cm 1; 8 h  (200 
MHz, CDCh) 0.92-1.22 (6H, m, CH2 chain), 1.22-1.44 (4H, m, CH2 ring), 1.55-1.89 
(8H, m, CJ±>CHN, CH2 ring), 1.66-2.28 and 2.62-2.82 (8H, m, CH2N ring and chain) 
and 3.35-3.70 (8H, m, C iiO H , CHN); 5C (50 MHz, CDCI3) 27.3, 27.5, 29.3, 29.2 
(C-3), (C-4), (C-9), (C-10), 32.6 (C-8), 54.1 (C-5), 54.7 (C-7), 62.0 (C-6), 64.9 (C-2); 
m/z (Cl+) 313.26 (MhT, 100 %) (found: MH+ 313.2852. CieHarN^O;* requires 
313.2855).
N,M'-(1|2-Ethanediyl)bis(2S-2-chloromethylpyrrolidine) 27
Chloride 27 as the free base was prepared using general method (c) with 20 
(0.30 g, 1.31 mmol) and thionyl chloride (30 ml). The product was obtained as an off 
white solid and recrystallised from EtOH and diethyl ether (0.20 g, 57 %); i w  (KBr 
disc) 764, 2873, 2947 and 2983 cm 1; 8H (200 MHz, D20 )  1.67-1.85 (2H, m, CH2 
chain), 1.86-1.99 (4H, m, ChbCHN, CH2 ring), 2.00-2.16 (2H, m, CHzCHN), 3.29-4.06 
(4H, m, CH2N), 3.51-3.54 (2H, m, CH2N ring), 3.80-4.06 (6H, CH2CI, CHN); 8C (50 
MHz, D20 )  24.2 (C-4), 29.3 (C-3), 55.8 (C-5), 55.9 (C-7), 61.8 (C-6) and 66.2 (C-2); 
m/z (Cl+) 265.1237 (M H \ 100%) (found: MhT 265.1238. C^HzaN^Cfe requires 
265.1238).
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JV,N'-(1,3-Propanediyl)bis(2S-2-chloromethylpyrrolidine) 28
Chloride 28 as the free base was prepared using general method (c) with 21, 
(0 . 2 0  g, 0.80 mmol) and thionyl chloride (15 ml). The white solid obtained was 
recrystallised from EtOH and diethyl ether (0.15 g, 6 8  %); IW  (KBr disc) 752, 2871 
and 2939 cm 1; 5H (200 MHz, D20 )  1.66-1.84 (2H, m, CH2 chain), 1.86-1.96 (6 H, m, 
CJ±>CHN, CH2 ring), 1.98-2.19 (2H, m, CfchCHN), 3.01-3.11 (4H, m, CH2N chain), 
3.28-3.34 (2H, m, CH2N ring), 3.47-3.56 (2H, m, CH2N), 3.69-3.85 (6 H, m, CH2CI, 
CHN); 8c (50 MHz, D20 ) 22.8 (C-4), 23.4 (C-8 ), 27.2 (C-3), 43.9 (C-5), 54.0. (C-6 ),
57.0 (C-7) and 68.4 (C-2).
N,JV-(1,4-Butanediyl)bis(2S-2-chloromethylproline) 29
Chloride 29 as the free base was prepared by general method (c) using 22 
(0.70 g, 2 . 8  mmol) and thionyl chloride (15 ml). The white solid was recrystallised 
from EtOH and diethyl ether (0.27 g, 33 %); iw  (KBr disc) 752, 2947 and 2994 cm-1; 
5h (200 MHz, D20 ) 1.46-1.63 (8 H, m, NCH2CH2CH2CH2N, CifcCHN), 2.06-2.21 (4H, 
m, CH2CH2N), 2.46-2.49 (4H, m, NCH2 ring and chain), 2.71-2.80 (4H, m, CH2N ring),
3.07-3.13 (2H, m, CHN) and 3.35-3.56 (4H, m, CH2CI); 8 C (50 MHz, D20 ) 22.7, 23.03,
28.0 (C-3), (C-4), (C-8 ), 42.9 (C-5), 54.9 (C-7), 55.6 (C-6 ), 69.34 (C-2); m/z (Cl+) 
293.2 (MH+, 100 %) (found: MH+ 293.1551. CuH^N^Cb requires 293.1551).
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Af,Ar-(1,5-Pentanediyl)bis(2S-2-chloromethylpyrrolidine) 30
Chloride 30 as the free base was prepared by general method (c) using 23, 
(0.80 g, 2.96 mmol) and thionyl chloride (30 ml). The product was obtained as an off 
white/ yellow solid and recrystallised from EtOH and diethyl ether (0.37 g, 40 %); iw  
(KBr disc 750, 2874 and 2940 cm 1; 8H (200 MHz, D20 )  1.27-1.30 (2H, m, Chh chain),
1.59-1.62 (4H, m, Chh chain), 1.84-1.98 (6H, m, ChhCHN, CH* ring), 2.06-2.19 (2H, 
m, ChhCHN), 2.94-3.07 (4H, m, CH2N ring ), 3.19-3.33 and 3.49-3.54 (4H, m, CH2N 
ring), 3.69-3.85 (6H, m, CH2CI, CHN); 8C (50 MHz, D20 )  22.7, 23.8, 25.3, 28.0 (C-3), 
(C-4), (C-8), (C-9), 43.0 (C-5), 55.3 (C-7), 55.5 (C-6) and 69.2 (C-2); m/z (Cl+) 
307.19 (MAT, 100 %) (found: MH* 307.1700. CisH^N^Ch requires MhT 307.1708).
N,N'-( 1,6-Hexanediyl)bis(2S-2-chloromethylpyrrolidine) 31
Chloride 31 as the free base was prepared using general method (c) from 24 
(0.95 g, 3.34 mmol) and thionyl chloride (20 ml). The white solid obtained was 
recrystallised from EtOH and diethyl ether (1.07 g, 100 %); Umax (KBr disc) 741, 2871 
and 2940 cm 1; 8 h  (200 MHz, D20 )  1.16-1.24 (4H, m, Chh chain), 1.44-1.58 (4H, m, 
CJ±  chain), 1.69-1.99 (6H, m, ChhCHN, Chb ring), 2.03-2.20 (2H, m, ChhCHN), 
2.86-3.07 (4H, m, CH2N chain), 3.11-3.29 and 3.45-3.57 (4H, m, CH2N) and
3.60-3.85 (6H, m, CH2CI, CHN); 8C (50 MHz, D20 )  22.6, 25.5 ,26 .1 , 27.9 (C-3), (C-4),
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(C-8) (C-9), 43.0 (C-5), 55.5 (C-7), 55.8 (C-6) and 69.1 (C-2); m/z (Cl+) 321.23 (M H \ 
50%) (found: MH+ 321.1864. CieHaiN^Ch requires 321.1864).
N,N-(1,7-Heptanediyl)bis(2S-2-chloromethylpyrrolidine) 32
Chloride 32 as the free base was prepared using general method (c) with 25 
(1.40 g, 4.7 mmol) and thionyl chloride (30 ml). The product was obtained as a 
brown solid and recrystallised from EtOH and diethyl ether (0.40 g, 26 %); i w  (KBr 
disc) 749, 2860 and 2936 cm 1; 8H (200 MHz, D20 )  1.00-1.15 (6H, m, CH2 chain),
1.51-1.70 (4H, m, CH2 chain), 1.72-1.94 (6H, m, ChhCHN, CH2 ring), 1.98-2.15 (2H, 
m, ChhCHN), 2.81-3.02 (4H, m, CH2N chain), 3.06-3.23 and 3.29-3.50 (4H, m, CH2N 
ring) and 3.65-3.81 (6H, m, CH2CI, CHN); 5C (50 MHz, D20 )  22.6, 25.5, 26.3, 28.0,
28.4 (C-3), (C-4), (C-8), (C-9), (C-10), 43.1 (C-5), 54.5 (C-7), 55.9 (C-2) and 69.0 
(C-6); m/z (Cl+) 335.2 (MhT, 85 %) (found: MH* 335.2021. C i7H33N235CI2 requires 
335.2021).
,8-Octanediyl)bis(2S-2-chloromethylpyrrolidine) 33
Chloride 33 as the free base was prepared using general method (c) with 26 
(1.19 g, 3.8 mmol) and thionyl chloride (20 ml). The product was obtained as a beige 
solid and recrystallised from EtOH and diethyl ether (1.17 g, 88 %); i w  (KBr disc)
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750 and 2932 cm'1; 8H (200 MHz, D20 )  1.02-1.17 (8H, m, CH2 chain), 1.56-1.71 (4H, 
m, CH2 chain), 1.76-2.20 (8H, m, CH2CHN, CH2 ring), 2.86-3.21 (4H, m, CH2N chain), 
3.23-3.32 and 3.49-3.61 (4H, m, CH2N ring) and 3.70-3.86 (6H, m, C H ^ I, CHN); 8c 
(50 MHz, D20 )  22.6 (C-4), 25.6 (C-10), 26.4 (C-9), 28.0 (C-3), 28.6 (C-8), 43.0 (C-5),
55.5 (C-7), 56.0 (C-6) and 69.0 (C-2); m/z (Cl+) 349.2 (MW*, 100 %) (found: MW* 
349.2175. CisHssN^Cb requires 349.2177).
Methyl DL-prolinate hydrochloride 35
NH
.HCI
Ester 35 was prepared as in literature preparation56 using DL-proline (5.00 g, 
43.4 mmol) in MeOH (45 ml) and thionyl chloride (6 ml) as a white solid (19.0 g, 88 
%); Umax (KBr disc) 1747 and 2738,cm 1; 8H (200 MHz, CDCb) 2.04- 2.43 (4H, m, ring 
CH2), 3.49-3.69 (2H, m, NCH2), 3.84 (3H, s, CH3), 4.46-4.52 (1H, m, CHN); 8c (50 
MHz, CDCb) 24.0 (C-4), 29.07 (C-3), 46.4 (C-5), 53.9 (C-8), 59.6 (C-2), 169.6 (C-6).
A/,Af-(1,4-Dioxo-1,4-butanediyl)bis(2RS-2-methoxycarbonylpyrrolidine) 36
Bispyrrolidine 36 was prepared as in general method (a) using 35 (1.50 g, 9.05 
mmol) in chloroform (10 ml), dry triethylamine (2.29 g, 23 mmol) and freshly distilled 
succinyl chloride (0.70 g, 4.5 mmol) . The product was obtained as a light pink oil 
(1.57 g, 78 % );o m a x  (thin film) 1169, 1440, 1635, 1735, 2885 and 2948 cm 1; 8 h  (200 
MHz, CDCb) 1.82-2.00 (8H, m, CHzCHN, CJ±>CH2N), 2.43-2.79 (4H, m, NCH2), 
3.45-3.60 (4H, m, COCH2), 3.65 (6H, s, CH3) and 4.07-4.41 (2H, m, CHN); 8c (50
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MHz, CDCb) 25.1, 29.49, 29.6, 29.7, 29.8, 47.2, 47.3, 52.2, 52.2, (C-3 ), (C-4), (C-5), 
(C-8), (C-10 ), 59.0 and 57.1 (C-2), 171.2 and 171.3 (C-6), 173.2 and 173 3 (C-7); 
(m/z) (El+) 340.1 (M*t 100 %) (found: M* 340.1634 C 16H24N2O6 requires 340.1634).
A/,^-(1,5-Dioxo-pentanediyl)bis(2RS-2-methoxycarbonylpyrrolidine) 37
Bispyrrolidine 37 was prepared by general method (a) using 35 (1.50 g, 9.0 
mmol) in chloroform (30 ml), dry triethylamine (2.29 g, 23 mmol) and freshly distilled 
glutaryl dichloride (0.76 g, 4.5 mmol). The product was afforded as an off white solid 
(1.44 g, 68 %); i w  (thin film) 1203, 1639, 1738, 28812, 2958 and 2980 cm'1; 8H (200 
MHz, CDCb) 1.80-2.05 (10H, m, ChhCHN, CH2CH2N, COCH2CH2), 2.18-2.34 (4H, m, 
NCH2), 3.48-3.60 (4H, m, COCH2), 3.58 (6H, m, CH3), 4.30-4.38 (2H, m, CHN); 5C 
(50 MHz, CDCb) 19.7, 19.9, 24.7, 29.1, 31.2, 32.9 (C-3), (C-4), (C-8), (C-9), 46.1 and
465.8 (C-5), 51.98 and 52.4 (C-11), 58.4 and 59.1 (C-2), 171.4 and 172.6 (C-6),
172.8 and 173.2 (C-7); m/z (El+) 354.1 (M \ 100 %) (found: M+ 354.1719. Ci/HzeNzOe 
requires 354.1719).
N,N'-( 1,6-Dioxo-1,6-hexanediyl)bis(2RS-2-methoxycarbonylpyrrolidine) 38
Bispyrrolidine 38 was prepared using general method (a) with 35 (1.50 g, 9.05 
mmol) in chloroform (30 ml), dry triethylamine (2.29 g, 23 mmol) and freshly distilled
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adipoyl dichloride (0.83 g, 4.5 mmol). The product was obtained as a white oil (1.92 
g, 87 %);umn (thin film) 1173, 1435, 1632, 1742, 2874, 2950 and 2980 cm 1; SH (200 
MHz, CDCU) 1.59-1.69 (4H, m, COCH 2CH2), 1.90-2.17 (8H, m,ChhCHN, ChkCH2N), 
2.27 (4H, s, COCH2), 3.42-3.77 (4H, M, CH2N), 3.59 (6H, s, CH3) and 4.33-4.40 (2H, 
m, CHN); 5c (50 MHz, CDCU) 22.9, 24.6, 24.9, 29.6, 34.6, (C-3), (C-4), (C-8), (C-9),
46.3, 46.7 (C-5), 52.5, 52.9 (C-11), 58.9 and 59.7 (C-2), 172.1 and 173.3 (C-6),
174.1 (C-7); m/z (Eh) 368.2 (MH*, 100 %) (found: MH* 368.1947. C isHaN^e requires 
368.1947).
Af,Af'-(1,4-Butanediyl)bis(2RS-2-hydroxymethylpyrrolidine) 39
OH
HO
Diol 39 was synthesised using general method (b) with 36 (1.00 g, 2.7 mmol) 
in dry THF (10 ml) and lithium aluminium hydride (0.82 g, 20 mmol) in dry THF (15 
ml) as a clear oil (0.73 g, 82 %); Umax (thin film) 1074, 1397, 3422 and 3612 cm'1; 5 h  
(200 MHz, CDCU) 1.36-1.46, 1.47-1.71, 1.76-1.83 and 2.11-2.21 (12H, m, CH2CH2N 
ring and chain), 2.24-2.47 (2H, m, CH2N), 2.49-2.69 (2H, m, CH2N), 3.07-3.10 (2H, 
m, CHN), 3.31 (2H, bs, OH), 3.25-3.34 (4H, m, CH2N) and 3.55-3.76 (4H, m, 
ChhOH); 8c (50 MHz, CDCU) 23.1, 26.6, 27.2 (C-3), (C-4), (C-8), 54.2 (C-5), 54.9 
(C-7), 63.0 (C-6), 65.5 (C-2); m/z (Cl+) 257.0 (MH*, 100%), 313.2 (IW* C4Ha, 18 %) 
(found: MH* 257.2226. C u H ^ N ^  requires 257.2229).
N,N'-(1,5-Pentanediyl)bis(2RS-2-hydroxymethylpyrrolidine) 40
.OH
HO
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Diol 40 was synthesised by general method (b) using 37 (.40 g, 6.8 mmol) in 
dry THF (30 ml) and lithium aluminium hydride (1.01 g, 30 mmol) in dry THF (30 ml) 
as a yellow oil (1.01 g, 55 %); Umax (thin film) 1071, 1404, 3429 and 3627 cm*1; 5H 
(200 MHz, CDCb) 1.17-1.81 (10H, m, Cj±>CH2CH2N, CH2CH2N ring and chain),
2.11-2.19 (4H, m, ChhCHN), 2.46-2.48 and 2.49-2.66 (4H, m, NCH2 chain), 3.02-3.10 
and 3.29-3.32 (4H, m, CH2N ring) and 3.33-3.74 (8H, m, CH2OH, OH); 8C (50 MHz, 
CDCb) 23.6, 25.5, 27.5, 28.5 (C-3), (C-4), (C-8), (C-9), 54.1 (C-5), 54.6 (C-7), 62.2 
(C-6), 64.9 (C-2); m/z (Cl+) 271.26 (MH+, 100%), 327.2 (M+ C4H9, 18 %) (found: MhT 
271.2381. C15H31N2O2 requires 271.2386).
M,M-(1,6-Hexanediyl)bis(2RS-2-hydroxymethylpyrrolidine) 41
.OH
HO'
Diol 41 was formed using general method (b) with 38 (2.40 g, 6.5 mmol) in dry 
THF (30 ml) and lithium aluminium hydride (1.10 g, 29 mmol) in dry THF (30 ml) as a 
yellowish oil (1.07 g, 75 %); i w  (thin film) 1074, 1408, 3422 and 3627 cm*1; 5H (200 
MHz, CDCb) 1.21-1.82 (16H, m, CJ±>CHN, ChhCH2N ring and chain), 2.11-2.19 
(4H,m, CH2N), 2.45-2.49 (2H, m, CH2N ring), 2.58-2.66 (2H, m, CH2N ring), 3.11-3.31 
(2H, m, CHN), 3.31-3.66 (6H, m, CJ±>OH}; 5C (50 MHz, CDCb) 27.1, 27.5, 28.7, 32.6 
(C-3), (C-4), (C-8), (C-9), 54.1 (C-5), 54.7 (C-7), 62.1 (C-6), 64.9 (C-2); m/z (Cl+) 
285.23 (M H \ 100 %), 341.2 (M+C4H9, 18 %) (found: MH* 285.2539. CieHsaNzCh 
requires 285.2542).
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N,N'-(1,4-Butanediyl)bis(2RS-2-chloromethylpyrrolidine) 42
,ci
4
Cl
Chloride 42 was prepared by general method (c) using 39 (0.85 g, 3.3 mmol) 
and thionyl chloride (20 ml). 42 Was obtained as an off white solid which was 
recrystallised from EtOH and diethyl ether (0.40 g, 41 %); m.p. 245-247 °C as the 
HCI sat; i w  (KBr disc) 752, 2947 and 2994 cnrr1; 8H (200 MHz, D20 )  1.78-2.28 (12H, 
m, ChhCH2N ring and chain, ChhCHN), 3.14-3.21 (4H, m, CH2N chain), 3.31-3.54 
(4H, m, CH2N ring), 3.59-3.69 (2H, m, CHN) and 3.82-3.98 (4H,m, CH2CI); 8C (50 
MHz, CDCIa) 22.7, 23.0, 27.9 (C-3), (C-4), (C-8), 42.9 (C-5), 54.9 (C-7), 55.6 (C-6), 
69.3 (C-2); m/z (Cl+) 293.1 (MH*, 100 %) (found: MH* 293.1551. C u H ^N ^ C h  
requires 293.1551).
N,N'-(1,5-Pentanediyl)bis(2RS-2-chloromethylpyrrolidine) 43
Chloride 43 as the free base was afforded by general method (c) using 40 
(1.00 g, 3.7 mmol) and thionyl chloride (20 ml). The product was obtained as an off 
white/ yellow solid and recrystallised from EtOH and diethyl ether (0.81 g, 71 %); i w  
(KBr disc) 750, 2874 and 2940 cnrr1; SH (200 MHz, D20 )  1.25-1.44 (2H, m, CH2 
chain), 1.70-1.79 (4H, m, CH2 chain), 1.79-2.08 (6H,m, ChhCHN, ChhCH2N ring), 
2.22-2.29 (2H, m, ChhCHN), 3.04-3.20 (4H, m, CH2N chain), 3.35-3.46 and 3.62-3.68 
(4H, m, CH2N ring) and 3.82-3.97 (6H, m, CH2CI, CHN); 8C (50 MHz, D20 )  22.7, 23.8,
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25.3, 27.9 (C-3), (C-4), (C-8), (C-9), 43.0 (C-5), 55.3 (C-7), 55.5 (C-6) and 69.2 
(C-2); m/z (Cl+) 307.19 (MH*, 100 %) (found: MH* 307.1680. C i5H29N235Cl2 requires 
307.1680).
N,N-(1,6-Hexanediyl)bis(2RS-2-chloromethylpyrrolidine) 44
Chloride 44 was prepared by general method (c) using 41 (1.00 g, 3.5 mmol) 
and thionyl chloride (20 ml). The product was obtained as an off white solid and 
recrystallised from EtOH and diethyl ether (0.85 g, 76 %); m.p. 232-234 °C; i w  (KBr 
disc) 741, 2871 and 2940 cm-1; SH (200 MHz, D20 )  1.10-1.36 (8H, m, CH2 chain),
1.67-2.09 (6H, m, ChhCHN, ChhCH2N ring), 2.22-2.29 (2H, m, ChhCHN). 3.33-3.40 
and 3.61-3.67 (8H, m, CH2N) and (6H, m, CH2CI, CHN); 8C (50 MHz, D20 )  22.6, 25.5, 
26.1, 27.9 (C-3), (C-4), (C-8), (C-9), 43.0 (C-5), 55.5 (C-7), 55.8 (C-6) and 69.1 
(C-2); m/z (Cl+) 321.23 (MH*, 50%) (found: MH* 321.1862. C ieH^N^Ch requires 
321.1864).
2-Chloromethyl-M-methyl piperidine 46
Chloride 46 was prepared by general method (c) using 2-hydroxymethyl-/V- 
methylpiperidine (1.4 g, 10.8 mmol) and thionyl chloride (20 ml) as a yellow solid and 
recrystallised from EtOH and diethyl ether (1.34 g, 84 %), m.p. 161-163 °C; umax (KBr 
disc) 750, 2802, 2870, 2945 and 3001 cm 1; 5H (200 MHz, D20 )  1.01-1.12 (1H, m, 
ChhCHN), 1.22-1.44 (5H, m, CH2 ring), 1.69-1.94 (2H, m, NCH2), 2.02 (3H, s, CH3),
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2.57-2.62 (1H, m, CHN) and 3.22-3.44 (2H, dd, CH2CI); 5C (50 MHz, D20 )  23.3 (C-7), 
25.1 (C-6), 28.9 (C-5), 42.2 (C-4), 46.1 (C-2), 53.2 (C-1) and 63.4 (C-3); m/z (El+)
147.06 (M H \ 100 %).
2-(p-Nitrophenylaminocarbonyloxymethyl)-A/-methylpiperidine 47
NH-
Carbamate 47 was obtained by general method (d) as a yellow solid using 46 
(0.5 g, 3.87 mmol), p-nitrophenylisocyanate ( 0.95 g, 5.8 mmol), DCM (30 ml) and 
dibutyltin diacetate (3 drops). (0.46 g, 40 %); m.p. 165-167 °C; Umax (KBr disc) 1110, 
1333, 1508, 1559, 1598, 1739 and 3426 cnrr1; 5H (200 MHz, DMSO) 1.42-1.48 (2H, 
m, CH2 ring), 1.81-1.96 (5H, m, CH2 ring), 2.51-2.59 (1H, dd, CH2 ring), 2.65 (3H, s, 
CH3), 3.30-3.36 (1H, d, CHN), 4.27-4.46 (2H, m, CH20 ), 5.05 (1H, bs, NH) and
7.61-8.21 (4H, AA'BB' system, Ar-H).
2-(2,4-Difluorophenylcarbonyloxymethyl)-N-methylpiperidine 48
NH
Carbamate 48 was prepared by general method (d) using 46 (0.5 g, 3.87 
mmol), 2,4-difluorophenylisocyanate (0.90 g, 5.8 mmol), DCM (30 ml) and dibutyltin 
diacetate (3 drops). The product was obtained as a white solid (0.20 g, 18 %); m.p. 
165-167 °C; umax (KBr disc) 728, 1376, 1536, 1612, 1730, 2788, 2858, 2938, 3074 
and 3218 cm 1; 8H (200 MHz, DMSO) 1.40-1.46 (1H, m, CH2 ring), 1.52-1.71 (5H, m, 
CH2 ring), 2.55-2.59 (1H, dt, NCH2 ring), 2.56 (3H, s, CH3), 3.13-3.28 (1H, d, CH2),
4.07-4.40 (2H, m, CH20 ), 6.73-6.91 and 7.29-7.41 (3H, m, Ar-H).
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2-Hydroxyethyl-M-methylpiperidine 50
OH
Alcohol 50 was obtained from 2-hydroxyethylpiperidine (3.0 g, 23 mmol), 
formaldehyde 37 % (3.84 g, 0.126 mol) [3.66 ml], formic acid 90 %( 4.8 ml) and H2O 
(3 ml). The solution was heated overnight at reflux before being cooled to room 
temperature and basified with sodium hydroxide solution. The aqueous solution was 
extracted with chloroform (4 x 60 ml). The extracts were washed with saturated brine 
(3 x 30 ml) before being dried over M gS04, filtered and concentrated under reduced 
pressure to leave a clear oil. This was purified by column chromatography on 
alumina with EtOAc and chloroform, (3.0 g, 90 %); Rf= 0.3 (EtOAc); i w  (thin film) 
1075, 1373, 2790, 2855 and 2933 cnrr1; 8H (200 MHz, CDCb) 1.17-1.39 (5H, m, CH2 
ring), 1.64-1.84 (1H, m, CH2 ring), 1.88-1.90 (2H, dt, ChhCOH), 2.23 (3H, s, CH3), 
2.76-2.79 (1H, m, CHN), 3.44-3.48 and 3.59-3.65 (4H, m, CH2OH, CH2N) and 4.21 
(1H, bs, OH); 5C (50 MHz, CDCb) 22.2, 23.8 (C-3), (C-4), 28.9 (C-5), 32.9 (C-6), 41.6 
(C-1), 57.3 (C-7), 58.1 (C-2), 64.2 (C-8)
2-Chloroethyl-tf-methylpiperidine 51
Chloride 51 was obtained by stirring 50 (0.5 g, 3.5 mmol) in thionyl chloride 
(20 ml) overnight, as in general method (c), before being concentrated under reduced 
pressure to leave a light brown solid which was recrystallised from EtOH and diethyl 
ether (0.40 g, 70 %); i w  (KBr disc) 740 cnrr1; SH (200 MHz, D20 )  1.34-1.42, 
1.43-1.63, 1.72-1.91 and 1.92-2.01 (7H, ChhCH2N, C]±>CH2CH2N, CH2 CH2CI),
2.26-2.33 (1H, m, ChhCHN), 2.75 (3H, s, CH3), 2.94-2.99 (2H, m, CH2N) and
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3.47-3.70 (3H, m, CH2CI, CHN); 6C (50 MHz, D20 )  21.2, 23.2 (C-3), (C-4), 27.3 (C-5),
32.8 (C-6), 40.5 (C-7), 41.1 (C-1), 56.8 (C-1) and 57.6 (C-2); m/z (Cl+) 162.1 (MhT, 
15 %) (found: MhT 162.1050. CbHitN^CI requires 162.1050).
2-(p-Nitrophenylcarbonyloxyethyl)-N-methylpiperidine 52
NH
Carbamate 52 was obtained as in general method (d) using 50 (0.5 g, 3.5 
mmol), DCM (30 ml) and dibutyltin diacetate (3 drops) as a bright yellow solid (0.25 g, 
23 %); Rf = 0.6 (EtOAc); mp 143-147 °C; i w  (KBr disc) 1350, 1506, 1599 and 1741 
cm'1;8H (200 MHz, DMSO) 1.19-1.41 (5H, m, ring CH2), 1.70-2.03 (1H, m, ring CH2), 
2.10 (3H, s, CH3), 3.25-3.34 (3H, m, CHN), 3.65-4.05 (4H, m, CH20 , CH2N),
7.67-7.79 and 8.09-8.20 (4H, AA'BB* system, Ar-H); m/z (El+) 308 (MhT, 100 %).
2-(2,4-Difluorophenylcarbonyloxyethyl)-/V-methylpiperidine 53
NH
Difluorophenylcarbamate 53 was made as in general method (d) using 50 (1.0 
g, 6.9 mmol), 2,4-difluorophenyl isocyanate (1.08 g, 7.0 mmol), DCM (30ml) and 
dibutyltindiacetate (3 drops). The product was obtained as a white solid (0.20 g, 20 
%); Rf= 0.8 (EtOAc); i w  (KBr disc) 730, 1381, 1526, 1520, 1612, 1734, 2869, 2952 
and 3430 cnrr1; 5h (200 MHz, DMSO) 1.22-1.37 (1H, m, CH2 ring), 1.55-1.90 (5H, m, 
CH2 ring), 2.15 (3H, s, CH3), 3.05-3.27 (4H, m, CH20 , CH2N), 3.58-3.69 (1H, m, 
CHN), 4.06-4.29 (2H, dd, ChhCHN), 4.42 (1H, bs, NH), 6.73 (2H, m, Ar-H) and
7.27-7.39 (1H, m, Ar-H); 8C (50 MHz, DMSO) 22.0, 22.8 (C-7), (C-4), 28.3, 29.9 
(C-3), (C-5), 39.8 (C-1), 55.6 (C-6), 62.2 (C-2), 104.8, 111.2, 111.6, 122.4, 124.1 and
124.2 (aromatic) and 154.2 (C-9).
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tf,N-Dihydroxyethyl-N,N>-dimethylhexane-1, 6-diam ine 55
OH
HO
Diol 55 was obained as in general method (e) using 
/V,/^dimethyl-1,6-hexanediamine (2.0 g, 13.9 mmol) in EtOH (10 ml) and ethylene 
oxide (1.32 g, 30.0 mmol) as a white solid (2.0 g, 63 %); i w  (thin film) 1040, 1467, 
2934 and 3387 cm 1; 8H (200 MHz, CDCb) 1.12-1.39 (8H, m, CH2 chain), 3.47 (6H, s, 
CH3), 3.44-3.58 (8H, m, CH2N) and 3.59-3.64 (4H, m, CH20 ); 8C (50 MHz, CDCb)
45.9 (C-6), 50.9 (C-5), 54.11 (C-4), 56.1 (C-3), 56.9 (C-2) and 61.8 (C-1); m/z (El+)
233.2 (MhT, 10 %), (found MhT 233.2229. Ci2H29N20 2 requires 233.2229).
Chloride 56 was obained using general method (c) with 
/V,/\T-dihydroxyethyl-/V,A/,-dimethylhexane-1,6-diamine (1.5 g, 6.4 mmol) and thionyl 
chloride (15 ml) as a white/ yellow solid which was recrystallised from EtOH and 
diethyl ether (1.05 g, 60 %);m.p. >212 °C; i w  (KBr disc) 619, 2805, 2861 and 2939 
cm'1; 8 h ( 2 0 0  MHz, CDCb) 1.36-1.70 (8H, m, CH2 chain), 2.86 (6H, s, CH3),
3.12-3.21, 3.47-3.70 and 3.87-3.89 (12H, m, CH2N, CH2CI); S c  (50 MHz, CDCb) 23.9
N ^-D ich loroethyl-tf'N -d im ethylhexane-l ,6-diamine 56
159
(C-6), 25.9 (C-5), 38.4 (C-1), 40.7 (C-2), 56.6 (C-4) and 57.2 (C-3); m/z (Cl+) 269.1 
(MH*, 65 %) (found: M* 269.1551. C^HzeN^Cfe requires 269.1551).
M,Nf-p-(Nitrophenylcarbonyloxyethyl)-N,N'-dimethylhexane-1,6-diamine 57
NO- NH
'NH-
Carbamate 57 was obtained as in general method (d) with 55 (1.0 g, 4.4 
mmol) in DCM (20 ml) with p-nitrophenyl isocyanate (1.96 g, 12 mmol) and three 
drops of dibutyltin diacetate as a yellow solid (1.0 g, 41 %); Umax (KBr disc) 1328, 
1498, 1554, 1598, 1733, 2950, 3077 and 3365 cm 1; 8 h (200 MHz, D20 )  1.10-1.61 
(8H, m, CH2 chain), 2.97 (6H, s, CH3), 3.14-3.58 (8H, m, CH2N), 3.75-3.91 (4H, m, 
CH20 ), 6.55-6.60 and 7.87-7.92 (8H, AA'BB' system, Ar-H).
^ V - ( 2 y4-Difluorophenylcarbonyloxyethyl)-AflAT-dimethyihexane-1l6-diamine 58
NH .CH
CH
Bisdifluorophenyl carbamate 58 was obtained as in general method (d) with 55 
(1.0 g, 4.4 mmol) in DCM (20 ml) 2,4-difluorophenyl isocyanate (1.86 g, 12 mmol) 
and three drops of dibutyltin diacetate as white crystals (0.99 g, 42 %); m.p. 179-180 
°C; umax (KBr disc) 760, 1381, 1520, 1526, 1626, 1734, 2870, 2953 and 3441 cm 1; 5H 
(200 MHz, DMSO) 1.34-1.85 (8H, m, CH2 chain), 2.67 (6H, s, CH3), 2.80-3.13 (4H, 
m, CH2N), 3.24-3.32 (4H, m, CJ±>CH2OH), 4.04 (4H, m, CH20 ), 6.72-6.90 (4H, m, 
ar-H) and 7.26-7.38 (2H, m, Ar-H); 5C (50 MHz, DMSO) 27.7 (C-4),28.3 (C-3), 29.4
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(C-2), 39.8 (C-1), 55.5 (C-5), 62.2 (C-6), 104.3, 104.5, 104.8, 111.4, 111.6, 122.9 
(aromatic) and 154.2 (C-7).
A/,N'-Dihydroxypropyl-tf,N,-dimethylhexane-1,6-diamine 60
HO
Diol 60 was obained as in general method (e) using A/.AT-dimethyl 
-1,6-hexanediamine (2.0 g, 13.9 mmol) in acetonitrile (50 ml) and bromopropanol 
(3.89 g, 2.53 ml, 28.0 mmol); (1.10 g, 30 %); i w  (thin film) 1096, 1162, 2826, 2884 
and 3642 cm"1; 8H (200 MHz, D20 )  0.91-1.28 (8H, m, CH2 chain), 1.32-1.44 (4H, m, 
ChbCHO), 1.77 (6H, s, CH3), 1.94-2.36 (8H, m, CH2N) and 3.70-3.81 (4H, m, CH20); 
5 c  (50 MHz, D20 )  28.5 (C-7), 29.3 (C-6), 35.2 (C-2), 41.9 (C-4), 54.5 (C-5), 57.6 
(C-3) and 60 9 (C-1).
N,AT-Dichloropropyl-tf)N(-dimethylhexane-1,6-diamine 61
Dichloride 61 was obained as the free base using general method (c) with 60 
(0.5 g, 1.9 mmol) and thionyl chloride (15 ml) as a white/ yellow solid which was
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recrystallised from EtOH and diethyl ether (0.35 g, 60 %); Rf=0.3 (CH3OH:NH3); iw  
(KBr disc) 750, 2825 and 2950 cnrr1; 8 h  ( 2 0 0  MHz, D20 )  1.21-1.58 (8H, m, CH2 
chain), 1.61-1.85 (4H, m, NCH2C]i>CH2CI), 2.04 (6H, s, CH3), 2.16-2.70 (8H, m, 
CH2N) and 3.25-3.52 (4H, m, CH2CI); 8C (50 MHz, D20 )  25.9 (C-7), 26.4 (C-6), 28.2 
(C-2), 38.9 (C-4), 53.9 (C-5), 55.2 (C-3) and 56.7 (C-1); m/z (CI/NH3) 120 {M* 
C5H9NCI, 97 %), 152 (M* C7H15NCI, 6 %), 112 (M+CsHgN, 31 %) (found: MhT 
297.1864. CuH^Nz^Cb requires 297.1864).
N,N,-(p-Nitrophenylcarbonyloxypropyl)-tf,Nl-dimethylhexane-1,6-diamine 62
Biscarbamate 62 was obained using general method (d) with 60 (2.0 g, 0.77 
mmol), DCM (20 ml), p-nitrophenyl isocyanate (0.28 g, 1.7 mmol) and 
dibutyltindiacetate (3 drops) (2.26 g, 58 %), Rf= 0.87 (EtOAc); Umax (KBr disc) 1301, 
1503, 1508, 1591, 1628, 1736, 2924, 3371 and 3483 cnrr1; 5 h  (200 MHz, DMSO) 
0.90-1.00 and 1.20-1.25 (12H, m, CH2CH2CH2), 1.65 (8H, m, CH2N), 2.25-2.30 (4H, 
m, CH20 ), 3.05 (6H, s, CH3), 4.37 (2H, bs, NH), 6.60-6.65 and 8.10-8.18 (8H, AA'BB' 
system, Ar-H); m/z (El+) 295 (1.7 %) and 138 (80 %).
N, N*-(2,4-Difluorophenylcarbonyloxypropyl)-/V,A/’-dimethylhexane-1,6-diamine
63
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Bisdifluorophenyl carbamate 63 was obained as in general method (d) using 
60 (1.0 g, 3.84 mmol), DCM (20 ml), 2,4-difluorophenylisocyanate (1.86 g, 12.0 
mmol) and dibutyltindiacetate (3 drops) (0.22 g, 6 %); i w  (KBr disc) 750, 1205, 
1512, 1612, 1728, 2934 and 3083 cnrr1.
8.4.1 Experimental to Chapter 4
AT-Chloroethylaziridine 64
Chloride 64 was obtained from A/-hydroxyethylaziridine 63 (2.0 g, 23 mmol) 
and thionyl chloride (10 ml) using general method (c) and recrystallised from EtOH 
and diethyl ether (0.87 g, 36 %); Umax (KBr disc) 779, 2981 and 3466 cnrr1; 5H (200 
MHz, D20 )  2.90-3.43 and 3.66-4.09 (8H, m, NCH2, CICH2); 8C (50 MHz, D20 )  28.2 
(C-1), 48.8 (C-2) and 55.07 (C-3).
N,AT-Di(hydroxyethyl)piperazine 66
A/,A/-Di(hydroxyethyl)piperazine 56 was obtained as in general method (e) 
using piperazine 65 (4.0 g, 46 mmol) in dry EtOH (10 ml) and ethylene oxide (4.05 g,
4.5 ml, 92 mmol) as a white solid. This was recrystallised using EtOH and diethyl 
ether (3.16 g, 47 %); m.p. 128-128.5 °C; 5H (200 MHz, CDCb) 2.26-2.32 (12H, t, 
CH2N), 3.39-3.49 (4H, t, CH2OH); 5C (50 MHz, CDCb) 53.3 (C-1), 57.9 (C-2), 59.5 
(C-3); lit69 53.13, 58.4 and 60.2; m/z (El+) 175.14 (MhT, 100 %) (found: MhT 
175.1446. C8Hi9N20 2 requires 175.1447).
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N,tf-Di(chloroethyl)piperazine 67
Iv  N NL vv
V /
Dichloride 67 was obtained as a white solid from 66 (1.50 g, 8.5 mmol) and 
thionyl chloride (15 ml) using general method (c). The resulting white precipitate 
was filtered and washed with diethyl ether and recrystallised from hot EtOH (1.47 g, 
81 %); 197-198.5 °C; Umax (KBr disc) 625, 2850, 2927 and 2987 cm 1; 5H (200 MHz, 
D20 ) 3.23-3.28 (4H, t, NCH2CH2N), 3.57 (4H, s, CH2CI) and 3.71-3.76 (8H, t, 
NCH2CH2CI); 5 c  (50 MHz, D20 )  49.3 (C-2), 55.6 (C-1) and 58.9 (C-3); m/z (Cl+) 213 
(MH*, 8 %).
NfN1-Di(hydroxyethyl)-1,4-diazacycloheptane 69
Diol 69 was synthesised with 1,4-diazacycloheptane 68 (2.0 g, 20 mmol) and 
ethylene oxide (2.65 g, 60 mmol) in EtOH (10 ml) using general method (e) as an 
orange oil (1.14 g, 30 %); Umax (Nujol mull) 1052, 1252 and 2828 cm-1; 5H (200 MHz, 
CDCI3) 1.66-1.79 (2H, m, CHzCJiCHz), 2.56-2.87 (12H, dt, NCH2), 3.49-3.61 (4H, m, 
OCH2) and 4.05 (2H, bs, OH); 5C (50 MHz, CDCU) 27.5 (C-1), 54.12 (C-2), 54.6 
(C-3), 58.6 (C-5) and 59.5 (C-4); m/z (Cl+) 189.19 (MH*, 100 %), 245.26 (MH* C4H9+, 
20 %) (found: MH* 189.1603. C9H20N2O2 requires 189.1603).
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MjN'-DKchloroethy l)-1,4-diazacycloheptane 70
N,/V-DKchloroethylJ-l ,4-diazacycloheptane 70 was prepared from 69 (0.80 g,
4.2 mmol) and thionyl chloride (20 ml) in the manner of general method (c). A beige 
solid formed after 48 h stirring at room temperature. This was filtered and washed 
with diethyl ether (3 x 20 ml) (0.90 g, 96 %); m.p. 205-207 °C; um« (KBr disc) 750 
and 2852 cm1; 5H (200 MHz, D20 ) 2.16-2.21 (2H, m, CH2CH2), 3.23-3.58 (8H, m, 
CH2N,) and 3.73-3.79 (8H, m, CICH2| NChfcC^CI); 5C (50 MHz, D20 ) 20.8 (C-1), 38.0 
(C-4), 49.2 (C-3), 54.2 (C-2) and 58.8 (C-5); m/z (Cl+) 225.07 (MH*t 100 %) (found: 
MhT 225.0926. CgHisN^Cb requires 225.0928).
M,N',Ar,N'”-Tetra(hydroxyethyl)-1,4,7,10-tetraazacyclododecane 72
Tetraol 72 was synthesised from 1,4,7,10-tetraazacyclododecane 71 (1.94 g, 
88 mmol) and an excess of ethylene oxide (4.70 g, 360 mmol) in water (20 ml) using 
general method (e) as white crystals (2.23 g, 57 %); SH (200 MHz, CDCb) 2.16-2.23 
(24H, m, NCH2), 3.27-3.31 (8H, m, OCH2) 4.87 (4H, bs, OH) ; 5C (50 MHz, CDCb)
48.8 (C-2), 54.1 (C-3) and 60.1 (C-1).
165
N,N’,tf” tf'”-Tetra(chloroethyl)-1,4,7,10-tetraazacyclododecane 73
Cl
C l\ ___ 2 /
V X
1
3
N N C
0/ Cl
Tetrachloride 73 was prepared using 72 (2.41 g, 6.9 mmol) and thionyl 
chloride (80 ml) in the manner of general method (c). A light beige solid formed after 
48 h stirring at room temperature which was filtered off and washed with diethyl ether 
(2.28 g, 67 %); i w  (KBr disc) 727, 2852 and 2965 cm 1; 8H (200 MHz, D20 )
3.17-3.25 (24H, m, NCH2, CH2CI), 3.65-3.76 (8H, OCH2); 8C (50 MHz, D20 ) 39.3 
(C-1), 49.1 (C-2), 54.9 (C-3); (found: C, 38.65; H, 7.09; N, 11.10 %. C16H32N4CI4 
requires C, 38.81 ;H, 6.92; N, 11.31 %).
N,N’,N”, A/”’-Tetra(hydroxyethyl)-1,4,8,11 -tetraazacyclotetradecane 75
OH
OH
Tetraol 75 was synthesised from 1,4,8,11-tetraazacyclododecane 74 (1 . 0  g,
5.0 mmol) and excess ethylene oxide (1.5 ml) in EtOH (10 ml) using general method 
(e) as colourless crystals (1.84 g, 98 %); 5H ( 2 0 0  MHz, CDCb) 1.48-1.61 (4H, m, 
CHzChbCHz), 2.48-2.59 (24H, m, NCH2), 3.52-3.58 (8 H, m, CH2OH); 8 C (50 MHz, 
CDCb) 25.1 (C-1 ), 49.1 (C-4), 51.9, 55.6 (C-2)(C-3) and 59.3 (C-5).
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N,W',/V",W”’-Tetra(chloroethyl)-1,4,8,11-tetraazacyclotetradecane 76
Tetrachlorinated cyclam derivative, 76 was prepared from 75 (0.4 g, 1.0 
mmol), chloroform (10 ml) and thionyl chloride (10 ml) in the manner of general 
method (c). A beige solid formed after 36 h stirring at room temperature and the 
tetrahydrochloride salt was afforded on treatment with ethereal hydrochloric acid 
(0.14 g, 30 %); i w  (KBr disc) 766, 2893 and 2925 cm1; 6H (200 MHz, D20 )  
1.92-2.18 (4H, m, CH2), 3.13-3.37 (16H, m, NCH2), 3.72-3.79 (16H, m, NCH2, 
CICH2);5c (50 MHz, D20 ) 17.5 (C-1), 43.5 (C-5), 47.9 (C-3), 56.1 (C-7) and 57.9 
(C-3); (found: C, 36.42; N, 9.45 %. C18H40N4CI8 requires C, 36.26; N, 9.40 %).
AT’-Tetra(hydroxyethyl)-1,4,8,12-tetraazacyclopentadecane 78
N, N’, A/" AT-Tetra(hydroxyethyl)-1,4,8,12-tetraazacyclopentadecane 78 was 
formed using 1,4,8,12-tetraazacyclopentadecane 77 (0.2 g, 0.9 mmol), EtOH (15 ml) 
and excess ethylene oxide (0.2 g, 5.0 mmol) as in general method (e) (0.30 g, 86 %), 
5 h  (200 MHz, CDCb) 1.02-1.33 (6H, m, NCH2Cii>), 1.98-2.70 (24H, m, NCH2),
3.00-3.20 (8H, m, OCH2); 5C (50 MHz, CDCb) 25.0 (C-6), 26.6 (C-3), 53.4, 54.4, 54.7 
(C-2)(C-4)(C-5), 58.9, 59.6 (C-1)(C-4) and 63.8 (C-8); m/z (Cl+) 391.3 (MhT, 100 %) 
(found: MH+ 391.3284 Ci9H27N204 requires 391.3284).
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N,N’,N ”,N m- Tetra(chloroethyl)-1,4,8,12-tetraazacyclopentadecane 79
N, N\ AT, AT-Tetra(chloroethyl)-1,4,8,12-tetraazacyclopentadecane 79 was
formed on stirring 78 (0.30 g, 0.8 mmol) in thionyl chloride (20 ml) as in general 
method (c) (0.26 g, 74 %); Umax (KBr disc) 730, 2840 and 2975 cm 1; 8H (200 MHz, 
D20) 1.81-2.10 (6H, m, NCH2CHh), 2.85-3.55 (24H, m, NCH2), 3.62-3.81 (8H, m, 
CH2CI); 8 c (50 MHz, D20 ) 25.5 (C-6), 26.9 (C-3), 41.2 (C-8), 53.7, 54.8, 54.9 
(C-2)(C-4)(C-5), 59.3 and 59.9 (C-1)(C-4); m/z 463.2 (MhT, 100 %) (found: MhT 
463.1927. CigHssN^CU requires 463.1929).
1,4-Di(hydroxyethyl)-1,4,8,11 -tetraazacyc!ododecane-5,7-dione 81
1,4,8,11-Tetraazacyclododecane-5,7-dione 80 (0.36g, 1.6 mmol) was used with 
ethylene oxide (0.5 ml) and EtOH (8 ml) to form 1,4-di(hydroxyethyl)-1,4,8,11- 
tetraazacyclododecane-5,7-dione 81 according to general method (e) (0.3 g, 60 %); 
Umax (KBr disc) 1370, 1556, 1685 and 3224 cm 1; SH (200 MHz, CDCh) 0.90-097 (2H, 
m, NCH2CH2), 2.32 (2H, s, CH2CO), 3.03-3.44 (16H, m, NCH2), 3.71-3.92 (4H, m, 
OCH2) and 5.46 (2H, bs, OH);8c (50 MHz, CDCh) 25.0 (C-6), 38.7 (C-1), 52.8, 54.1,
57.4, 59.2 (C-7)(C-3)(C-4)(C-5), 63.5 (C-8), 167.7 (C-2); m/z (El+) 317 (MH+, 10 %) 
(found: MH+ 315.1558. Ci4H28N40 4 requires 315.1558).
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1,4-Di(chloroethyl)-1,4,8,11-Tetraazacyclododecane-5,7-dione 82
1,4-Di(chloroethyl)-1,4,8,11 -tetraazacyclododecane-5,7-dione 82 was
prepared as in general method (c) by stirring 81 (0.7 g, 2.2 mmol) in thionyl chloride 
(30 ml) and chloroform (10 ml). The off white solid obtained was recrystallised from 
EtOH and diethyl ether (0.75 g, 54 %); i w  (KBr disc) 745, 1686, 2960 and 2980 
cm*1; 5C (50 MHz, D20 ) 27.5 (C-6), 38.9 (C-1), 42.9 (C-8), 52.9, 54.3, 57.4, 59.3 (C-7) 
(C-3)(C-4)(C-5) and 167.9 (C-2); mb (El+) 353 (M H \ 40 %).
0 ,0 ’-Di(p-toluenesulfonyl)-1,2-ethanediol 84
CHTs=
TsO OTs
Tosylated compound 0,0'-di(p-toluenesulfonyl)-1,2-ethanediol 84 was formed 
using general method (h) with p-toluenesulfonyl chloride (190 g, 1.0 mol),
1,2-ethanediol 83 (6.2 g, 0.1 mol), 30% sodium hydroxide, TEBA ( 0.50 g, 0.002 
mmol) and DCM (200 ml) as white crystals (27.2 g, 73 %); Umax (KBr disc) 1037, 
1373, 1452, 1495 and 1597 cm*1; 5H (200 MHz, CDCIs) 2.45 (6H, s, CH3), 4.18 (4H, s, 
OCH2), 7.69-7.74, 7.31-7.36 (8H, dd, AA’BB’ system Ar-H); 5C (50 MHz, D20 ) 21.6 
(C-1), 66.7 (C-6), 127.5, 129.6 (C-3)(C-5), 132.2 (C-4) and 145.3 (C-2); lit152 21.6,
66.9, 128.1, 130.2, 132.7, 145.5.
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N,N',N"- Tri(p-toluenesulfonyl)diethylene triamine 86
HTsN NTs NTsHv_y\_/
7 6
N, A/', A/"- Tri(p-toluenesulfonyl)diethylene triamine 8 6  was obtained using general 
method (f) using diethylenetriamine 85 (15.0 g, 0.15 mol), p-toluenesulfonyl chloride 
(83.6 g, 0.44 mol), sodium hydroxide solution and diethyl ether (250 ml). The white 
solid was obtained in quantitative yield (75.0 g, 93 %); m.p. 180-183 °C; i w  (KBr) 
1036, 1445, 1494 and 1598 cm'1; 8 H ( 2 0 0  MHz, CDCI3) 2.58 (9H, s, Ar-CH3), 2.97 
(4H, t, tsNCH2), 3.10 (4H, t, NCH2), 7.45 (12H, dd, AA’BB system Ar-H), 8c (50 MHz, 
CDCI3) 21.5 (C-1), 42.5 (C-8 ), 50.3 (C-9), 127.3 (C-4), 129.9 (C-2), 136.5 (C-3),
143.5 (C-5); lit15321.8, 42.7, 50.8, 127.6, 130.3, 130.5, 135.2, 137.1, 144.1, 144.6.
M,Nr,/V,<-Tri(p-toluenesulfonyl)-1,4,7-triazacyclononane 8 8
NTs
/V,A/',A/"-Tri(p-toluenesulfonyl)-1,4,7-triazacyclononane 8 8  was obtained using 
general method (j) as a white solid from the disodium salt of 87 (230 g, 0.38 mol), dry 
DMF (1.4 I) and O ,0 ’-di(p-toluenesulfonyl)-1,2-ethanediol 84 (140 g, 0.38 mol) (195 
g, 87%); o™, (KBr) 1376, 1451, 1494 and 1597 cm 1; 5H ( 2 0 0  MHz, CDCI3) 2.42 (9H, 
s, Ar-CHa), 3.50 (12H, s, NCH2), 7.70, 7.33 (12H, dd, AA’BB’ system Ar-H); 8c (50 
MHz, CDCIa) 21.5 (C-1), 51.8 (C-8 ), 127.5 (C-4), 129.8 (C-3), 135.2 (C-2), 143.2 
(C-5); lit114 21.5, 51.8, 127.4, 129.7, 134.5, 143.9 ; m/z (FAB*) 614 (MNa\ 60 %) 
(found: C, 54.19; H, 5.63; N, 6.96 %. C27H33N3S3O6 requires C, 54.87 ;H, 5.63; N, 
7.11%).
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1,4,7-Triazacyclononane 89
c
1,4,7-Triazacyclononane 89 was prepared using a literature method113 with 88 
(10.0 g, 17 mmol) and concentrated sulfuric acid (75 ml). The white solid was 
recrystallised from chloroform (1.2 g, 20 %); 5 h  (200 MHz, CDCI3) 1.75 (3H, bs, NH), 
2.47 (12H, s, CH2); 5 c  (50 MHz, CDCI3) 47.0; lit114 8 C (50 MHz, CDCI3) 45.9.
N,N’,N”- T ri[(S)-2-hydroxypropyl]-1,4,7-triazacyclononane 90
CO
N,N\A/”-Tri[(S)-2-hydroxypropy]-1,4,7-triazacyclononane 90 was formed from 
89 (0.19 g, 1.5 mmol) and (S)-propylene oxide (0.38 g, 6.6 mmol) using literature 
method.154 The product 90 was obtained as a yellow oil which crystallised on cooling 
(0.43 g, 96 %); 5H (200 MHz, CDCI3) 1.14-1.16 (9H, s, CH3), 2.41-2.55 (18H, m, 
NCH2), 3.71-3.90 (3H, m, CH); 8C (50 MHz, CDCI3) 50.0, 50.8, 54.1 (C-1)(C-2)(C-4) 
and 64.3 (C-3); m/z (El+) 303 (MH+, 0.5 %).
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N,N’,N”-T ri[(S)-2-chloropropyl]-1,4,7-triazacyclononane 91
.......
.3HCI
N,N’,A/”-Tri[(S)-2-chloropropyl]-1,4,7-triazacyclononane 91 was formed using 
90 in chloroform (40 ml) and cooled in an ice bath. Dry HCI was bubbled through for 
30 min to afford a white precipitate. Chloroform (40 ml) was added to the slurry, 
followed by thionyl chloride (80 ml) slowly in portions. The ice bath was removed and 
the mixture stirred at room temperature for 10 d. The solution was concentrated in 
vacuo and the residue was taken up in water (30 ml) and washed with ethyl acetate 
(3 x 80 ml). The aqueous layer was evaporated to dryness to yield a yellow/ brown 
solid (3.15 g, 85 %); i w  (KBr disc) 780 and 2969 cm*1; SH (200 MHz, D20 ) 1.26-1.30 
(9H, d, CH3), 3.02-3.38 (18H, m, NCH2), 4.26-4.33 (3H, m, CH); 8C (200 MHz, D20 )
23.0 (C-4), 50.9 (C-1), 53.7 (C-3) and 64.3 (C-2); (found: C, 38.48; H, 7.38; N, 8.80 
% requires C, 38.48 ;H, 7.20; N, 8.98 %).
0 ,0 ’-Di(p-toluenesulfonyl)-1,3-propanediol 93
OTs OTs
• u
7
0,0-Di(p-toluenesulfonyl)-1,3-propanediol 93 was formed using general 
method (h) with 1,3-propane diol 92 (11.41 g, 0.15 mol), p-toluenesulfonyl chloride 
(69.23 g, 0.30 mol) sodium hydroxide solution, TEBA (0.92 g, 4 mmol) and DCM (100 
ml). The product was afforded as a white solid (52 g, 91 %); 8H (200 MHz, CDCb)
1.58-1.71 (2H, m, CH2CH2), 2.45 (6H, s, CH3), 3.97 (4H, m, OCH2) and 7.30-7.34,
7.71-7.75 (8H, dd, AA’BB’ system); 8C (50 MHz, CDCb) 22.0 (C-1), 25.6 (C-7), 66.3 
(C-6), 127.4, 130.7 (C-3)(C-4), 138.5 (C-2), 147.3 (C-5); lit80 21.6, 28.7, 66.0, 128.1,
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130.1, 132.9 and 145.3; m/z (Cl+) 385.1 (MhT, 54 %) (found: MH* 385.0780 
C17H21O6S2 requires 385.0780).
N,N’,N”-T ri(p-toluenesulfonyl)-1,4,7-triazacyclodecane 94
NTs TsN
\  M Tc /
Compound 94 was formed using general method (e) with the disodium salt of 
87 (2.5 g, 4.05 mmol) and 93 (1.55 g, 4.05 mmol). The product was obtained as a 
white solid (0.89 g, 36 %); 8 H ( 2 0 0  MHz, CDCb) 1.62-1.74 (2 H, m, CH2CH2), 2.45 (9H, 
s, CH3), 3.45-3.70 (12H, m, NCH2), 7.36-7.73 (12H, dd, AA’BB’ aromatic system); 8 C 
(50 MHz, CDCb) 21.5 (C-1 ), 25.4 (C-7), 51.3, 51.8 (C-6 )(C-8 ), 127.6, 129.7, 135.4 
(C-2)(C-3)(C-4) and 144.1 (C-5;.
A/,/V',/V”-Tri(p-toluenesulfonyl)-1,4,7-triazacyclounadecane 95
Compound 95 was formed using general method (e) with the disodium salt of 
N,/V'AT-tri(p-toluenesulfonyl)-dipropyl-1,5,8 -triamine (2.5 g, 4.05 mmol) and 84 (1.40 
g, 4.05 mmol). The product was obtained as a white solid (0.67 g, 28 %); SH ( 2 0 0  
MHz, CDCb) 1.52-1.69 (4H, m, CH2CH2), 2.48 (9H, s, CH3), 3.35-3.67 (1 2 H, m, 
NCH2), 7.40-7.82 (12H, dd, AA’BB’ aromatic system); lit155 6.56 (t, 4H), 6.71 (s, 4H), 
6.98 (t, 4H), 8 . 1 0  (m 4H); 5C (50 MHz, CDCb) 2 1 . 8  (C-1 ), 24.9 (C-7), 51.8, 52.4, 52.6 
(C-6)(C-7)(C-9), 27.4, 129.3, 135.4 (C-2)(C-3)(C-4) and 145.3 (C-5;.
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N,N’,N”’T ri(p-toluenesulfonyl)spermidine 97
HTsN. / v  NTs
v  ^  v  NTsH
/V,/V'/\f-Tri(p-toluenesulfonyl)spermidine 97 was formed by general method (f) 
using spermidine 96 (1.0 g, 7.0 mmol), sodium hydroxide solution, diethyl ether (15 
ml), and p-toluenesulfonyl chloride (3.81 g, 21 mmol) to afford the product as a white 
solid (2.52 g, 60 %); 5H (200 MHz, CDCI3) 1.32 (4H, m, CH2ChbCH2), 1.54-1.60 (2H, t, 
NCHzCik), 2.24 (9H, s, CH3), 2.68-2.97 (8H, m, NCH2), 7.09-7.14, 7.54-7.59 (12H, 
dd, AA’BB’ aromatic system); m/z (FAB+) 608.1 (MH*t 100 %) (found: MH* 608.1926. 
CzsHsgNsOeSs requires 608.1923).
N,N',N”-Tri(p-toluenesulfonyl)-1,5,9-triazacyclotridecane 99
sN-
NTs
TsN
A/lA/,,A/”-Tri(p-toluenesulfonyl)-1,5l9-triazacyclotridecane 99 was formed by 
general method (j) using 93 (0.29 g, 0.90 mmol) and the disodium salt of 98 (0.50 g, 
0.75 mmol) in dry DMF (30 ml) (0.2, 41 %); i w  (KBr disc) 1168, 1380, 1501, 1604 
and 3300 cm*1; 8H (200 MHz, CDCb) 1.32-1.76 (8H, m, CH2CH2), 2.29 (9H, s, CH3), 
3.34-3.87(12H, m, NCH2) and 7.28-7.67 (12H, m, Ar-H) ; 8C (50 MHz, CDCb) 21.6 
(C-1), 23.3 (C-10), 26.5 (C-7), 51.0, 53.2, 53.5 (C-6)(C-8)(C-9), 126.5, 128.6 (C-3) 
(C-4), 133.5 (C-2) and 145.0 (C-5).
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N, O, O'- T ri(p-toluenesulfonyl)diethanolamine 101
TsO NTs OTs
N, O, O’-Tri(p-toluenesulfonyl)diethanolamine 101 was obtained as white 
crystals by general method (f) from diethanolamine (5.26 g, 50 mmol), 30 % sodium 
hydroxide solution (35 ml), p-toluenesulfonyl chloride (31.5 g, 150 mmol), TEBA (0.46 
g, 20 mmol) and DCM (50 ml) (26 g, 93%); iw (K B r) 1164, 1350, 1500 and 1600 
cm1; Sh (200 MHz, CDCb) 2.45 (9H, s, Ar-CH3), 3.34 (4H, t, NCH2), 4.06-4.17 (4H, t, 
OCH2), 7.65-7.91, 7.91-7.56 (12H, dd, AA’BB’ system Ar-H); 5c(50 MHz, CDCb) 21.7 
(C-1), 48.4 (C-6), 66.7 (C-7), 126.9, 129.97 (C-3)(C-4), 132.4 (C-2), 143.4 (C-5); lit152 
5 21.6, 21.7, 48.5, 68.4, 127.5, 128.2, 130.3, 132.8, 135.7 and 144.4; m/z (Cl*)
568.2 (MH*, 90 %) (found: MH* 568.1130. CaHsoNOaSs requires 568.1134).
/V,W’,W”,/V”’-Tetra(p-toluenesulfonyl)-1,4,7,11 -tetraazacyclopentadecane 102
A/, A/’, A/" A/’”-Tetra(p-toluenesulfonyl)-1,4,7,11-tetraazacyclopentadecane 102 was
formed by general method (e) using 101 (0.25 g, 0.44 mmol) and the disodium salt of 
98 (0.28 g, 0.44 mmol) in dry DMF (20 ml) (0.18, 50 %); SH (200 MHz, CDCb) 
2.32-2.40 (6H, m, ChfcC^N), 2.75 (6H, s, Ar-CH3), 2.84 (6H, s, Ar-H), 3.18-3.31, 
3.55-3.62 (16H, dt, NCH2), 7.16-7.26 (8H, m, AA’BB' system Ar-H), 7.50-7.69 (8H, m, 
Ar-H); 8c (50 MHz, CDCb) 21.3 (C-1), 31.1 (C-14)(C-15), 36.3 (C-11), 41.6, 42.0, 
45.8, 49.3, 49.4 (C-10)(C-12)(C-13 (C-16)(C-6), 51.4 , 65.7, 69.6 (C-7)(C-8)(C-9), 
127.7, 129.8 (C-3)(C-4), 135.3 (C-2), and 143.8 (C-5).
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JV”’-Tetra(p-toluenesulfonyl)spermine 104
NTs "NTsH
HTsNoo NTs 7
N ,N \ AP,AT-Tetra(p-toluenesulfonyl)spermine 104 was formed using general 
amine tosylation method (d) to afford the product as a white solid using spemine 103 
(1.0 g, 5.0 mmol), 30 % sodium hydroxide solution, diethyl ether (15 ml) and 
p-toluenesulfonyl chloride (3.81 g, 20 mmol) (1.84 g, 46 %); 8 h (200 MHz, CDCb) 
1.47-1.60 (4H, m, NCHzCHzCfcb), 1.68-1.79 (4H, m, NCH2CH2), 2.42 (12H, s, 
Ar-CH3), 2.95 (12H, m, NCH2), 7.25-7.30, 7.62-7.74 (16H, m, Ar-H); S c  (50 MHz, 
CDCb) 21.4 (C-1), 26.3 (C-6), 28.9 (C-9), 42.4 (C-7), 45.9 (C-10), 48.6 (C-8), 128.7, 
129.6 (C-3)(C-4), 135.9 (C-2), 136.8 (C-5).
/V,AT,AT,AT',AT’
-Penta(p-toluenesulfonyl)-1,4,7,11,16-pentaazacyclononadecane 105
NTs
TsN
N, N ’, AT, A/'” AT-Penta(p-toluenesulfonyl)-14,7,11,16-pentaazacyclononadecane 
105 was formed using general method (g) with 104 (1.0 g, 1.2 mmol), caesium 
carbonate (0.20 g, 0.6 mmol), dry DMF (30 ml) and 86 (0.70 g, 1.2 mmol) (0.30 g, 23 
%); Sh (200 MHz, CDCb) 2.31-2.50 (8H, m, ChfcCHzN), 2.74 (15H, s, Ar-CH3), 
2.94-3.19 (6H, m, NCH2), 3.26-3.62 (10H, m, NCH2), 3.99-4.12 (4H, m, NCH2),
7.17-7.29, 7.48-7.67 (20H, m, Ar-H); S c  (50 MHz, CDCb) 21.4 (C-1), 25.6 (C-15),
28.9 (C-18), 40.1, 41.6 (C-11), 45.9, 48.5 (C-8)(C-10), 51.4, 51.4 (C-6)(C-7), 126.9,
129.9 (C-3)(C-4), 135.9 (C-2) and 143.3 (C-5).
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M,JV’-Di(p-toluenesulfonyl)ethylenediamine 107
HTsN NTsH
eV_7
A/,A/-Di(p-toluenesulfonyl)ethylenediamine 107 was prepared by general 
method (f) as white crystals using ethylendiamine (9.61 g, 0.16 mol), water (100 ml), 
sodium hydroxide (12.8 g, 0.32 mol), diethyl ether (100 ml) and p-toluenesulfonyl 
chloride (61.07 g, 0.32 mol) (58.46 g, 99%); mp 163-165 °C; lit152 162-164 °C; 
iw (K B r) 1165, 1340, 1460, 1510 and 1610 cnrr1; 8h (200 MHz, CDCb) 2.41 (6H, s, 
Ar-CH3), 2.77 (4H, t, CH2), 3.47 (2H, s, NH), 7.47 (8H, 2 x AA'BB', Ar-H); 5c (50 MHz, 
CDCb) 21.0 (C-1), 40.7 (C-6), 126.6, 129.7 (C-3)(C-4), 137.4 (C-2), 142.8 (C-5); lit152 
21.6, 43.2, 127.4, 130.1, 135.1, 144.2; m/z (Cl+) 369.1 (MH+, 100 %) ( found: MhT 
369.0943, C, 52.10; H, 5.46; N, 7.33 % C16H20N2O4S2 requires 369.0942, C, 51.72; 
H, 5.47; N, 7.60 %).
AT, A/”-Di(p-toluenesulfonyl)-4,7-diazadecanedinitrile 108
7 6
9 8________________________________
A/’ Af-Di(p-toluenesulfonyl)-4,7-diazadecanedinitrile 108 was formed from 107 
(19.50 g, 53 mmol), potassium carbonate (21.68 g, 0.21 mol) and acrylonitrile (13.8 
ml, 0.21 mol) in dry DMF (160 ml) as in the literature95 (19.7 g, 78 %); umax (KBr disc) 
1140, 1339, 1496, 1599 and 2250 cm 1; 5H (200 MHz, CDCb) 2.38 (6H, s Ar-CH3),
2.65-2.68 (4H, t, CH2), 3.31-3.38 (4H, t, CH2N) 3.42 (4H, s, CH2N), 7.29-7.31,
7.66-7.68 (8H, dd, AA’BB’ system); 5c (50 MHz, CDCb) 19.5 (C-8), 21.9 (C-1), 47.3 
(C-7), 50.8 (C-6), 118.2 (C-9), 127.8, 130.6 (C-3)(C-4), 134.7 (C-2), 145.0 (C-5).
N A/”-Di(p-toluenesulfonyl)-4,7-diazadecanedinitrile-1,10-diamine 109
9 7 6
NTs .NH2
H2N ^ NTs ^  n /
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AT, Af-Di(p-toluenesulfonyl)-4,7-diazadecanedinitrile-1,10-diamine 109 was
formed by reducing 108 (19.0 g, 40 mmol) using 1 M borane/ THF solution (300 ml) 
according to the literature95 (9.07 g, 47 %); 0 ™  (KBr disc) 2258, 1340, 1491, 1594, 
2258 and 3376 cm 1; 8H (200 MHz, CDCI3) 1.55 (4H, bs, NH), 1.60-1.66 (4H, m, 
CH2CH2N ), 2.37 (6H, s, Ar-CHs), 2.68-2.70 (4H, t, CH2N ), 3.10-3.14 (4H, t, CH2N),
3.26 (4H, s, CH2N), 7.24-7.26, 7.64-7.66 (8H, dd, AA’BB’ system); 5c (50 MHz, 
CDCI3) 21.9 (C-1), 32.6 (C-8), 39.2 (C-9), 48.0 (C-7), 49.3 (C-6), 127.6, 130.2 
(C-3)(C-4), 135.9 (C-2), 144.0 (C-5).
Arw,W'””-Hexa(p-toluenesulfonyl)-1,5,9,12,16,20-hexaazaisocosane
110
.NTsH
N, N', N", A/'” N m, A/"”-Hexa(p-toluenesulfonyl)-1,5,9,12,16,20-hexaazaisocosane 
110 was formed by a linear extension using the last three steps repeated as a white 
solid by reported procedures95 using the amine obtained on repeating the previous 
two steps (3.30 g, 3.65 mmol) in water (15 ml), sodium hydroxide (0.30 g, 7.3 mmol), 
diethyl ether (20 ml) and p-toluenesulfonyl chloride (1.40 g, 7.3 mmol). (4.40 g, 99 
%); Umax (KBr disc) 1158, 1333, 1493, 1597 and 3285 cm 1; 5H (200 MHz, CDCb)
1.72-1.75, 1.82-1.86 (8H, t, CH2CH2CH2), 2.30, 2.36 (18H, s, Ar-CH3), 2.81-2.91 (4H, 
m, CH2N), 3.01 (12H, m, CH2N), 3.21 (4H, s, NCH^HzN), 5.23 (2H, bs, NH),
7.14-7.26, 7.58-7.74 (24H, dd, AA’BB’ system); 8C (50 MHz, CDCb) 21.9, 22.0 (C-1), 
29.0, 29.9 (C-8), (C-11), 40.6 (C-12), 47.1, 47.9, 48.7 (C-7)(C-9)(C-10), 49.9 (C-6),
127.4, 127.5, 127.6, 130.3, 130.4 (C-3)(C-4), 135.3, 135.8, 137.3, 138.5 (C-2), 143.5,
144.0 and 144.3 (C-5).
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N,N’,N",N’",N””,Nmn 
-Hexa(p-toluenesulfonyl)1,4,B,12,16,20-hexaazacycfotriisocosane 112
NTs TsN-
NTs
N, N ’, AT, AT, AT' AT”-Hexa(p-toluenesulfonyl)-1,4,8,12,16,20-hexaazacyclotri 
isocosane 112 was formed using 110 (2.0 g, 1.6 mmol) in dry DMF (60 ml) and 93 
(0.60 g, 1.6 mmol) in DMF (40 ml) by general method (e). The product was obtained 
as a light beige solid (1.45 g, 73 %); Umax (KBr disc) 1159, 1339, 1494, 1597 and 
3289 cm 1; SH (200 MHz, CDCb) 1.70-1.82 (10H, dt, CH2CH2N), 2.36 (18H, s, Ar-CH3), 
2.88-2.91 (4H, m, NCH2), 3.06-3.21 (14H, m, NCH2), 3.29 (4H, m, NCH2CH2N),
7.14-7.26, 7.56-7.67 (24H, dd, AA’BB’ system).
N,N',N”,N”’,N””,N”’” 
-Hexa(p-toluenesulfonyl)-1,5,9,13,17,21-hexaazacyclotetraisocosane 113
NTs
NTs
N, A/', AT, AT, A/ww,A/*”’-Hexa(p-toluenesulfonyl)-1,5,9,13,17,21-hexaazacyclotetra 
isocosane 113 was formed by general method (e) with A/', AT, A/'” AT” A/””-hexa 
(p-toluenesulfonyl)-1,5,9,13,17,21-hexaazacyclounaisocosane (2.38 g, 2.0 mmol) in 
dry DMF and 93 (0.74 g, 2.0 mmol); 8H (200 MHz, CDCb) 1.60-1.90 (12H, m, 
CH2CH2CH2), 2.45 (18 H, s, CH3), 3.05-3.30 (24H, m, NCH2), 7.35-7.92 (24H, m,
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AA'BB’ system Ar-H); 8C (50 MHz, CDCb) 21.9 (C-1), 29.9, 30.4 (C-7), 47.6, 47.9 
(C-6)(C-8), 125.5, 127.6 (C-3), 130.2, 130.4 (C-4), 136.2 (C-2) and 144.0 (C-5).
1,5,8-T riazacyclodecane-2,4-dione 115
1
4
1,5,8-Triazacyclododecane-2,4-dione 115 was prepared as in the literature97 
by heating diethyl malonate 114 (16.0 g, 0.1 mol), diethylenetriamine 85 (10.3 g, 0.1 
mol) and EtOH (1000 ml) at reflux for 5 d under nitrogen with a drying tube attached. 
The solvent was removed under reduced pressure to leave a deep red viscous oil 
which solidified on standing at room temperature (10.2 g, 64 %); i w  (KBr disc) 
1550, 1690, 2830, 2950 and 3320 cm 1; 8H (200 MHz, CDCb) 2.61 (2H, s, COCH2), 
2.59-2.65 (4H, t, NCH2), 3.15-3.24 (4H, t, NCH2); 8 c  (50 MHz, CDCb) 39.1 (C-1),
43.4, 47.1 (C-3)(C-4), 170.0 (C-2).
1,5,9-T riazacyclododecane-2,4-dione 117
1,5,9-Triazacyclododecane-2,4-dione 117 was prepared by heating 
A/-(3-aminopropyl)-1,3-propanediamine 116 (5.0 g, 38 mmol), diethylmalonate 114 
(7.30 g, 46 mmol) and MeOH (200 ml) at reflux for 4 d under nitrogen. The solvent 
was removed under reduced pressure to leave a light brown oil which solidified on 
standing at room temperature (7.2 g, 78 %); Umax (KBr disc) 1449, 1684, 2850, 2900 
and 3400 cm'1; SH (200 MHz, D20 )  1.58-1.79 (4H, m, NCH2CH2), 2.27 (2H, s,
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COCH2), 2.58-2.79 (4H, m, NCH2), 3.16-3.24 (4H, m, NCH2); lit97 1.66, 1.85, 2.76, 
3.13, 3.40, 8.56; 8c (50 MHz, D20) 28.4 (C-4), 36.9 (C-1), 45.7, 45.9 (C-3)(C-5),
170.0 (C-2).
1 -Oxa-4,7,10-triazacyclododecane-3,11 -dione 119
HNNH
NH
1-Oxa-4,7,10-triazacyclododecane-3,11-dione 119 was prepared by heating 
diglycolic dimethylate 118 (4.0 g, 25 mmol), 85 (2.06 g, 20 mmol) and dry MeOH (150 
ml) at reflux for 3 d under nitrogen. The solvent was removed invacuo to leave a 
light beige oil which solidified on standing at room temperature. The solid was taken 
up in DCM (50 ml) and washed with water (3x 50 ml). The DCM was dried over 
MgSC>4 , filtered and concentrated to a yellow oil (0.34 g, 8 %); Umax (KBr disc) 1125, 
1330, 1552, 1680, 2800, 2925, and 3380 cm 1; SH (200 MHz, D20 )  2.74 (3H, bs, NH),
3.34 (8H, m, NCH2), 4.07 (4H, m, OCH2); 8C (50 MHz, D20 )  38.3 (C-3), 47.4 (C-3),
69.9 (C-1), 177.6 (C-2).
8.5.1 Experimental to Chapter 5
/V-Hydroxyethylmorpholine 121
Alcohol 121 was obtained as a light yellow oil from morpholine 120 (2.0 g, 23 
mmol) and ethylene oxide (1.41 g, 32 mmol) in EtOH (5 ml) using general method (e) 
(2.04 g, 68 %); 5H (200 MHz, CDCb) 1.96-2.01 (6H, m, CH2N), 3.08-3.19 (6H, m, 
CH20 ) and 3.47 (1H, s, OH); 8c (50 MHz, CDCb) 53.4 (C-2), 57.7 (C-4), 60.3 (C-3) 
and 67.4
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N-Chloroethylmorpholine 122
Chloride product 122 was obtained from 121 (2.0 g, 15 mmol) in chloroform 
(15 ml) and thionyl chloride (20 ml) by general method (c). The cream coloured 
precipitate which occurred after stirring overnight at room temperature was filtered 
and washed with diethyl ether (1.95 g, 86 %); Umax (KBr disc) 659, 2870 and 3011 
cm 1; 5h (200 MHz, D20 )  2.98-3.15 (2H, m, NCH2CH2CI), 3.33-3.52 (4H, m, 
NCH2CH2O) and 3.58-3.98 (6H, m, CH20 , CH2CI); 8C (50 MHz, D20 )  37.3 (C-4), 52.4 
(C-3),58.5 (C-2) and 64.2 (C-1); m/z (Cl+) 150.06 (MH*, 100 %) (found: MH* 
150.0685 CeHiaNO^CI requires 150.0686).
tf,N'-Di(hydroxyethyl)-1,7-dioxa-4,10-diazacyclododecane 124
1,7-Dioxa-4,10-diazacyclododecane 123 (0.1 g, 0.57 mmol) was treated with 
ethelyene oxide (0.18 g, 4 mmol) in EtOH (4 ml) according to general method (e) to 
afford A/,A/-di(hydroxyethyl)-1,7-dioxa-4,10-diazacyclododecane 124 as an orange oil 
(0.12 g, 92 %); Umax (KBr disc) 1095, 1105, 1267 and 2865 cm 1; SH (200 MHz, CDCb)
2.58-2.63 (12H, m, NCH2), 3.33-3.53 (12H, m, OCH2), 4.78 (2H, bs, OH); 8C (50 MHz, 
CDCb) 55.3, 56.3 (C-2) (C-3), 59.1 (C-4), 65.1 (C-1).
N,/V'-Di(chloroethyl)-1,7-dioxa-4,10-diazacyclododecane 125
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124 (0.40 g, 1.5 mmol) was taken up in chloroform (10 ml) and added to 
thionyl chloride as in general method (c). The chloride 125 was afforded as a light 
brown solid (0.20 gf 80 %); Umax (KBr disc) 729, 2970 and 3100 cm 1; Sh (200 MHz, 
CDCb) 2.43-2.65 (12H, m, NCH2), 3.20-3.78 (12H, m, OCH2l CH2CI); Sc (50 MHz, 
CDCb) 39.2 (C-4), 55.4, 56.6 (C-2) (C-3), 65.0 (C-1); m/z (Cl+) 269 (MH*, 100 %).
AT,AT-Di(hydroxyethyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane 127
OH
N, A/-Di(hydroxyethyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane 127 was 
formed according to general method (e) using 1,4,10,13-tetraoxa-7,16- 
diazacyclooctadecane 126 (0.05 g, 0.14 mmol), ethylene oxide (0.05g, 1.2 mmol) and 
EtOH (10 ml) (0.06 g, 55 %); Umax (KBr disc) 1065, 1098, 1250 and 2880 cm 1; Sc (50 
MHz, D20 )  53.7, 56.3, 59.1 (C-3) (C-4) (C-5), 68.8 (C-2) and 70.1 (C-1); nVz (Cl+)
351.5 (MH*, 100 %).
N, AT-Di(chloroethyl)-1,4,10,13-tetraoxa-7y16-diazacyclooctadecane 128
127 (2.63 g, 7.5 mmol) was taken up in DCM (30 ml) and cooled to 0 °C. 
Thionyl chloride (15 mmol) was slowly added to the stirring solution. The solution 
was then heated at 60 °C for 6 h. Solvent and excess thionyl chloride were removed 
invacuo to leave a brown liquid. The residue was taken up in water (30 ml). Sodium 
bicarbonate was added until an oily layer occurred. The oily layer was removed and 
extracted with diethyl ether (5 x 50 ml). The combined organic were dried over
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M gS04, filtered and concentrated invacuo to leave a yellow solid which when taken 
up in chloroform afforded the product 128 as a white solid (2.80 g, 62 %); i w  (KBr 
disc) 713, 2920 and 2870 cm 1; 5H (200 MHz, D20 )  1.65-2.41 (12H, m, NCH2), 
3.40-3.85 (20H, m, OCH2, CICH2); 5c (50 MHz, D20 )  43.1 (C-5), 44.9 (C-4), 62.3 
(C-3), 70.9, 71.7 (C-1) (C-2); mfz (Cl+) 356.2 (Mht, 45 %).
o
1,4 -B is (0 ,0 ’-2’-formylphenyl)-1,2-ethanediol 130
130 Was obtained as in the literature method101 using salicylaldehyde 129 (24.4 
g, 0.2 mol) in EtOH (20 ml), sodium hydroxide (8.0 g, 0.2 mol) in water (400 ml) and
1,2-dibromoethane (18.4 g, 8.45 ml, 0.1 mol) as a beige solid (13.34 g, 25 %); i w  
(KBr disc) 1484, 1597, 1696 and 2866 cm 1; 5H (200 MHz, CDCb) 4.56 (4H, s, OCH2),
7.59-7.62, 7.86-7.88 (8H, m, Ar-H) and 10.48 (2H, s, COH); lit101 4.53, 7-8, 10.38; 5C 
(50 MHz, CDCb) 67.4 (C-8), 113.1, 125.6,129.1, 136.3 (C-3) (C-4) (C-5) (C-6), 161.1 
(C-7), 189.7 (C-1); m/z (El+) 307.1 (MhT, 86 % ).
5,6:14,15-Dibenzo-1,12-diaza-1,4-dioxacyclopentadecane-7,12-diene 131
5,6:14,15-Dibenzo-1,12-diaza-1,4-dioxacyclopentadecane-7,12-diene 131 was 
obtained as in the literature101 using 130 (10.0 g, 0.037 mol) in MeOH (500 ml) and
1,3-diaminopropane (2.7 g, 0.037 mol) in MeOH (115 ml). The product was obtained
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as fluffy beige needles (5.60 g, 48 %); i w  (KBr disc) 1451, 1599, 1633 and 2872 
crrr1; 8h (200 MHz, CDCb) 2.28-2.34 (2H, quintet, CH2CI±>), 3.61-3.66 (4H, t, NCH2),
4.42 (4H, s, OCH2), 6.98-7.99 (8H, m, Ar-H), 8.81 (2H, s, CHN); lit101 2.29, 3.63, 4.35,
6.8-8.0, 8.7; 8C (50 MHz,CDCb) 28.9 (C-10), 58.3 (C-1), 68.4 (C-8), 113.9, 122.2,
127.5 ,132.1 , 158.9, 159.2 (C-2)(C-3) (C-4)(C-5)(C-6)(C-7).
5,6:14,15-Dibenzo-1,12-diaza-1,4-dioxacyclopentadecane 132
5,6:14,15-Dibenzo-1,12-diaza-1,4-dioxacyclopentadecane 132 was obtained by 
the literature method.101 using 131 (1.0 g, 3.25 mmol) in dry THF (20 ml) and 1M 
borane THF (30 ml) as a white solid (0.57 g, 56 %); 8H (200 MHz, CDCb) 2.03 (2H, s, 
NH), 2.54-2.57 (2H, m, NCH2CH2), 3.67 (4H, m, NCH2), 4.26 (4H, s, OCH2), 5.19 (4H, 
s, Ar-CH2), 6.77-6.84, 7.10-7.19 (8H, dt, Ar-H); 8c (50 MHz, CDCb) 28.2 (C-10), 46.4  
(C-9), 50.6 (C-8), 64.7 (C-1), 109.1, 119.6, 127.2, 127.5, 130.2, 156.0 
(C-2)(C-3)(C-4)(C-5)(C-6)(C-7).
A/,N-Di(hydroxyethyl)-5,6:14,15-dibenzo-1,12-diaza-1,4-dioxacyclopentadecane
133
HO* OH
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Using 132 (0.5 g, 1.25 mmol), ethylene oxide in EtOH (15 ml) as in general 
method (c), the product 133 was afforded on refrigeration overnight as a white solid 
(0.45 g, 81 %); 0 ™  (KBr disc) 1050, 1270, 1490, 1598, 2950 and 3400 cm'1; 8H (200 
MHz, CDCb) 1.50-1.64 (2H, m, NCH2CH2 ), 2.46-2.62 (8H, m, NCH2), 3.34-3.46 (8H, 
m, NCH2), 3.61 (4H, m, CH2OH), 4.27-4.36 (4H, m, OCH2), 5.22 (2H, s, OH),
7.15-7.25, 7.53-7.69 (8H, m, Ar-H); lit1"  1.65, 2.53-2.57, 3.56, 4.37, 6.91-7.3; 8C (50 
MHz, CDCb) 24.4 (C-10), 50.5 (C-9), 52.2 (C-8), 53.2 (C-11), 58.2 (C-12), 65.9 (C-1),
110.9, 120.5, 125.7, 128.7, 132.6, 157.0 (C-2)(C-3)(C-4)(C-5)(C-6)(C-7).
N,N-Di(chloroethyl)-5,6:14,15-dibenzo-1,12-diaza-1,4-dioxacyclopentadecane
134
133 (0.50 g, 1.25 mmol) was added to thionyl chloride (15 ml) as in general 
method (c) in DCM (8 ml). The solution was returned to room temperature and stirred 
overnight followed by heating at reflux for 2 h. The solution was returned to room 
temperature and EtOH (20 ml) was added. No further gas was evolved and the 
mixture was stirred for 2 h. The product 134 precipitated at 0 °C overnight as a white 
solid; (0.21 g, 40 %); 8H (200 MHz, D20 )  1.12-1.18 (2H, m, NCH^hh), 1.59-1.61 (4H, 
m, NCH2), 2.36 (4H, s, OCH2), 3.04-3.11 (4H, m, NCH2), 3.60-3.66 (4H, m, CH2CI), 
4.27-4.36 (4H, m, OCH2), 7.15-7.25, 7.53-7.69 (8H, m, Ar-H); lit102 1.60, 2.49, 2.79, 
3.45, 3.69, 4.35, 6.88-7.29; 5c (50 MHz, D20 )  21.9(C-10), 30.1 (C-12), 42.9, 43.5 
(C-9)(C-11), 50.9 (C-8), 63.2 (C-1), 127.5, 127.7, 130.2, 130.4, 138.5, 144.0 
(C-2)(C-3)(C-4)(C-5) (C-6) (C-7).
The hydrochloride salt was obtained on treatment with ethereal hydrochloric acid as a 
white solid (0.86 g, 78%); Umax (KBr) 780, 1496 and 1600 cm*1; (found: C, 51.03, H,
5.95 , N, 5.21 % C 2 3 H 3 2 N 2 O 2 C I4 requires C, 51.3, H, 5.99, N, 5.20 %).
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0,0"Di(p-toluenesulfonyl)dipropylene glycol 136
OTs 0  Ts?
7
Tosylated compound 0,0"-di(p-toluenesulfonyl)dipropylene glycol 136 was 
formed using general method (h) with p-toluenesulfonyl chloride (190.6 g, 1.0 mol), 
dipropylene glycol 135 (10 .0  g, 0.075 mol), 30% sodium hydroxide, TEBA ( 0.50 g, 
0.002 mmol) and DCM (200 ml) as white crystals (25.4 g, 76 %); i w  (KBr) 1198, 
1352, 1497 and 1599 cm 1; 5 h  (200 MHz, D20 )  1.80 (4H, m, CH2CH2), 2.46 (6H, s, 
CH3), 3.26 (8H, m, OCH2), 7.34-7.79 (8H, dd, AA’BB’ system Ar-H); 5c (50 MHz, D20 )
21.4 (C-1), 27.5 (C-7), 42.1, 42.3 (C-6), (C-8), 127.5, 129.6 (C-3) (C-4), 134.9 (C-2) 
and 145.3 (C-5).
N,tf'-Di(p-toluenesulfonyl)-5,8-diaza-1-oxacyclounadecane 137
/V,Af-Di(p-toluenesulfonyl)-1-oxa-4,7-diazacyclononane 137 was obtained by 
general method (j) using the disodium salt of 107 (1.0 g, 2.4 mmol) in dry DMF (50 
ml) and OtO"-di(p-toluenesulfonyl)dipropylene glycol 136 (1.06 g, 2.4 mmol) in dry 
DMF (50 ml) as a beige solid (0.25 g, 22 %); mp 195-197 °C; lit105199-201 °C; iw  
(KBr disc) 1160, 1337, 1450, 1501, 1601 and 2940 cm 1; 5H (200 MHz, D20 )  1.80 (4H, 
m, CH2CH2), 2.45 (6H, s, CH3), 3.15-3.33 (4H, m, CH2N), 3.40 (4, NChhCHjjO),
3.03-3.83 (4H, m, CH20 ), 7.74-7.78, 7.47-7.51 (8H, dd, AA’BB1 system Ar-H); 5c (50 
MHz, D20 )  21.9 (C-1), 25.4 (C-8), 52.3 (C-6), 52.7 (C-7), 67.6 (C-9), 127.5 , 129.3 
(C-2)(C-3)(C-4) and 145.1 (C-5).
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0,0"-Di(p-toluenesulfonyl)diethylene glycol 139
TsO O OTs
7 6
0,0"-Di(p-toluenesulfonyl)diethylene glycol 139 was formed using general 
method (h) using p-toluenesulfonyl chloride (190.6 g, 1.0 mol), diethylene glycol 138 
(50.06 g, 0.5 mol), 30% sodium hydroxide (350 ml), TEBA (4.6 g, 20 mmol) and DCM 
(500 ml) as white crystals (165.34 g, 80 %); mp 86-87 °C; lit156 87-87.5 °C; i w  (KBr) 
1192, 1358, 1494, 1597 and 3429 cm 1; 8H (200 MHz, CDCb), 2.36 (6H, s, CH3), 3.49 
(4H, t, tsOCHzCHsO), 4.00 (4H, t, OCH2CH2O),7.20-7.84 (8H, 2 x AA'BB', Ar-H); 5C 
(50 MHz, CDCb) 21.7 (C-1), 68.5 (C-6), 69.2 (C-7), 127.8 129.8 (C-3) (C-4), 132.6 
(C-2) and 144.9 (C-5); m/z (Cl+) 414 (MH*, 100 %) (found: C,52.71; H, 4.89; N, 17.65 
% requires C, 52.74; H, 4.97; N, 17.60 %).
A/,N’-Di(p-toluenesulfonyl-1-oxa-4l7-diazacyclononane 141
NTs
/V,A/’-Di(p-toluenesulfonyl)-1-oxa-4,7-diazacyclononane 141 was obtained by 
general method 0) using the disodium salt of 140 (1.0 g, 2.4 mmol) in dry DMF (50 
ml) and 139 (1.0 g, 2.4 mmol) in dry DMF (50 ml) as a light yellow solid (0.66 g, 62 
% ) ;  Umax (KBr disc) 1119, 1157, 1335, 1447, 1495, 1598 and 2924 cnrr1; 8 H (200 MHz, 
CDCb) 2.43 (6H, s, Ar-CH3), 3.20-3.31 (4H, s, NCH2), 3.37 (4H, s, NCH2CH20),
3.00-3.78 (4H, m, CH20 ), 7.30-7.46, 7.77-7.73 (8H, dd, AA’BB’ system Ar-H); 8C (50 
MHz, CDCb) 21.9 (C-1), 52.3 (C-6), 52.5 (C-7), 72.3 (C-8), 127.7, 130.2 (C-3) (C-4), 
135.3 (C-2), 144.0 (C-5); m/z (Cl+) 439.1 (MH*, 100 %) (found: MH* 439.1361. 
C uoH ^I^C ^  requires 439.1361).
The [1+1] was prepared according to general cyclisation method (i): Caesium 
carbonate (8.26 g, 25.4 mmol) was added to 0,0 ''-d i (p-toluenesulfonyl)ethylene 
glycol 139 (5.01 g 12.1 mmol) in dry DMF (50 ml) along with
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/V,/V’’-di(p-toluenesulfonyl)ethylene diamine 107 (4.44 g,12.1 mmol) in dry DMF (50 
ml). The product was afforded as a white solid (1.00 g, 57%).
0 >0 " ,-Di(p-toluenesulfonyl)triethyleneglycol 143
TsO O 0 OTsv _ y \_ /v _ y
8 7 6
O.C'-Difp-toluenesulfonylJtriethyleneglycol 143 was formed using general 
method (h) with p-toluenesulfonyl chloride (31.5 g, 0.15 mol) in DCM (40 ml), 
triethylene glycol 142 (11.27 g, 0.075 mol), 30% sodium hydroxide solution [15 g 
NaOH in 35 ml water], DCM (50 ml) and TEBA (0.46 g, 2 mmol) at 0 °C as white 
crystals (27.7 g, 81%), i w  (KBr) 1130, 1353, 1496 and 1596 cm 1; 5H (200 MHz, 
CDCb) 2.45 (6H, s, CH3), 3.42 (4H, s, tsOCH2), 3.57 (4H, t, tsCHzCJiO), 4.13 (4H,t, 
OCH2CH2O), 7.60-7.64, 7.49-7.53 (8H, 2 x AA'BB1, Ar-H); lit108 2.37, 3.50, 3.62, 4.06, 
7.25, 7.72; 5C (50 MHz, CDCb) 21.2 (C-1), 67.9 (C-6), 69. (C-7), 70.0 (C-8), 127.7,
130.2 (C-3) (C-4), 132.4 (C-2), 145.0 (C-5); m/z (Cl+) 459.1 (M H *, 100 %)(found: MH* 
459.1148. C20H27O8S2 requires 459.1147).
N,N*-Di(p-toluenesulfonyl)-1,4-dioxa-7,10-diazacyclododecane 144
NTs
N, /V-Di(p-toluenesulfonyl)-1,4-dioxa-7,10-diazacyclododecane 144 was
obtained by general method (j) using the disodium salt of 107 (2.0 g, 4.8 mmol) in dry 
DMF (50 ml) and 143 (2.22 g, 4.85 mmol) in dry DMF (50 ml) as a white solid (1.50 g, 
63 %); 5 h  (200 MHz, CDCb) 2.36 (6H, s, Ar-CH3), 3.08-3.13 (4H, m, NCH2), 3.45 (4H, 
s, OCH2), 3.57-3.65 (4H, m, NCH2CH2 O), 7.24-7.26, 7.66-7.68 (8H, dd, AA’BB’ 
system Ar-H); lit105 3.36, 3.50, 3.70, 3.73 (no aromatic moeities quoted); 8c (50 MHz, 
CDCb) 21.9 (C-1), 49.9 (C-6), 50.2 (C-7), 70.3 (C-8), 72.9 (C-9), 127.8, 130.1 (C-3)
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(C-4), 135.9 (C-2), 143.7 (C-5); m/z (Cl+) 483.2 (MH*, 100 %) (found: MH* 483.1624. 
C22H31N2O6 requires 483.1624).
The [1+1] product was prepared according to general cyclisation method (i): 
Caesium carbonate (8.26 g, 25.4 mmol), 143 (5.84 g, 12.1 mmol) in dry DMF (50 ml) 
and 107 (4.44 g, 12.1 mmol) in dry DMF (50 ml). The filtrate was left at 0  °C 
overnight. The precipitatewas filtered off to give N, A/'-di(p-toluenesulfonyl)-1,4-dioxa- 
7,10-diazacyclododecane; 5C (200 MHz, CDCb) 21.20 (C-1), 41.4 (C-8), 62.4 (C-9),
63.4 (C-12), 64.6 (C-11), 119.9, 121.9 (C-3) (C-4), 128.2 (C-2), 137.4 (C-5).
O, O w"-Di(p-toluenesulfony Itetraethy lene-1,4,7,10,13-tetraoxatridecane 146
TsO O O O OTs 
9 8 7 6
O, O^-DiOD-toluenesulfonylJtetraethylene-l ,4,7,10,13-tetraoxatridecane 146 was 
prepared using general method (h) with tetraethyleneglycol 145 (14.57 g, 75 mmol), 
p-toluenesulfonyl chloride (31.5 g, 150 mmol), TEBA (0.05 g, 2.0 mmol), 30 % 
sodium hydroxide solution (40 ml) and DCM (100 ml) as a clear viscous oil (21.3 g, 
56 %); 5h (200 MHz, CDCb) 2.30 (6H, s, Ar-CH3), 3.42 (8H, s, OCH2), 3.51-3.57 (4H, 
m, OCH2), 4.02-4.05 (4H, t, OCH2), 7.21-7.23, 7.64-7.66 (8H, dd, Ar-H); lit106 2.42, 
3.55, 3.67, 4.16, 7.35, 7.80; 8C (50 MHz, CDCb) 21.8 (C-1), 69.6 (C-8), 70.7 (C-7),
70.8 (C-6), 128.3, 130.5 (C-3) (C-4), 133.2 (C-2), 145.2 (C-5).
N,N’-Di(p-toluenesulfonyl)-1,4,7-trioxa-10,13-diazacyclopentadecane 147
A/,A/-Di(p-toluenesulfonyl-1,4,7-trioxa-10,13-diazacyclopentadecane 147 was 
afforded as a white solid using general cyclisation method G) with the disodium salt of 
107 (2.0 g, 4.8 mmol) in dry DMF (50 ml) and 146 (2.44 g, 4.8 mmol) in dry DMF (50
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ml) (1.79 g, 70 %); o™  (KBr disc) 1158, 1344, 1450, 1492, 1598 and 2935 cm 1; 8H 
(200 MHz, CDCb) 2.36 (6H, s, Ar-CH3), 3.09-3.15 (4H, m, NCH2), 3.31 (4H, s, 
NCH2CH2O), 3.48 (8H, s, CH2O), 3.61-3.64 (4H, m, CH2O), 7.23-7.25, 7.69-7.71 (8H, 
dd, M 'B B ' system Ar-H); 8c (50 MHz, CDCb) 21.9 (C-1), 49.8 (C-6), 50.7 (C-7), 70.6 
(C-8), 71.4 (C-9), 71.5 (C-10), 128.8, 130.1 (C-3) (C-4), 136.4 (C-2), 143.7 (C-5); m/z 
(Cl*) 527.1 (MH*, 100 %) (found: MH* 527.1886 C24H35N2O7S2  requires 527.1886).
/V,A/’,W”-Tri(p-toluenesulfonyl)-1-oxa-4,7,10-triazacyclododecane 148
/V,A/'A/B-Tri(p-toluenesulfonyl)-1-oxa-4,7,10-triazacyclododecane 148 was 
formed as a white solid using general cyclisation method Q) with the disodium salt of 
86 (4.0 g, 6.6 mmol) in dry DMF (100 ml) and 139 (2.72 g, 6.6 mmol) in dry DMF (100 
ml) (2.29 g, 55 %); 5H (200 MHz, CDCb) 2.42 (9H, s, Ar-CH3), 3.07-3.20 (8H, m, 
NCH2), 3.48-3.54, 3.62-3.66 (8H, m, NChhCthO), 7.25-7.28, 7.60-7.65 (8H, dd, 
Ar-H), 7.32-7.37, 7.79-7.83 (4H, dd, AA’BB’ systemAr-H); lit108 3.07 (12H, t, NCH2),
3.43 (4H, t, OCH2), 7.30 (12H, m, Ar-H); 8C (50 MHz, CDCb) 21.9 (C-1), 42.9 (C-6),
50.9 (C-7), 58.8 (C-8), 72.4 (C-9), 127.5, 130.19 (C-3)(C-4), 137.1 (C-2), 144.5 (C-5); 
m/z (Cl+) 718.1 (MhT, 100 %).
N, A/',/V”-T ri(p-toluenesulfonyl)-1,4-dioxa-7,10,13-triazacyclopentadecane 149
NTs
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N, N \ AT-T ri(p-toluenesulfonyl)-1,4-dioxa-7,10,13-triazacyclopentadecane 149
was afforded as a white solid using general cyclisation method (j) with the disodium 
salt of 86 (4.0 g, 6.6 mmol) in dry DMF (100 ml) and 143 (3.0 g, 6.6 mmol) in dry 
DMF (100 ml). The product 149 was afforded as a white solid (2.39 g, 54 %); i w  
(KBr disc) 1106, 1156, 1349, 1447, 1497,1597 and 2922 cm 1; 8H (200 MHz, CDCb)
2.35 (9H, s, Ar-CHa), 3.06-3.22 (8H, m, NCH2), 3.20-3.22 (4H, m, NCH2CH2O), 3.42 
(4H, s, CH2O), 3.46-3.53 (4H, m, CH20 ), 7.19-7.26, 7.66-7.76 (12H, m, Ar-H) lit100
2.27 (9H, s, CH3), 3.30 (20H, m, OCH2, NCH2), 7.30 (12H, m, Ar-H); 5c (50 MHz, 
CDCb) 21.8 (C-1), 40.4 (C-6), 47.4 (C-7), 48.3 (C-8), 56.3 (C-9), 56.3 (C-10) 
(C-11), 129.8, 130.1 (C-3) (C-4), 136.4 (C-2), 143.7 (C-5);; m/z (Cl+) 680 {MH*, 15 %), 
697 (iMNHS, 20 %).
N,N’,N”-T ri(p-toluenesulfonyl)-1,4,7-trioxa-10,13,16-triazacyclooctadecane 150
NTs
NTs
N, N \ AT-T ri(p-toluenesulfonyl)-1,4,7-trioxa-10,13,16-triazacyclooctadecane 150 
was afforded as a light beige solid using general cyclisation method Q) with the 
disodium salt of 86 (2.0 g, 2.2 mmol) in dry DMF (50 ml) and 146 (1.65 g, 3.3 mmol) 
in dry DMF (50 ml). The product was obtained as a white solid (1.44 g, 64 %); SH 
(200 MHz, CDCb) 2.35 (9H, s, Ar-CH3), 3.01-3.12 (8H, m, NCH2), 3.24-3.31 (4H, m, 
NCH2), 3.26-3.52 (4H, m, OCH2), 3.42-3.61 (8H, m, OCH2), 7.20-7.28, 7.66-7.75 
(12H, m, Ar-H) lit108 2.43 (9H, s, CH3), 3.41 (24H, m, OCH2, NCH2), 7.40 (12H, m, 
Ar-H); 5C (50 MHz, CDCb) 21.9 (C-1), 42.8 (C-6), 52.1 (C-7) (C-8), 69.7 (C-9), 69.8 
(C-10), 71.2 (C-11), 127.6, 130.2 (C-3) (C-4), 135.1 (C-2), 143.2 (C-5); m/z (FAB+)
724.2 (MhT, 100 %) (found: MH* 724.2396. CsaHaeNgOgSa requires 724.2396).
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N,N’,N",Nm-
Tetra(p-toluenesulfonyl)-1,10-dioxa-4,7,13,16-tetraazacyclooctadecane 151
NTs
NTs TsN‘
Caesium carbonate (8.26 g, 25.4 mmol) was added to 139 (5.01 g 12.1 mmol) 
in dry DMF (50 ml) as in general cyclisation method (i) along with 107 (4.44 g,12.1 
mmol) in dry DMF (50 ml). The product 151 was afforded as a white solid (1.56 g, 
44%); Omax(KBr) 118, 1334, 1499 and 1597 cnrr1 ; 8H(200 MHz,CDCb) 2.36 (12H, s, 
Ar-CHa) 3.16-3.20 (8H, m, NCH2CH20 ), 3.20 (8H, s, NCH2), 3.80-3.84 (8H, t, OCH2), 
7.22-7.26, 7.64-7.69 (16H, dd, AA’BB’ system Ar-H); lit94 2.44, 3.22, 3.32, 3.54, 7.31, 
7.71; 8c (200 MHz,CDCb) 21.5 (C-1), 51.8 (C-6), 52.0 (C-7), 71.9 (C-8), 127.3, 129.8 
(C-3) (C-4), 135.0 (C-2), 143.6 (C-5)\mfr (FAB+) 877 (MhT, 8 %), 899 (M N a\ 3 %).
W,W',/V",N'”-Tetra(p-toluenesulfonyl)-1,4,13,16-tetraoxa-7,10,19,22- 
Tetraazacyclododecosane 152
.NTs
NTs
Caesium carbonate (8.26 g, 25.4 mmol), 143 (5.84 g, 12.1 mmol) in dry DMF 
(50 ml) and 107 (4.44 g, 12.1 mmol) in dry DMF (50 ml) were treated as in general 
cyclisation method (i). A  light beige/yellow precipitate was found to be the desired 
152 (5.39 g, 46 %); i w  (KBr disc) 1160, 1345, 1500, 1598 and 2960 cm'1; SH (200 
MHz, CDCb) 2.43 (12H, s, Ar-CHa), 3.28-3.35 (8H, m, NCH2), 3.51 (16H, s, OCH2),
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3.63-3.67 (8 H, m, NCH2), 7.30-7.34, 7.72-7.76 (16H, m, Ar-H); 8C (50 MHz, CDCb)
21.5 (C-1), 49.5 (C-6 ), 49.8 (C-7), 69.9 (C-8 ), 72.5 (C-9), 127.3, 129.7 (C-3) (C-4),
135.6 (C-2), 143.0 (C-5); m/z (FAB+) 965 (MH+, 20 %) (found: C, 54.87; H, 6.36; N,
5.96 %. C44H60N4O12S4 requires C, 54.75; H, 6.27; N, 5.80 %).
N,N’-Di(chloroacetyl)-1,4,10,13-tetrathia-7,13-diazacyclopentadecane 154
/ k
L
N, Af-Di(chloroacetyl)-1,4,10,13-tetrathia-7,13-diazacyclopentadecane 154 was 
afforded on the treatment of 1,4,10,13-tetrathia-7,13-diazacyclopentadecane (0.1 g, 
0.31 mmol) with chloroacetyl chloride (0.087 g, 0.78 mmol) and triethylamine (0.078 
g, 0.78 mmol) according to literature preperation. 109 The product was obtained as a 
pale yellow solid (0 . 1 2  g, 85 %); 8 H ( 2 0 0  MHz, CDCb) 2.63-2.86 (16H, m, CH2S), 
3.43-3.66 (8H, m, CH2N), 4.17 (COCH2); 5C (50 MHz, CDCb) 41.5 (C-1), 47.3, 47.6 
(C-3)(C-4), 49.4 (C-5) and 166.9 (C-2).
tffN*-Di(chloroethyl)-1,4,10,13-tetrathia-7y13-diazacyclopentadecane 155
N,A/’-Di(chloroethyl)-1,4,10,13-tetrathia-7,13-diazacyclopentadecane 155 was 
obtained by the reduction of 154 (0.12 g, 0.26 mmol) in dry DMF (8 ml) to a stirring 
solution of 1M borane THF (15 ml) under nitrogen at 0 °C. The solution was heated 
at reflux for 5 h before cooling to 0 °C. 6M Hydrochloric acid (3 ml) was slowly added
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followed by water (10 ml). The solvents were distilled off and the residue was taken 
up in MeOH (20 ml). 3 Drops of concentrated hydrochloric acid were added to 
remove any methyl borate formed. The solution was concentrated in vacuo and the 
last three steps repeated until no further weight was noted. The orange oil was taken 
up in chloroform (10 ml) and triethylamine (2.5 ml) was added and the mixture was 
stirred for 30 min. The solution was concentrated under reduced pressure to a white/ 
yellow solid which was taken up in water (10 ml) and extracted with EtOAc (3 x 30 
ml). The organic extracts were combined, dried over MgS0 4  and concentrated in 
vacuo to leave the desired product as a viscous colourless oil (0.09 g, 77 %); Um» 
(KBr disc) 775, 2520 and 2940 cm'1; 6c (50 MHz, D20 ) 29.0 (C-5), 29.8 (C-4), 35.6 
(C-1) 54.7 (C-3), 54.8 (C-2); m/z (El+) 420.1 (MhT, 55 %).
The product 156 was obtained using a literature procedure94 from 108 ( 25.0 g, 
45 mmol), EtOH (170 ml) and thiourea (7.6 g, 100 mmol). The yellow oil obtained 
was purified by column chromatography on silica to leave the product 156 as a white
(C-6), 126.9 129.9 (C-3) (C-4), 136.4 (C-2), 143.6 (C-5); m/z (Cl+) 290 (MhT, 80 %)
A/-(p-Toluenesulfonyl)-1,4-dithia-7-azacyclononane 157 & 
tf,A/-Bis(p-toluenesulfonyl)-1,4,10,13-tetrathia-7,16-diazacyclooctadecane 158
N-(p-Toluenesulfonyl)-4-azapentane-1,7-dithiol 156
solid (7.79 g, 59 %); Rf 0.5 (DCM:MeOH; 99:1) lit94 0.5; iw fK B r) 1164, 1332, 1598 
and 2600 cm 1; 8H (200 MHz, CDCb) 1.52 (4H, t, SCH2), 2.41 (3H, s, CH3), 3.62 (4H, 
t, NCH2), 7.28-7.69 (4H, dd, Ar-H); 8C(200 MHz, CDCb) 21.4 (C-1), 23.9 (C-7), 52.5
8
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To caesium carbonate (1.8 g, 5.5 mmol) in dry DMF (250 ml) was added at 55 
°C solutions of 1,2-dibromoethane (92.0 g, 5.0 mmol) in DMF (125 ml) and 156 (1.55 
g, 5.32 mmol) in DMF (125 ml). The two solutions were added at equal rates over a 
period of 12 h with vigorous stirring. After the final addition the temperature was 
raised to 60 °C and the mixture was stirred for a further 3 h. The solvent was 
removed by distillation and the residue taken up in DCM (50 ml). The organic layer 
was washed several times with water, dried over MgSO^ filtered and concentrated 
in vacuo. The beige solid was taken up in warm toluene (10 ml) and hexane was 
added (2.5 ml). The solution was allowed to cool overnight. The brown solid was 
filtered off as N, A/-di(p-toluenesulfonyl)-1,4,10,13-tetrathia-7,16-diazacyclo
octadecane. 158 mp. 123-125 °C; lit94 122-124 °C. Hexane was added for
A/-(p-toluenesulfonyl)-1,4-dithia-7-azacyclononane to precipitate out. 157 mp. 
206-208 °C; lit94 206 °C.
Procedure was carried out as in literature using /V,/V',Af-tri(p-toluenesulfonyl)-
1,4,7-trioxa-10,13,16-triazacyclooctadecane 150 (1.50 g, 2.0 mmol), in dry THF (20 
ml) and dimethylphenylsilyl lithium (10.4 ml, 11.4 mmol) and the mixture was stirred 
at 0 °C for 5 h. The white solid obtained on characterisation showed some 
detosylation but also impurities which proved to be difficult to remove.
1,4,7-T rioxa-10,13,16-triazacyclooctadecane 160
1,4,7-Trioxa-10,13-diazacyclopentadecane 161
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Procedure was carried out as in the literature using 
A/,/V’-di(p-toluenesuifonyl)-1,4,7 trioxa-10,13-diazacyclopenadecane 147 (1.50 g, 2.85 
mmol), in dry THF (20 ml) and dimethylphenylsilyl lithium (10.4 ml, 11.4 mmol) and 
the mixture was stirred at 0 °C for 5 h. The white solid obtained on crystallisation 
showed some detosylation but also impurities which proved to be difficult to remove.
8.6.1 Experimental to Chapter 6
yv,/V,-Di(hydroxyethyl)-N,N'-di(o-nitrobenzyl)piperazinium dichloride 161a
.OH
HO'
2CI
AAAMihydroxyethyl-tyA/'-dKo-nitrobenzyOpiperazinium dichloride 161a was 
obtained as in literature method139 using 66 (0.25 g, 1.45 mmol) in acetonitrile (10 ml) 
and o-nitrobenzyl chloride (0.5 g, 2.91 mmol); i w  (KBr) 1078, 1609, 2853, 2924 and 
3387 cm1; 5H (200 MHz, D20 ) 2.85-3.02 (12H, m NCH2), 3.80-3.90 (4H, m, OCH2), 
4.92 (4H, s, CH2Ar), 7.35-7.42, 7.55-7.77 (8H, m, Ar-H); 5C (50 MHz, D20 ) 43.2 (C-3),
47.3 (C-2), 56.6 (C-4), 58.2 (C-1), 125.6, 129.8, 131.9, 132.8, 134.1 138.5 
(C-5)(C-6)(C-7)(C-8)(C-9); m/z (FAB+) 310.3 (M-NitrobenzylCI, 30 %), 445 2 (M-2CI, 
1 %), 481.4 (M-CI, 1.6 %).
N,N'-Di(hydroxyethyl)-di(p-nitrobenzyl)-N,JV>-piperazinium dibromide 161 b
OHO2N
HO‘
.2Br
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A/,AT-Di(hydroxyethyl)-di(p-nitrobenzyl)-A/,A/,-piperazinium dibromide 161b was 
obtained as in literature method139 using 66 (3.0 g, 17.2 mmol) in EtOH (30 ml), 
p-nitrobenzyl bromide (3.72 g, 17.2 mmol) (0.7 g, 37 %); i w  (KBr) 1082, 1350, 
1496,1519, 1604, 2858, 2967, 3107, 3292 and 3546 cm 1; 8H (200 MHz, D20 )  
3.32-3.72 (16H, m, NCH2), 4.74 (4H, m, Ar-CH2), 7.44-8.20 (8H, AA'BB', Ar-H); m/z 
(Cl+) 445.3 (M-2Brt 100 %).
f/,N>-Di(chloroethyl)-M,N'-di(o-nitrobenzyl)piperazinium dichloride 162a
no2
3 2 1 X I
s —  \ — f
, /  4 V
©
.2CI r 6 7
0,
a '
A/,A/'-Di(chloroethyl)-A/,A/,-di(o-nitrobenzyl)piperazinium dichloride 162a was 
obtained as in literature method139 161a (0.07 g, 0.14 mmol) in thionyl chloride (10 
ml), as in general method (c) (0.04 g, 55 %); IW  (KBr) 780, 1369, 1530 and 1631 
citv1;8h (200 MHz, D20 )  2.97-3.85 (12H, m, NCH2), 3.86-3.94 (4H, m, CH2CI), 
4.78-4.85 (4H, s, Ar-CH2), 7.51-7.78 (8H, m, Ar-H); 8C (50 MHz, D20 ) 36.3 (C-1), 43.5 
(C-3), 48.1 (C-2), 57.5 (C-4), 125.9, 130.2, 131.6, 133.0, 138.5
(C-5)(C-6)(C-7)(C-8)(C-9)(C-10).
/V,Ar-Di(chloroethyl)-/V,/V-di(p-nitrobenzyl)piperazinium dibromide 162b
.2Br
A/,A/,-Di(chloroethyl)-A/,A/-di(p-nitrobenzyl)piperazinium dibromide 162b was 
obtained as in literature method139 using 161b (0.70 g, 1.15 mmol) and thionyl
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chloride (20 ml) as in general method (c). The product was obtained as a pale yellow 
solid and recrystallised twice from EtOH and diethyl ether (0.46 g, 62 %); i w  (KBr) 
752, 1351, 1496, 1525, 1608 and 2971 (br) cm 1; 8H (200 MHz, D20), 3.64-3.97 (12H, 
m, NCH2), 4.04-4.09 (4H, m, CH2CI), 4.81-4.88 (4H, bs, Ar-CH2), 7.66-7.70, 8.22-8.62 
(8H, AA'BB', Ar-H); 8c (50 MHz, D20 ) 35.7 (C-1), 46.4, 55.4, 58.4 (C-2)(C-3)(C-4), 
125.4 (C-5), 132.8 (C-7), 135.4 (C-6), 150.0 (C-8); m/z (FAB+) 729.4 (M+Br2, 100 %).
Methyl DL-pipecolinate hydrochloride 164
.ci
Methyl DL-pipecolinate hydrochloride 164 was prepared as in the literature 
preparation54 with DL-pipecolinic acid (5.0 g, 38.7 mmol), MeOH (50 ml) and thionyl 
chloride (5.13 ml) as a white solid. This was recrystallised from EtOH and diethyl 
ether (6.35 g, 91 %); 8C (50 MHz, CDCb) 21.9 (C-1), 22.1 (C-2), 26.3 (C-3), 44.8 
(C-4), 54.4 (C-5), 57.5 (C-6), 170.9 (C-7); lit54 22.0 (C-1), 22.1 (C-2), 26.5 (C-3), 44.9 
(C-4), 54.4 (C-5), 57.6 (C-6), 171.1 (C-7).
tf,M-(1,4-Dioxo-1,4-butanediyl)bis(2-methoxycarbonylpiperidine) 165
A/,A/-(1,4-Dioxo-1,4-butanediyl)bis(2-methoxycarbonyl piperidine) 165 was 
prepared by literature preparation54 using 164 (5.0 g, 27.8 mmol), chloroform (30 ml), 
triethylamine (6.80 g, 66.7 mmol) and succinyl dichloride (1.44 ml, 13.0 mmol) as a 
colourless oil (4.67 g, 91 %); 5C (50 MHz, CDCb) 20.8 (C-8), 25.1 (C-7), 27.0 (C-6),
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28.1 (C-2), 43.0 (C-9), 52.0 (C-5), 54.2 (C-3), 171.8, (C-1) 172.0 (C-4); lit54 20.8 
(C-8), 25.0 (C-7), 27.0 (C-6) 28.2 (C-2), 42.9 (C-9), 52.0 (C-5), 53.8 (C-3), 167.2 
(C-1), 171.9 (C-4).
Af,Ar-(1,4-Butanediyl)bis(2-hydroxymethylpiperidine) 10
OH
HO
A/,/V-(1,4-Butanediyl)bis (2-hydroxymethylpiperidine) 10 was prepared as in 
literature preparation54 with 165 (5.0 g, 13.5 mmol) and lithium aluminium hydride 
(4.00 g, 0.11 mol) in dry THF (40 ml) as a clear viscous oil (1.68 g, 87 %); 5C (50 
MHz, CDCIa) 23.5 (C-3), 24.0 (C-2), 24.3 (C-7), 27.5 (C-4), 51.1 (C-6), 53.0 (C-5),
61.0 (C-1), 62.4 (C-8); lit54 23.3 (C-3), 23.5 (C-2), 24.5 (C-7), 27.8 (C-4), 51.3 (C-6),
53.1 (C-5), 61.0 (C-1), 62.4 (C-8).
Af,N-Di(o-mtrobenzylH1,4-butanediyl)bis(2-hydroxymethylpiperidinium)
dichloride 166a
OH
NOo ©  ^  2CI
/V,/V-Di(o-nitrobenzyl)-(1,4-butanediyl)bis(2-hydroxymethylpiperidinium) 
dichloride 166a was obtained by literature method139 using 10 (0.84 g, 2.95 mmol) in 
acetonitrile (30 ml) and o-nitrobenzyl chloride (1.30 g, 6.0 mmol) as a brown oil which 
was crystallised from EtOH and diethyl ether (1.2 g, 61 %); iw  (KBr) 1040,1363,
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1528, 1618 and 3480 cm 1; SH (200 MHZ, D20 ) 1.22-1.78 (18H, m, ring and chain 
CH2CH2), 2.72-3.74 (12H, m, ring and chain CH2N, CHN), 4.56 (4H, s, CHz-Ar), 7.66 
(2H, bs, Ar-H), 7.47 (6H, bs, Ar-H);8c (50 MHZ, D20 ) 21.9 (C-3), 23.4 (C-4), 25.0 
(C-2), 27.1 (C-8), 36.1 (C-1), 51.4 (C-6), 57.5 (C-5), 62.1 (C-7), 63.5 (C-9), 122.1, 
128.5, 129.0, 133.0, 145.5 (C-9)(C-10)(C-11)(C-12)(C-13).
/V,/V-Di(p-nitrobenzyl)-(1,4-butanediyl)bis(2-hydroxymethylpiperidinium)
dibromide 166b
.OH
2Br
/V,A/-Di(p-nitrobenzyl)-(1,4-butanediyl)bis(2-hydroxymethylpiperidinium) 
dibromide 166b was obtained by literature method139 using 10 (0.84 g, 2.95 mmol) in 
acetonitrile (30 ml), p-nitrobenzyl bromide (1.30 g, 6.0 mmol) as a brown oil which 
was crystallised from EtOH and diethyl ether ( 1.4 g, 63 %); IW  (KBr) 1035, 1369, 
1535, 1621 and 3400 cm*1; 8H (200 MHz, D20 ) 1.41-2.00 (18H, m, ring and chain 
CH2CH2), 2.83-3.59 (12H, m, ring and chain CH2N, CHN), 4.11 (4H, s, CH M r), 
7.12-7.18 and 7.64-7.70 (8H, AA'BB' system, Ar-H); 8C (50 MHz, D20 ) 22.5 (C-3), 
23.7 (C-4), 25.0 (C-2), 27.4 (C-8), 36.1 (C-7), 51.4 (C-6), 57.9 (C-5), 62.5 (C-1), 63.9 
(C-9), 123.0 (C-10), 129.8 (C-12), 133.9 (C-11) 148.3 (C-13).
A/,A/-Di(o-nitrobenzyl)-(1,4-butanediyl)bis(2-chloromethylpiperidinium)
dichloride 167a
NO 2CI
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N, A/-Di(o-nitrobenzyl)-( 1,4-butanediyl)bis(2-chloromethylpiperidinium) 
dichloride 167a was obtained as in literature method139 using 166a (0.5 g, 1.7 mmol) 
in thionyl chloride (25 ml) as a solid which was recrystallised from EtOH and diethyl 
ether (0.35 g, 70 %), 5H (200 MHz, D20 )  1.50-2.98 (18H, m, ring and chain CH2CH2), 
2.82-4.01 (12H, m, ring and chain CH2N, CHN), 4.51 (4H, s, CHr-Ar), 7.54 (2H, bs 
Ar-H), 8.03 (6H, bs, Ar-H);8c (50 MHZ, D20 )  22.5 (C-3), 23.9 (C-4), 25.4 (C-2), 27.9 
(C-8), 36.5 (C-1), 39.4 (C-6), 57.9 (C-5), 63.0 (C-7), 64.1 (C-9), 122.8, 128.6, 129.4,
133.4, 145.9 (C-10)(C-11 )(C-12)(C-13)(C-14)(C-15).
N,/V-Di(p-nitrobenzyl)-(1,4-butanediyl)bis(2-ch1oromethylpiperidine) dibrom ide
167b
.2Br
N, A/-Di(p-nitrobenzyl)-(1,4-butanediyl)bis(2-chloromethylpiperidine) dibromide 
167b was obtained as in literature preparation139 using 166b (0.5 g, 1.7 mmol) in 
thionyl chloride (20 ml) as a green crystalline solid which was recrystallised from 
EtOH and diethyl ether (0.23 g, 25 %); i w  (KBr) 759, 1337, 1523 and 1636 cm 1; 5H 
(200 MHZ, D20 )  1.54-2.05 (18H, m, ring and chain CH2CH2), 2.65-3.98 (12H, m, ring 
and chain CH2N, CHN), 4.50 (4H, s, CHz-Ar), 7.52 and 8.02 (8H, AA'BB' system, 
Ar-H); 8C (50 MHZ, D20 )  20.5 (C-3), 21.6 (C-4), 22.8 (C-2), 25.1 (C-8), 37.1 (C-6),
50.5 (C-7), 60.1 (C-5), 61.9 (C-1), 64.1 (C-9), 122.0, 128.1, 131.9, 146.9 (C-10) 
(C-11 )(C-12)(C-13)(C-14)(C-15); m/z (FAB+) 591.0 (M-Br, 1 %), 627.3, 629.3 (M-C/, 
Brt 3 %), 647.3 (M-Br*, 1.5 %).
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2-Hydroxymethyl-N-methyl-tf-(o-nitrobenzyl)piperidinium chloride 168a
CH
2-Hydroxymethyl-A/-methyl-A/-(o-nitrobenzyl)piperidinium chloride 168a was 
obtained as in literature preparation139 using 45 (0.37 g, 2.91 mmol) in acetonitrile (20 
ml), o-nitrobenzyl chloride (0.5 g, 2.91 mmol) as a light yellow solid (0.6g, 71 %); I W  
(KBr) 1064, 1341, 1527, 1604, 2871, 2945, 3231 and 3447 cm 1; 8H (200 MHz, D20 )  
1.40-1.86 (6H, m , ring CH2), 2.80 (3H, s, CH3N), 2.97-3.31 (2H, m, CH2N), 3.48-3.59 
(1H, m, CHN), 3.99 (2H, s, Ar-CH2), 4.74-4.81, 5.34-5.41 (2H, d, CH20 ), 7.52-7.71, 
7.99-8.04 (4H, m, Ar-H); 8C (50 MHz, D20 )  20.1 (C-3), 21.7 (C-4), 24.3 (C-2), 41.3 
(C-6), 60.0 (C-5) 62.8 (C-7) 64.7 (C-14), 73.6 (C-1), 121.7 (C-10), 127.3 (C-12),
133.2 (C-9), 135.0 (C-8), 137.2 (C-13), 151.1 (C-11); m/z (FAB+) 265.1 (MH+, 100 
%).
2-Hydroxymethyl-/V-methyl-N- (p-nitrobenzyl)piperidinium  bromide 168b
.Br
2-Hydroxymethyl-A/-methyl-A/-(p-nitrobenzyl)piperidinium bromide 168b was 
obtained as in literature method139 using 45 (4.0 g, 31 mmol) in acetonitrile (75 ml), 
p-nitrobenzyl bromide (6.69 g, 31 mmol) as a light yellow solid (11.4g, 106 %); IW
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(KBr) 1045, 1330, 1352, 1518, 1604, 2869, 2943, 3338 and 3505 cm'1; 5h (200 MHz, 
D20 )  1.62-1.80 (6H, m, ring CH2), 2.95 (3H, s, CH3), 3.14-3.19 (2H, m, CH2N), 3.42 
(1H, m, CHN), 4.79 (2H, s, Ar-CH2), 4.36-4.63 (2H, m, CH20 ), 7.63-8.19 (4H, AA'BB' 
system, Ar-H); 6c (50 MHz, D/O) 20.2 (C-3), 21.6 (C-4), 24.1 (C-2), 43.7 (C-6), 60.7 
(C-5), 63.3 (C-7), 68.3 (C-1), 72.0 (C-12), 124.7 (C-8), 134.8 (C-10), 135.4 
(C-9),148.2 (C-11); m/z (Cl+) 264 ( M-Br-Af, 8 %), 345 (MH+,0.5 %).
2-Chloroethyl-N-methyl-N-(o-nitrobenzyl)piperidinium chloride 169a
CH
2-Chloroethyl-A/-methyl-A/-(o-nitrobenzyl)piperidinechloride 169a was obtained 
as in literature preparation139 using 168a (0.5 g, 1.7 mmol) in thionyl chloride (10 ml), 
as in general method (c), as white crystals which were recrystallised from EtOH and 
diethyl ether (0.25 g, 46 %); i w  (KBr) 749, 1347, 1533, 1633, 2872 and 2959 cm 1; 
8h (200 MHz, D20 )  1.20-1.61 (6H, m, ring CH2), 2.43 (3H, s CH3), 2.62-2.88 (2H, m, 
CHN), 3.35-3.49 (1H, m, CH), 3.62-3.75 (2H, m, CH2CI), 4.88 (2H, s, Ar-CH2), 
7.15-7.29, 7.56-7.61 (4H, m, Ar-H); 8C (50 MHz, D20 )  20.0 (C-3), 21.4 (C-4), 25.3 
(C-2), 42.0 (C-6), 58.0 (C-9), 63.1 (C-5), 63.9 (C-7), 72.7 (C-1), 121.4, 127.1, 133.4,
135.2, 137.2, 150.7 (C-8)(C-9)(C-10)(C-11)(C-12)(C-13); m /z(C \+) 320.9 (MAT, 1 %).
N-Methyl-A/-(p-nitrobenzyl)piperidine-2-chloroethyl bromide 169b
3
s. 2
A ^ c i
j / K ^CH3
8 6
010V .Br
N02
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A/-Methyl-/V-(p-nitrobenzyl)piperidine-2-chloroethyl bromide 169b was obtained 
as in literature method139 using 168b (3.0 g, 8.7 mmol) in thionyl chloride (30 ml), as 
in general method (c), as white crystals which were recrystallised from EtOH and 
diethyl ether (3.1 g, 98 %); i w  (KBr) 750, 1351, 1492, 1523 and 1606 cm 1; SH (200 
MHz, D20 )  1.62-1.80 (6H, m, ring CH2), 2.99 (3H, s, CH3), 3.14-3.19 (2H, m, CH2N), 
3.42 (1H, m, CHN), 3.65-3.85 (2H, m, CH2CI), 4.79 (2H, s, Ar-CH2), 8.15-7.58 (4H, 
AA'BB' system, Ar-H); 8C (50 MHz, D20 )  20.2 (C-3) 21.5 (C-4), 25.2 (C-2), 41.9 
(C-12), 42.5 (C-6), 63.5 (C-5), 67.8 (C-7), 70.1 (C-1), 124.9 (C-8), 134.3 (C-10),
135.3 (C-9), 149.8 (C-11); m/z (Cl+) 148 (A4- Ar, Br, 100 %), 283 (M-Br, 82 %), 365 
(MH+, 0.2 %) (found: 283.1226 CuHaofe^CI requires 283.1213).
Diethyl-2,6-pyridinedicarboxylate 2
Diethyl-2,6-pyridinecarboxylate 2 was obtained as in previous literature 
preparation141 using dipicolinic acid (5.0 g, 30 mmol) and thionyl chloride (15 ml) as 
white crystals afforded from MeOH (3.16 g, 47.2 %); 8c (50 MHz, CDCI3) 14.1 (C-6),
62.3 (C-5) 127.8 (C-2), 138.7 (C-1), 148.4 (C-3), 164.5 (C-4); lit54 14.1 (C-6), 62.2 
(C-5), 127.7 (C-2), 138.1 (C-1), 148.4 (C-3), 164.4 (C-4).
Diethyl f/-methyl-c/s-piperidinedicarboxylate
Diethyl A/-methyl-c/s-piperidinedicarboxylate was obtained as in literature 
preparation54 as a white coloured oil using 2 (3.16 g, 14 mmol), glacial acetic acid (50 
ml), platinum dioxide (0.2 g), 36 % formaldehyde solution (20 ml) and 10 % palladium
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on carbon (0.20 g). (1.4 g, 44 %); 5C (50 MHz, CDCb) 14.0 (C-6), 24.8 (C-1), 34.1 
(C-2), 45.2 (C-3), 62.3 (C-5), 169.9 (C-4); lit5413.9 (C-6), 25.0 (C-1), 33.9 (C-2), 45.3 
(C-3), 62.1 (C-5), 169.6 (C-4).
N-Methyl-c/s-2,6-bis(hydroxymethyl)piperidine 3
HO
A/-Methyl-c/s-2,6-bis(hydroxymethyl)piperidine 3 was obtained as a white solid 
using literature preparation54 from 2 (1.42 g, 6.22 mmol) in dry THF (20 ml) and 
lithium aluminium hydride (0.5 g, 13 mmol) in dry THF (20 ml) under nitrogen (0.2 g, 
20 %); 8c  (50 MHz, CDCb) 23.6 (C-1),26.7 (C-2), 34.7 (C-5), 63.3 (C-4), 63.7 (C-3); 
lit54 23.7 (C-1), 26.7 (C-2), 34.9 (C-5), 63.5, 64.1 (C-3)(C-4).
2,6-Di(hydroxymethyl)-/V-methyl-W-(p-nitrobenzyl)piperidinium bromide 170
.Br
2,6-Di(hydroxymethyl)-A/-methyl-A/-(p-nitrobenzyl)piperidinium bromide 170 
was obtained as in literature method139 using A/-methyl-c/s-2 3 (0.20 g, 1.25 mmol) in 
acetonitrile (30 ml) and p-nitrobenzyl bromide (0.27 g, 1.25 mmol) as a yellow/ 
orange solid residue (0.3 g, 64 %); Umax (KBr) 1040, 1347, 1520, 1604 and 3421 cm-1; 
8h (200 MHz, D20 )  1.16-1.79 (6H, m, ring CH2), 3.02 (3H, s, NCH3), 3.45 (2H, dd, 
CH20 ), 3.86- 4.01 (2H, dd, CH20 ), 5.32 (2H, s, Ar-CH2), 7.70-8.17 (4H, AA'BB'
system, Ar-H); 8C (50 MHz, D20 )  24.1 (C-8), 26.9 (C-9), 56.3 (C-6), 67.0 (C-7), 68.0  
(C-5), 69.1 (C-10), 122.1, 123.9, 135.0, 158.4 (C-1)(C-2)(C-3)(C-4).
2,6-Di(chloroethyl)-N-methyl-N-(p-nitrobenzyl)piperidinium bromide 171
2,6-Di(chloroethyl)-A/-methyl-A/-(p-nitrobenzyl)piperidinium bromide 171 was 
obtained as in literature method139 using 170 (0.30 g, 0.80 mmol) and thionyl chloride 
(20 ml), as in general method (c), as a pale yellow solid which was recrystallised 
twice from EtOH and diethyl ether (0.06 g, 20 %); i w  (KBr) 704, 1348, 1473, 1522 
and 1605 crrr1; 8H (200 MHz, D20 )  1.54-1.90 (6H, m, CH2 ring), 2.68 (3H, s CH3), 
2.80 (2H, s, Ar-CH2), 3.27-3;39 (2H, m, CHN), 3.63-3.90 (4H, dd, CH2CI), 7.63-7.70,
8.07-8.15 (4H, AA'BB' system, Ar-H); 8C(50 MHz, D20 )  22.1 (C-8), 24.3 (C-9), 39.3 
(C-10), 58.2 (C-6), 67.4 (C-7), 68.1 (C-5), 124.9 (C-4), 125.3 (C-2), 135.2 (C-3), 159.4 
(C-1); m/z (Cl+) 205 (MhT, 100 %).
N,A/-Di(hydroxyethyl)-5,6:14,15-dibenzo-1,12-diaza-1,4-dioxacyclopentadecane 
N,N'-(p-nitrobenzyl)piperidinium dibromide 172
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N, A/-Di(hydroxyethyl)-5,6:14,15-dibenzo-1,12-diaza-1,4-dioxacyclo 
pentadecane-A/,A/-(p-nitrobenzyl)piperidinium dibromide 172 was obtained as in 
literature method139 using 133 (0.20 g, 1.25 mmol) in acetonitrile (30 ml), p-nitrobenzyl 
bromide (0.75 g, 3.2 mmol) as a light yellow solid residue (1.15 g, 86 %); i w  (KBr) 
1051, 1360, 1498, 1598, 2958 and 3357 cm 1; 8H (200 MHz, D20 )  1.73-1.83 (2H, m, 
CH2CH2), 3.0-3.65 (12H, m, NCH2), 3.70 (4H, s, Ar-CH2), 3.82-4.10 (8H, m, OCH2),
7.08-7.45, 7.56-7.83 (16H, m, Ar-H); 8C (50 MHz, D20 )  21.9 (C-12), 30.0 (C-10), 
42.9, 50.9, 57.4 (C-8) (C-9) (C-11), 64.5 (C-13), 68.2 (C-1), 127.0, 127.4, 131.2,
133.2, 136.5, 138.9, 149.1 (C-2)(C-3)(C-4) (C-5)(C-6)(C-7)(C-14)(C-15)(C-16)(C-17).
N,/V-Di(chloroethyl)-5,6:14,15-dibenzo-1,12-diaza-1,4-dioxacyclopentadecane 
N,N'-(p-nitrobenzyl)piperidinium dibromide 173
N, /V-Di(chloroethyl)-5,6:14,15-dibenzo-1,12-diaza-1,4-dioxacyclopentadecane 
A/,A/-(p-nitrobenzyl)piperidinium dibromide 173 was obtained by general method (c) 
using 172 (1.15 g, 1.4 mmol) and neat thionyl chloride (30 ml). The product was 
obtained as a biege solid which was recrystallised from EtOH and diethyl ether (0.50 
g, 43 %); (KBr) 758, 1348, 1494, 1525 and 1603 cm 1; 8H (200 MHz, D20 )
1.59-1.61 (2H, m, CH2CH2), 3.04-3.11 (12H, m, NCH2), 3.40 (2H, s, Ar-CH2),
3.59-3.67 (8H, m, OCH2, CH2CI), 7.00-7.25, 7.52-7.69 (16H, m, Ar-H); 8C (50 MHz, 
D20 ) 21.9 (C-12), 30.0 (C-10), 42.9, 50.9, 55.2 (C-8) (C-9) (C-11), 64.5 (C-13), 68.2 
(C-1), 127.5, 127.7, 130.2, 130.4, 136.3, 138.5, 144.0 (C-2)(C-3)
(C-4)(C-5)(C-6)(C-7)(C-14)(C-15)(C-16)(C-17).
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N,N’,N ”,N m -Tetra(ch loroethyl)-1,4,7,10-tetraazacyclododecaneN-(p-n itrobenzy I)
piperidinium  bromide 175
N, N AT, /\T-tetra(chloroethyl)-1,4,7,10-tetraazacyclododecane/V-(p-nitrobenzyl) 
piperidinium bromide 175 was obtained by general method (c) using 174 (1.00 g, 1.0 
mmol) and neat thionyl chloride (30 ml). The product was obtained as a white solid 
and recrystallised from EtOH and diethyl ether (0.32 g, 31 %); i w  (KBr) 744, 1350, 
1443, 1526 and 1608 cm 1; 5H (200 MHz, D20 )  3.09-3.79 (24H, m, NCH2), 3.52 (2H, 
s, Ar-CH2), 3.74-3.81 (8H, m, CICH2), 7.62-8.22 (4H, dd, Ar-H); 5C (50 MHz, DzO)
39.2 (C-3), 48.9, 55.1, 62.2 (C-1)(C-2)(C-4), 125.1, 136.1, 137.3, 149.8
(C-5)(C-6)(C-7)(C-8).
1,4-Di(hydroxyethyl)-1,4,8,11 -tetraazacyclododecane-5,7-dione-W, 
AT-(o-nitrobenzyl) dichloride 177
1,4-Di(chloroethyl)-1,4,8,11-tetraazacyclododecane-5,7-dione-A/,A/- 
(o-nitrobenzyl) dichloride 177 was obtained by general method (c) using 176 (0.1 g,
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0.15 mmol) and neat thionyl chloride (20 ml), th e  product was obtained as an off 
white solid and recrystallised from EtOH and diethyl ether (0.05 g, 48 %); i w  (KBr) 
749, 1334, 1483, 152, 1605 and 1685 cm'1; 8C (50 MHz, D20 )  28.2 (C-6), 39.2, 41.2 
(C-1 )(C-8),53.5, 55.5, 58.1, 58.9 (C-3)(C-4)(C-5)(C-7), 62.9 (C-9), 123.1, 127.5,
134.5, 135.9, 136.1, 137.6, 152.1 (C-10)(C-11)(C-12)(C-13)(C-14) (C-15) and 169.2 
(C-2); m/z (FAB+) 659.2 (M-CI, 6 %).
/V,N',Af,-Tri(hydroxyethyl)-tf,N, N >>-tri(p-nitrobenzyl)-1,4,7-triazacyclononamum
tribrom ide 179
OHHO.
.3Br
“OH
N, N', Af'-T ri(hydroxyethyl)-A/, N \ A/"-tri(p-nitrobenzyl)-1,4,7-triazacyclononanium 
tribromide 178 was obtained by literature method139 using 77 (0.43 g, 1.6 mmol) in 
acetonitrile (30 ml) and p-nitrobenzyl bromide (1.08 g, 5 mmol) as a off white solid 
(1.0 g, 69.4 %); Um« (KBr) 1079, 1349, 1524, 1608, 2856, 2959 and 3368 cm’1; 8h  
(200 MHz, D20 )  4.48 (6H, s, NCH2), 4.31-4.61 (2H, s, OCH2), 4.71 (2H, s, Ar-CH2), 
7.51-8.16 (4H, AA'BB' system, Ar-H); 8C (50 MHz, D20 )  50.0 (C-8), 58.0 (C-6), 58.6 
(C-7), 59.2 (C-5)4, 123.9 (C-2), 129.9 (C-3), 144.8 (C-1).
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N ,N 'tf>-Tri(chloroethyl)-tffN',NMri(p-nitrobenzyl)-1,4,7-triazacyclononanium
tribrom ide 180
.3Br
N, N \ A/"-tri(chloroethyl)-A/, N \ A/"-tri(p-nitrobenzyl)-1,4,7-triazacyclononane 
tribromide 179 was obtained as in literature method139 using 178 (1.0 g, 1.1 mmol) in 
thionyl chloride (20 ml) as an off white solid which was recrystallised from EtOH and 
diethyl ether (3.16 g, 47.2 %); i w  (KBr) 1111, 1299, 1349, 1603, 1524, 1606 cm 1; SH 
(200 MHz, CDCb) 3.57 (2H, CH2CI), 4.48 (4H, s, CH20 ), 4.31-4.38 (4H, s, NCH2), 
4.57 (4H, s, Ar-CH2), 7.48-8.15 (4H, AA'BB' system, Ar-H); 8c (50 MHz, CDCb) 44.4 
(C-8), 57.7 (C-7), 58.0 (C-6), 64.0 (C-5), 123.8 (C-2) 124.1 (C-4), 129.3 (C-3), 144.4 
(C-1); m/z (Cl+) 759.2 (M+-N02Ar, 100 %).
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